Methods for diagnosing and monitoring the status of systemic lupus erythematosus

ABSTRACT

The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.

PRIORITY

This application claims the benefit of U.S. Prov. App. No. 60/858,147,filed Nov. 9, 2006, which is incorporated by reference herein in itsentirety.

TECHNICAL FIELD

The invention provides for the use of gene expression and statisticalanalysis to diagnose and monitor the status of systemic lupuserythematosus.

BACKGROUND OF THE INVENTION

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic diseasecharacterized by dysregulation of the immune system and differentialexpression of genes in immunological pathways. In the United States, SLEaffects about 2 million patients and 90% of these patients are female.Targeted tissues and organs include the blood, central nervous system(CNS), joints, kidneys, lungs, skin, and vasculature, Symptoms includeabnormal blood panels, arthralgias, atherosclerosis, CNS disorders,infections, joint pain, malaise, rashes, ulcers, and the production ofautoantibodies. Since disease severity, symptomology, and response totherapy vary widely, SLE is difficult to diagnose, manage and treat.

As described in USSN 20040033498, SLE clearly involves differential geneexpression in SLE patients as compared to normal controls. Twolaboratories have reported on the role of the interferon (INF)-αinducible genes in SLE and on high levels of anti-RNA binding protein,anti-Ro antibodies, and renal disease (Baechler et al (2003)PNAS100:2610-2615; Kirou et al (2004) Arthritis and Rheumatism50:3958-3967). However, low positive correlation between diseaseactivity and IFN-inducible genes, the apparent heterogeneity of SLEpatients, and lack of longitudinal studies continue to presentchallenges for clinicians (Kirou et al. (2005) Arthritis and Rheumatism52:1491-1503).

These challenges point to a need in the art for better diagnosis,characterization, and follow-up of patients with SLE. To this end,longitudinal data from SLE patients was used with methods for detectingand analyzing gene expression to monitor status, quiescence versusflare, and to classify a patient as having type 1 SLE or type 2 SLE.

SUMMARY

The invention presents methods and compositions for diagnosing andmonitoring systemic lupus erythematosus (SLE). The methods use geneexpression based on nucleic acid or protein technologies, andstatistical methods to classify patients as having type 1 SLE or type 2SLE and to monitor disease activity, predict flare, and assess theefficacy of treatment administered to the patient.

The invention provides a method of diagnosing or monitoring the statusof systemic lupus erythematosus (SLE) in a subject or patient includesdetecting the expression of all genes of a diagnostic set in the subjector patient wherein the diagnostic set comprises two or more genes havingexpression correlated with the classification or status of SLE; anddiagnosing or monitoring the status of SLE in the subject or patient byapplying at least one statistical method to the expression of the genesof the diagnostic set. In one aspect, the statistical method is aprediction algorithm that produces a number or single value indicativeof the status of SLE in the subject or patient. In another aspect, thestatistical method further comprises classification of the subject orpatient into one of at least two classes of SLE, and is optimized tomaximize the separation among longitudinally stable classes of SLE. Themethod also provides a diagnostic set further comprising at least onegene selected from each of at least two gene clusters selected fromcluster 1, cluster 2, cluster 3, cluster 4, cluster 5, cluster 6,cluster 7, cluster 8, cluster 9, cluster 10, cluster 11; cluster 12,cluster 13, cluster 14, and cluster 15 of Table 1. The invention furtherprovides classification of the subject or patient into one of at leasttwo classes of SLE further comprising detecting the expression of two ormore gene whose expression correlates with the expression of the IFI27from about 0.5 to about 1.0 and from about −0.5 to about −1.0 calculatedusing a Pearson correlation; and classifying a subject or patient ashaving type 1 or type 2 SLE based on the expression of the two or moregenes. In one aspect, one of the two or more genes is selected fromTable 2 and the classifying step uses a linear algorithm to produce aninterferon response (INFr) score wherein a high IFNr score is correlatedwith type I SLE and a low IFNr score is correlated with type II SLE. Theinvention additionally provides at least one linear algorithm producingan IFNr score comprising IFI27+IFI144*(1.1296)+OAS3*(1.8136). Theinvention still further provides a Pearson correlation that is selectedfrom a range of 0.5, 0.4, 0.3, and 0.2 of the expressed genes.

The invention provides a method of diagnosing or monitoring the statusof systemic lupus erythematosus (SLE) in a subject or patient comprisingdetecting the expression of all genes of a diagnostic set in a subjector patient wherein the diagnostic set includes at least one gene fromeach of at least two gene clusters selected from cluster 1, cluster 2,cluster 3, cluster 4, cluster 5, cluster 6, cluster 7, cluster 8,cluster 9, cluster 10, cluster 11; cluster 12, cluster 13, cluster 14,and cluster 15 of Table 1; and diagnosing or monitoring the status ofSLE in the subject or patient based on expression of the genes in thediagnostic set. In one aspect, the expression of all genes in thediagnostic set is detected using a nucleic acid technology furtherincluding hybridization in solution or on a substrate or amplificationin a quantitative real-time polymerase chain reaction. In anotheraspect, expression of all genes is proportional to the amount of RNAisolated from a subject or patient sample further including a body fluidselected from whole blood or a blood fraction, ascites, cerebrospinalfluid, lymph, sputum, and urine or a tissue selected from centralnervous system, joints, kidneys, liver, lungs, oral cavity, sinuses,skin, and vasculature obtained by any sampling means selected fromaspiration of a body fluid, a biopsy of a tissue or an organ, drawing ofperipheral blood, endoscopy, and lavage followed by aspiration.

The invention provides for the use of at least one primer or probe setto detect the expression of each of the genes in the diagnostic set. Inone aspect, the primers or probe sets are oligonucleotides selected fromnatural or synthetic cDNA, genomic DNA, locked nucleic acids, peptidenucleic acids, and RNA and can be used in a diagnostic kit. Theinvention also provides a method of diagnosing a patient as having alongitudinally stable classification of SLE by detecting the expressionof two or more genes whose expression correlates with the expression ofthe IFI27 from about 0.5 to about 1.0 and from about −0.5 to about −1.0calculated using Pearson correlation; and diagnosing the patient ashaving type I or type II SLE based on analyzing the expression of thetwo or more genes using a statistical method.

The invention further provides for assigning a subject or patient to aclinical trial based on their classification as type I SLE or type 2SLE.

The invention provides for monitoring the status of SLE in a subject orpatient by predicting incipient flare or disease activity, and assessingresponse to a therapeutic agent administered to the patient or to animmunosuppressant administered to a patient. The invention also providesfor screening a subject exhibiting symptoms of a rheumatic diseaseselected from ankylosing spondylitis, dermatomyositis, autoimmunehepatitis, hepatitis-C (hep-C), polymyalgia rheumatica, polymyositis,rheumatoid arthritis (RA), scleroderma, systemic sclerosis, Sjogren'sdisease, systemic vasculitis, and Whipple's disease.

The invention provides method of producing a probe set for diagnosing ormonitoring SLE in a subject or patient by selecting at least one genefrom each of at least two of the gene clusters of Table 1 and at leasttwo genes from Table 2; and producing a probe set consisting of at leastone oligonucleotide that detects the expression of each of the selectedgenes. In one aspect, the probe set is used in a diagnostic kit.

The invention provides a method for predicting flare in a patientdiagnosed with SLE by analyzing gene expression in a sample from thepatient to produce a gene expression profile wherein a first portion ofthe analysis includes using expression of at least one gene selectedfrom each of at least two of the clusters 1 through 15 of Table 1 and atleast one statistical method to produce a patient expression profile,and a second portion of the analysis includes using expression of atleast two genes selected from Table 2 and a linear algorithm to classifythe patient as having type 1 SLE or type 2 SLE; and predicting flare bycomparing the patient gene expression profile at least one referenceprofile. In one aspect, the reference profile is selected from at leastone normal subject, at least one patient classified as having type 1 SLEwith quiescent status, at least one patient classified as having type 1SLE in flare, at least one patient classified as having type 2 SLE withquiescent status, at least one patient classified as having type 2 SLEin flare.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the Log₁₀ expression ration for Interferon Responsive GeneIFI27 in QF and F paired samples.

FIG. 2 shows the Interferon Response (INFr) score for normal controlsand SLE patient.

FIG. 3 shows the bimodal distribution for IFI27, IFI44, and OAS3 of SLEpatients.

DESCRIPTION OF THE TABLES

Table 1 shows 15 clusters of correlated genes that are differentiallyexpressed as SLE patients change status from quiescence to flare and canbe used with at least one statistical method to predict flare. Celltypes corresponding to each cluster are indicated as well as Array ID,Genbank ID, Gene ID, and the source of each gene. 60-mer sequences,which are unique identifiers for the genes, are also displayed inTable 1. The Sequence Listing provides the 60-mer sequences listed inTable 1.

Table 2 lists INFr genes with expression that positively correlates withIFI27 expression and can be used with at least one statistical method toclassify a patient as having either type 1 SLE or type 2 SLE. 60-mersequences, which are unique identifiers for the genes, are alsodisplayed in Table 2.

Table 3 presents longitudinal data for SLE patients showing stability inan individual's INFr score and its lack of correlation with SLEDAI.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Unless defined otherwise, all scientific and technical terms areunderstood to have the same meaning as commonly used in the art to whichthey pertain. In this application, the singular form—“a”, “an”, and“the”—includes plural references unless the context clearly dictatesotherwise. For example, the term “an agent” includes a plurality ofagents and mixtures thereof. For the purpose of this invention, thefollowing terms are defined below.

“Amplification” refers to any device, method or technique that can makecopies of a nucleic acid. It can be achieved using polymerase chainreaction (PCR) techniques such as linear amplification (cf. U.S. Pat.No. 6,132,997), rolling circle amplification, and the like. Further,amplification and detection can be combined as in TAQMAN Real-TimePCR(RT-PCR) using the TAQMAN protocols and the Prism 7900HT Sequencedetection system and software (Applied Biosystems (ABI), Foster CityCalif.).

“Array” refers to an ordered arrangement of at least tworeagents—antibodies, nucleic acids or proteins—in solution or on asubstrate where at least one of the reagents represents a normal controland the other, a sample of diagnostic or prognostic interest. Theordered arrangement insures that the size and signal intensity of eachlabeled complex, formed between at least one reagent and at least onenucleic acid or protein to which the reagent specifically binds, isindividually distinguishable.

The term “diagnostic set” generally refers to a set of two or more genesthat, when evaluated for differential expression of their products,collectively yields predictive data. Such predictive data typicallyrelates to diagnosis, prognosis, monitoring of therapeutic outcomes, andthe like. In general, the components of a diagnostic set aredistinguished from nucleotide sequences that are evaluated by analysisof the DNA to directly determine the genotype of an individual as itcorrelates with a specified trait or phenotype, such as a disease, inthat it is the pattern of expression of the components of the diagnosticset, rather than mutation or polymorphism of the DNA sequence thatprovides predictive value. It will be understood that a particularcomponent (or member) of a diagnostic set can, in some cases, alsopresent one or more mutations, or polymorphisms that are amenable todirect genotyping by any of a variety of well known analysis methods,e.g., Southern blotting, RFLP, AFLP, SSCP, SNP, and the like.

“cDNA” refers to an isolated polynucleotide, nucleic acid molecule, orany fragment or complement thereof that originated recombinantly orsynthetically, is double- or single-stranded, represents coding andnoncoding 3′ or 5′ sequence, and generally lacks introns.

“Classification” refers to the categorization of a subject or patientbased on gene expression as having type 1 SLE or type 2 SLE. SLE isconsidered to be type 1 if it primarily involves Type 1 T helper cellsand type 1-linked cytokines, such as interferon-gamma. SLE is consideredto be type 2 if there is more involvement of Type 2 helper cells whichactivate an antibody-driven immune response.

“Expression” refers differential gene expression—an increased (i.e.,upregulated) or a decreased (i.e., downregulated) expression as detectedby absence, presence, or change in the amount of messenger RNA orprotein for a gene in a sample.

“Flare” refers to onset of disease activity in a patient diagnosed withan immune disorder; in SLE, mild flare has been defined by an increasein systemic lupus erythematosus disease activity index (SLEDAI) by ≧fourunits over a previous score for that patient and severe flare, as anincrease in SLEDAI by ≧12 units. SLEDAI represents a compositeassessment of disease activity based on 16 clinical manifestations andeight laboratory measures including two immunological tests with apossible range of overall score from 0 to 105.

A “gene expression profile” refers to the identification,characterization, quantification, and representation of a plurality ofgenes expressed in a sample as measured using nucleic acid or proteintechnologies. A nucleic acid expression profile is produced using maturemRNA transcript and/or regulatory sequences such as promoters,enhancers, introns, mRNA-processing intermediates, and 3′ untranslatedregions in nucleic acid technologies. A protein expression profile,although time delayed, mirrors the nucleic acid expression profile andis produced using protein technologies and proteins and/or antibodies todetect protein expression in a sample. Results from subject or patientsamples are compared with reference profiles based on normal, diseased,or treated samples.

“Immunosuppressant” refers to any therapeutic agent that suppressesimmune response in a patient such as anticoagulents, antimalarials,heart drugs, non-steroidal anti-inflammatory drugs (NSAIDs), andsteroids including but not limited to aspirin, azathioprine,chloroquine, corticosteroids, cyclophosphamide, cyclosporin A,dehydroepiandrosterone, deoxyspergualin, dexarnethasone, everolimus,fenoprofen, hydralazine, hydroxychloroquine, immunoglobulin, ibuprofen,indomethacin, leflunomide, ketoprofen, meclophenamate, mepacrine,6-mercaptopurine, methotrexate, mizoribine, mycophenolate mofetil,naproxen, prednisone, methyprenisone, rapamycin (sirolimus), solumedrol,tacrolimus (FK506), thymoglobulin, tolmetin, tresperimus, triamcinoline,and the like.

“Longitudinally stable” refers to the behavior of one or more interferonresponse (INFr) genes expressed in samples collected at different timepoints from an individual or data derived from those samples.

“Diagnosis or monitoring” refers to the detection of gene expression atthe nucleic acid or protein level to provide useful information about anindividual's medical status, Monitoring status can include determinationof prognosis or complication, following progression of a disease,prediction of disease activity or flare, providing information relatingto a patient's health over a period of time, selection of a therapeuticagent and/or determining response or resistance to that agent, selectingan individual patient or small subsets of patients most likely tobenefit from an experimental therapy or clinical trial, and determiningclassification of a patient as having a particular disease status.

“Normal” refers to the medical status of an individual, or a sample froman individual, who does not have SLE or any diagnosis or manifestationof an infection or immune disorder and can be used as a negativecontrol.

“Nucleic acid technology” refers to any device, means or system used todetect gene expression or produce a gene expression profile and includesbut is not limited to methods using arrays for amplification in PCR,TAQMAN RT-PCR, quantitative RT-PCR, and the like, or hybridization insolution or on a substrate containing cDNAs, genomic DNAs, lockednucleic acids, oligonucleotide primers or probes, peptide nucleic acids,polynucleotides, and RNAs of any length either natural or synthetic, andthe like.

“Patient” refers to a human subject who is genetically predisposed to arheumatic disease or has been diagnosed with a SLE.

“Prediction” refers to the use of gene expression assessed using nucleicacid or protein technologies, algorithms and statistical analyses toprovide information about an individual's status; for example, beingpredisposed to, diagnosed with, or effectively treated for diseaseactivity or flare.

“Protein technology” includes but is not limited to activity assays,affinity antibody or protein arrays, chromatographic separation,calorimetric assays, two-dimensional gel electrophoresis, enzyme-linkedimmunosorbent assays (ELISA), fluorescent-activated cell sorting (FACS),mass spectrophotometric detection, western analysis, and the like.

A “reference profile” refers to gene expression or gene expressionprofiles from well-characterized normal, diseased or treated samplestaken from at least one subject and giving repeatable results wheneverused in or with a particular nucleic acid or protein technology.

A “rheumatic disease” is a condition or disorder selected fromankylosing spondylitis, dermatomyositis, autoimmune hepatitis,hepatitis-C (hep-C), polymyalgia rheumatica, polymyositis, rheumatoidarthritis (RA), scleroderma, systemic sclerosis, Sjogren's disease,systemic vasculitis, Whipple's disease and the like.

“Sample” is used in its broadest sense and refers to any biologicalmaterial used to obtain histological information or to measure geneexpression obtained by any means from a subject. A sample can be a bodyfluid such as ascites, bile, blood, cerebrospinal fluid, synovial fluid,lymph, pus, semen, sputum, urine; the soluble fraction of a cellpreparation, an aliquot of media in which cells were grown; achromosome, an organelle, or membrane isolated or extracted from a cell;cDNA, genomic DNA, or RNA in solution or bound to a substrate; a cell; atissue biopsy, and the like, Preferred samples for diagnosis, prognosis,or monitoring of SLE patients are leukocytes or serum derived from wholeblood, biopsies of the central nervous system (CNS), joints, kidneys,liver, lungs, oral cavity, sinuses, skin, vasculature, and any othertissues or organs affected by SLE.

“Sampling means” refers to aspiration, biopsy, endoscopy, lavage, needleaspiration or biopsy, puncturing with a lancet; bleeding, ejaculating,expectorating, seeping, or urinating into or onto a collection device,container, substrate, and the like.

“Status” refers to the deterioration, improvement, progression,remission, or stability of a patient with SLE, as determined fromanalyzing one or more samples from that patient. Status, or a changetherein, can be used to evaluate the need for administration of atherapeutic agent, to adjust dosage of such an agent, to change or useanother agent or treatment regime, and the like.

“Statistical methods” include but are not limited to analysis ofvariance, classification algorithms, classification and regressiontrees, Fisher's Exact Test, linear algorithm, linear discriminatoryanalysis, linear regression, logistic algorithm, multiple regression,nearest shrunken centroids classifier, Pearson correlation, predictionalgorithm, significance analysis of microarrays, one-tailed T-tests,two-tailed T-tests, voting algorithm, Wilcoxon's signed ranks test, andthe like.

“Substrate” refers to any rigid or semi-rigid support to whichantibodies, nucleic acids or proteins are bound and includes magnetic ornonmagnetic beads, capillaries or other tubing, chips, fibers, filters,gels, membranes, microparticles, plates, polymers, slides, and waferswith a variety of surface forms including channels, columns, pins,pores, trenches, wells and the like.

“Therapeutic agent” refers to any pharmaceutical molecule or compoundthat will bind specifically to a polynucleotide or to an epitope of aprotein and stabilize or modulate the activity of the polynucleotide orprotein. It can be composed of inorganic and/or organic substancesincluding minerals, cofactors, nucleic acids, proteins, carbohydrates,fats, and lipids and includes but is not limited to Ace inhibitors,aspirin, azathioprine, B7RP-1-fc, β-blockers, brequinar sodium,campath-1H, celecoxib, chloroquine, corticosteroids, coumadin,cyclophosphamide, cyclosporin A, dehydroepiandrosterone,deoxyspergualin, dexamethasone, diclofenac, dolobid, etodolac,everolimus, FK778, feldene, fenoprofen, flurbiprofen, heparin,hydralazine, hydroxychloroquine, CTLA-4 or LFA3 immunoglobulin,ibuprofen, indomethacin, ISAtx-247, ketoprofen, ketorolac, leflunomide,meclophenamate, mefenamic acid, mepacrine, 6-mercaptopurine, meloxicam,methotrexate, mizoribine, mycophenolate mofetil, naproxen, oxaprozin,Plaquenil, NOX-100, prednisone, methyprenisone, rapamycin (sirolimus),sulindac, tacrolimus (FK506), thymoglobulin, tolmetin, tresperimus,U0126, and antibodies including but not limited to alpha lymphocyteantibodies, adalimumab, anti-CD3, anti-CD25, anti-CD52 anti-IL2R, andanti-TAC antibodies, basiliximab, daclizumab, etanercept, hu5C8,infliximab, OKT4, natalizumab and the like.

DETAILED DESCRIPTION OF THE INVENTION Description

Microarray experiments have been used to find genes that aredifferentially expressed in patients diagnosed with systemic lupuserythrematosus (SLE). These genes were described in U.S. Pat. No.6,905,827 and U.S. Ser. No. 10/990,298, each incorporated by referenceherein in its entirety.

The invention provides methods of diagnosing or monitoring the status ofSLE in a subject or patient by detecting the expression of all genes ofa diagnostic set in the subject or patient wherein the diagnostic sethas two or more genes having expression correlated with theclassification or status of SLE; and diagnosing or monitoring the statusof SLE in the subject or patient by applying at least one statisticalmethod to the expression of the genes of the diagnostic set.

The methods of the invention also include classifying the subject orpatient as having type 1 SLE or type 2 SLE, predicting flare, andmonitoring disease activity and treatment efficacy.

Diagnostic Genes of the Invention

The invention provides diagnostic sets containing genes that can be usedto diagnosis and monitor SLE disease status. The diagnostic sets canalso be used to predict occurrence and future complication of thedisease.

Diagnostic genes were identified and validated for use in diagnosing andmonitoring of SLE status by identifying genes for which a correlationexists between the SLE status of an individual as determined based onvarious disease criteria and the individual's expression of RNA orprotein products corresponding to the gene. Disease criteria may includeclinical data such as symptom rash, joint pain, malaise, rashes, bloodcounts (white and red), tests of renal function (e.g. creatinine, bloodurea nitrogen, creative clearance), data obtained from laboratory tests,including complete blood counts with differentials, CRP, ESR, ANA, SerumIL6, Soluble CD40 ligand, LDL, HDL, Anti-DNA antibodies, rheumatoidfactor, C3, C4, serum creatinine and any medication levels, the need forpain medications, cumulative doses or immunosuppressive therapy,symptoms or any manifestation of carotid atherosclerosis (e.g.ultrasound diagnosis or any other manifestations of the disease), datafrom surgical procedures such as gross operative findings andpathological evaluation of resected tissues and biopsies (e.g., renal,CNS), information on pharmacological therapy and treatment changes,clinical diagnoses of disease “flare”, hospitalizations, death, responseto medications, quantitative joint exams, results from health assessmentquestionnaires (HAQs), and other clinical measures of patient symptomsand disability. Disease criteria also include the clinical score knownas SLEDAI (Bombadier C, Gladman D D, Urowitz M B, Caron D, Chang C H andthe Committee on Prognosis Studies in SLE: Derivation of the SLEDAI forLupus Patients. Arthritis Rheum 35:630-640, 1992.).

The diagnostic genes of this invention include sequences correspondingthose provided by the accession numbers and Unigene numbers provided inTable 1 and 2. The 60-mer sequences provided in the Tables are uniqueidentifiers for the diagnostic genes of this invention. Therefore, thediagnostic genes of this invention also include sequences containing the60-mer sequence provided in the Tables. In other words, the diagnosticgenes may be partially or totally contained in (or derived from) thefull-length gene sequences referenced in Tables 1 and 2.

In certain embodiments, the diagnostic genes of this invention includeany sequences whose expression correlates with the expression of allgenes which correlate with IFI27, such as the sequences provided by theaccession numbers and Unigene numbers provided in Table 2.

Homologs and variants of the nucleic acid molecules in Table 1 and Table2 may also be part of the diagnostic gene set. Homologs and variants ofthese nucleic acid molecules will possess a relatively high degree ofsequence identity when aligned using standard methods. The sequencesencompassed by the invention have at least 40-50, 50-60, 70-80, 80-85,85-90, 90-95, or 95-100% sequence identity to the sequences disclosedherein.

The diagnostic gene set may also include other genes that arecoexpressed with the correlated sequence or full-length gene. Genes mayshare expression patterns because they are regulated in the samemolecular pathway or in the same cell type. Because of the similarity ofexpression behavior, these genes are identified as surrogates in thatthey can substitute for a diagnostic gene in a diagnostic gene set.

In some embodiments, diagnostic genes of the invention are used as adiagnostic gene set in combination with genes that are known to beassociated with a disease state (“known markers”). The use of thediagnostic genes in combination with the known markers can provideinformation that is not obtainable through the known markers alone.

Gene Clusters

In some embodiments, the diagnostic genes of this invention aresegregrated into “clusters”. In preferred embodiments the diagnosticgenes of this invention are sorted into clusters as indicated in Table 1and diagnostic gene sets of this invention include at least one genefrom each of at least two of gene clusters 1 through 15.

As used herein the term “gene cluster” or “cluster” refers to a group ofgenes related by expression pattern. In other words, a cluster of genesis a group of genes with similar regulation across different conditions,such as a patient having SLE or a patient without SLE. The expressionprofile for each gene in a cluster should be correlated with theexpression profile of at least one other gene in that cluster.Correlation may be evaluated using a variety of statistical methods.

As used herein the term “surrogate” refers to a gene with an expressionprofile such that is so highly correlated with gene expression ofanother gene that it can substitute for a diagnostic gene in adiagnostic assay. Such genes are typically members of the same genecluster as the diagnostic gene. For each member of a diagnostic geneset, a set of potential surrogates can be identified throughidentification of genes with similar expression patterns as describedbelow.

Many statistical analyses produce a correlation coefficient to describethe relatedness between two gene expression patterns. Patterns may beconsidered correlated if the correlation coefficient is greater than orequal to 0.8. In preferred embodiments, the correlation coefficientshould be greater than 0.85, 0.9 or 0.95. Other statistical methodsproduce a measure of mutual information to describe the relatednessbetween two gene expression patterns. Patterns may be consideredcorrelated if the normalized mutual information value is greater than orequal to 0.7. In preferred embodiments, the normalized mutualinformation value should be greater than 0.8, 0.9 or 0.95. Patterns mayalso be considered similar if they cluster closely upon hierarchicalclustering of gene expression data (Eisen et al. 1998). Similar patternsmay be those genes that are among the 1, 2, 5, 10, 20, 50 or 100 nearestneighbors in a hierarchical clustering or have a similarity score (Eisenet al. 1998) of >0.5, 0.7, 0.8, 0.9, 0.95 or 0.99. Similar patterns mayalso be identified as those genes found to be surrogates in aclassification tree by CART (Breiman et al. 1994).

Often, but not always, members of a gene cluster have similar biologicalfunctions in addition to similar gene expression patterns. For example,all genes in a particular cluster may be associated with a particularbiological pathway or cell type. Representative cell types associatedwith diagnostic genes of this invention include granulocytes, NK cells,red blood cells, and platelets. Is is expected that the expressionpattern of other genes in the same pathway or cell type will also bepart of the same cluster and may be useful as surrogates.

Correlated genes, clusters and surrogates are all useful as diagnosticgenes of the invention. These surrogates may be used as diagnostic genesin an assay instead of, or in addition to, the diagnostic genes forwhich they are surrogates.

Clusters also provide a means to ensure that the diagnostic gene sets donot contain redundant information. Diagnostic gene sets of the inventiontherefore preferably include genes from different clusters. For example,diagnostic gene sets of the invention preferably include at least onegene from at least two gene clusters.

Primer and Probe Sets

The invention further provides methods for producing diagnostic primersets or probe sets. It is understood that a probe includes any reagentcapable of specifically identifying genes in diagnostic setss, andinclude but are not limited to DNA, RNA, cDNA, splice variants, primers,probe sets, peptide nucleic acids, locked nucleic acids, amplicons,synthetic oligonucleotide, and partial or full-length nucleic acidsequences. In addition, the probe may identify the protein product of adiagnostic gene, and include, for example, antibodies and other affinityreagents. In some applications, a probe set may include one or moreoligonucleotide that detects the expression of one or more of theselected genes for the diagnostic set.

It is also understood that each probe can correspond to one gene, ormultiple probes can correspond to one gene, or both, or one probe cancorrespond to more than one gene.

In some embodiments, a diagnostic probe set is immobilized on an array.The array may be a chip array, a plate array, a bead array, a pin array,a membrane array, a solid surface array, a liquid array, anoligonucleotide array, a polynucleotide array or a cDNA array, amicrotiter plate, a pin array, a bead array, a membrane or a chip.

Obtaining DNA, RNA and Protein Samples for Detection of Expression

Gene expression can be evaluated at the level of DNA, or RNA or proteinproducts. A variety of techniques are available for the isolation ofDNA, RNA and protein from bodily fluids.

A variety of techniques are available for the isolation of RNA fromsamples. Any technique that allows isolation of mRNA from cells (in thepresence or absence of rRNA and tRNA) can be utilized. For example, bymeans of aspiration of body fluid, biopsy of a tissue or organ, drawingof peripheral blood, endoscopy, and lavage followed by aspiration, RNAcan be isolated from ascites, bile, blood, cerebronspinal fluid, lymph,sputum, and/or urine. By the same methods, RNA can also be isolated fromthe central nervous system, joints, kidneys, liver, lungs, oral cavity,sinuses, skin, and vasculature.

Methods for Obtaining Expression Data

Numerous methods for obtaining expression data are known, and any one ormore of these techniques, singly or in combination, are suitable fordetecting expression in the context of the present invention.

For example, expression patterns can be evaluated by northern analysis,PCR, RT-PCR, Taq Man analysis, FRET detection, monitoring one or moremolecular beacons, hybridization to an oligonucleotide array,hybridization to a cDNA array, hybridization to a polynucleotide array,hybridization to a liquid microarray, hybridization to a microelectricarray, cDNA sequencing, clone hybridization, cDNA fragmentfingerprinting, serial analysis of gene expression (SAGE), subtractivehybridization, differential display and/or differential screening (see,e.g., Lockhart and Winzeler (2000) Nature 405:827-836, and referencescited therein). Oligonucleotide hybridization may occur in solution oron substrates including, but not limited to magnetic or nonmagneticbeads, chips, fibers, filters, gels, membranes, microparticles, plates,polymers, slides, capillary tubing, and wafers with surface featuresselected from channels, columns, pins, pores, trenches, and wells.

It is understood that for detection of gene expression, variations inthe disclosed sequences will still permit detection of gene expression.The degree of sequence identity required to detect gene expressionvaries depending on the length of the oligomer. For a 60 mer, 6-8 randommutations or 6-8 random deletions in a 60 mer do not affect geneexpression detection. Hughes, T R, et al. “Expression profiling usingmicroarrays fabricated by an ink-jet oligonucleotide synthesizer. NatureBiotechnology, 19:343-347 (2001). As the length of the DNA sequence isincreased, the number of mutations or deletions permitted while stillallowing the detection of gene expression is increased.

Alternatively, expression at the level of protein products of geneexpression can be performed. For example, protein expression in adisease patient can be evaluated by one or more methods including, butnot limited to Western analysis, two-dimensional gel analysis,chromatographic separation, mass spectrometric detection, protein-fusionreporter constructs, calorimetric assays, binding to a protein array andcharacterization of polysomal mRNA. One particularly favored approachinvolves binding of labeled protein expression products to an array ofantibodies specific for members of the candidate library. Methods forproducing and evaluating antibodies are widespread in the art, see,e.g., Coligan, supra; and Harlow and Lane (1989) Antibodies: ALaboratory Manual, Cold Spring Harbor Press, NY (“Harlow and Lane”).Additional details regarding a variety of immunological and immunoassayprocedures adaptable to the present invention by selection of antibodyreagents specific for the products of candidate nucleotide sequences canbe found in, e.g., Stites and Terr (eds.)(1991) Basic and ClinicalImmunology, 7.sup.th ed., and Paul, supra. Another approach uses systemsfor performing desorption spectrometry. Commercially available systems,e.g., from Ciphergen Biosystems, Inc. (Fremont, Calif.) are particularlywell suited to quantitative analysis of protein expression. Indeed,Protein Chip® arrays (see, e.g., the website, ciphergen.com) used indesorption spectrometry approaches provide arrays for detection ofprotein expression. Alternatively, affinity reagents (e.g., antibodies,small molecules, etc.) are developed that recognize epitopes of theprotein product. Affinity assays are used in protein array assays, e.g.to detect the presence or absence of particular proteins. Alternatively,affinity reagents are used to detect expression using the methodsdescribed above. In the case of a protein that is expressed on the cellsurface of leukocytes, labeled affinity reagents are bound topopulations of leukocytes, and leukocytes expressing the protein areidentified and counted using fluorescent activated cell sorting (FACS).

Expression Profiles

Expression patterns, or profiles, of a plurality of genes correspondingto members of the diagnostic set are evaluated in one or more SLEpatients. These expression patterns constitute a set of relative orabsolute expression values for some number of RNA or protein productscorresponding to the plurality of genes evaluated, which is referred toherein as the subject's “expression profile” for those genes. Whileexpression patterns for as few as one independent member of thediagnostic set can be obtained, it is generally preferable to obtainexpression patterns corresponding to a larger number of genes, e.g.,about 2, about 5, about 10, about 20, about 50, about 100, about 200,about 500, or about 1000, or more. The expression pattern for eachdifferentially expressed component member of the set provides a finitespecificity and sensitivity with respect to predictive value, e.g., fordiagnosis, prognosis, monitoring, and the like.

Evaluation of Expression Data and Profiles

Expression profiles can be evaluated by qualitative and/or quantitativemeasures. Certain techniques for evaluating gene expression (as RNA orprotein products) yield data that are predominantly qualitative innature. That is, the methods detect differences in expression thatclassify expression into distinct modes without providing significantinformation regarding quantitative aspects of expression. For example, atechnique can be described as a qualitative technique if it detects thepresence or absence of expression of a diagnostic nucleotide sequence,i.e., an on/off pattern of expression. Alternatively, a qualitativetechnique measures the presence (and/or absence) of different alleles,or variants, of a gene product.

In contrast, some methods provide data that characterizes expression ina quantitative manner. That is, the methods relate expression on anumerical scale. It will be understood that the numerical, and symbolicexamples provided are arbitrary, and that any graduated scale (or anysymbolic representation of a graduated scale) can be employed in thecontext of the present invention to describe quantitative differences innucleotide sequence expression. Typically, such methods yieldinformation corresponding to a relative increase or decrease inexpression.

Any method that yields either quantitative or qualitative expressiondata is suitable for evaluating expression of diagnostic nucleotidesequence in a SLE subject or patient. In some cases, e.g., when multiplemethods are employed to determine expression patterns for a plurality ofdiagnostic nucleotide sequences, the recovered data, e.g., theexpression profile for the nucleotide sequences is a combination ofquantitative and qualitative data.

In some applications, expression of the plurality of diagnosticnucleotide sequences is evaluated sequentially. This is typically thecase for methods that can be characterized as low- tomoderate-throughput. In contrast, as the throughput of the elected assayincreases, expression for the plurality of diagnostic nucleotidesequences in a sample or multiple samples of SLE subjects or patients isassayed simultaneously. Again, the methods (and throughput) are largelydetermined by the individual practitioner, although, typically, it ispreferable to employ methods that permit rapid, e.g. automated orpartially automated, preparation and detection, on a scale that istime-efficient and cost-effective.

In one some embodiments, once expression levels for a diagnostic set ofgenes are determined, a diagnostic classifier (a mathematical functionthat assigns samples to diagnostic categories based on expression data)is applied to unknown sample expression levels in order to diagnose ormonitor the status of the SLE in a subject or patient.

The diagnostic classifier is typically derived from a predictionalgorithm derived from statistical methods including, but not limitedto, analysis of variance, classification algorithms, classification andregression trees, Fisher's Exact Test, linear algorithm. lineardiscriminatory analysis, linear regression, logistic algorithm, multipleregression, nearest shrunken centroids classifier, Pearson correlation,prediction algorithm, significance analysis of microarrays, one-tailedT-test, two tailed T-tests, voting algorithm, Wilcoxon's signed rankstest and the like.

Expression Reference Standards

In other embodiments, comparison of patient gene expression withreference profiles is used to evaluate expression data and to monitorthe status of SLE, to predict flare, and to assess treatment efficacy.

For example, expression profiles derived from a patient (i.e., subjectsdiagnosed with, or exhibiting symptoms of, or exhibiting a diseasecriterion, or under a doctor's care for a disease) sample are comparedto a control or standard expression RNA to facilitate comparison ofexpression profiles (e.g. of a set of candidate nucleotide sequences)from a group of patients relative to each other (i.e., from one patientin the group to other patients in the group, or to patients in anothergroup).

The reference RNA used should have desirable features of low cost andsimplicity of production on a large scale. Additionally, the referenceRNA should contain measurable amounts of as many of the genes of thecandidate library as possible.

For example, in one approach to identifying diagnostic gene sets andevaluating expression data, expression profiles derived from patientsamples are compared to an expression reference “standard.” Standardexpression reference can be derived from samples from at least onenormal subject and from at least one patient diagnosed with SLE andinclude but are not limited to a gene expression from one or morepatients with quiescent type 1 SLE, from one or more patients withquiescent type 2 SLE, from one or more patients with type 1 SLE showingincreased disease activity or flare, from one or more patients with type2 SLE showing increased disease activity or flare, from one or morepatients with type 1 SLE that had been treated with animmunosuppressant, from one or more patients with type 2 SLE that hadbeen treated with an immunosuppressant, from one or more patients withtype 1 SLE that had been treated with a therapeutic agent, and from oneor more patients with type 2 SLE that had been treated with atherapeutic agent.

Use of an expression reference standard is particularly useful when theexpression of large numbers of nucleotide sequences is assayed, e.g. inan array, and in certain other applications, e.g. qualitative PCR,RT-PCR, etc., where it is desirable to compare a sample profile to astandard profile, and/or when large numbers of expression profiles, e.g.a patient population, are to be compared. Generally, an expressionreference standard should be available in large quantities, should be agood substrate for amplification and labeling reactions, and should becapable of detecting a large percentage of candidate nucleic acids usingsuitable expression profiling technology.

Alternatively, the expression reference standard can be derived from anysubject or class of subjects including healthy subjects or subjectsdiagnosed with the same or a different disease or disease criterion.Expression profiles from subjects in two distinct classes are comparedto determine which subset of genes in the diagnostic set bestdistinguish between the two subject classes. It will be appreciated thatin the present context, the term “distinct classes” is relevant to atleast one distinguishable criterion relevant to a disease of interest, a“disease criterion.” The classes can, of course, demonstrate significantoverlap (or identity) with respect to other disease criteria, or withrespect to disease diagnoses, prognoses, or the like. The mode ofdiscovery involves, e.g., comparing the molecular signature of differentsubject classes to each other (such as patient to control, patients witha first diagnosis to patients with a second diagnosis, etc.) or bycomparing the molecular signatures of a single individual taken atdifferent time points. The invention can be applied to a broad range ofdiseases, disease criteria, conditions and other clinical and/orepidemiological questions, as further discussed above/below.

In some applications, when a single patient sample is obtained, it maystill be desirable to compare the expression profile of that sample tosome reference expression profile. In this case, one can determine thechange of expression between the patient's sample and a referenceexpression profile that is appropriate for that patient and the medicalcondition in question. For example, a reference expression profile canbe determined for all patients without the disease criterion in questionwho have similar characteristics, such as age, sex, race, diagnoses,etc.

Classification of SLE Patients into Longitudinally Stable Classes of SLE

In some embodiments, the invention provides methods for diagnosis of apatient as having a longitudinally stable classification of SLE bydetecting the expression of genes whose expression correlates with theexpression of IFI27. In some embodiments, the method is practiced aspart of a method to diagnose or monitor the status of SLE in a patient.

In preferred embodiments, a subject is classified into one of at leasttwo classes of SLE by detecting the expression of at least two geneswhose expression corrrelates with the expression of IFI27 from about 0.5to about 1.0 and from about −0.5 to about −1.0 calculated using Pearsoncorrelation and classifying the subject as having type I or type II SLEbased on the expression of these two genes. In preferred embodiments,the genes are provided in Table 2.

Pharmacogenomics

Pharmocogenomics is the study of the individual propensity to respond toa particular drug therapy (combination of therapies). In this context,response can mean whether a particular drug will work on a particularpatient, e.g. some patients respond to one drug but not to another drug.Response can also refer to the likelihood of successful treatment or theassessment of progress in treatment. Titration of drug therapy to aparticular patient is also included in this description, e.g. differentpatients can respond to different doses of a given medication. Thisaspect may be important when drugs with side-effects or interactionswith other drug therapies are contemplated.

Diagnostic gene sets are developed and validated for use in assessingwhether a patient will respond to a particular therapy and/or monitoringresponse of a patient to drug therapy (therapies). Disease criteriacorrespond to presence or absence of clinical symptoms or clinicalendpoints, presence of side-effects or interaction with other drug(s).The diagnostic nucleotide set may further include nucleotide sequencesthat are targets of drug treatment or markers of active disease.

Example 1 describes the SLE patients, criteria for their diagnosis, andcollection and characterization of blood and tissue samples from normalsubjects and patients in periods of quiescence and flare. Althoughanalyses determined that expression profiles contained a subset ofgenes, designated interferon response genes (INFr), whose expressiongenerally correlated with disease severity, but not with change inpatient status from quiescence to flare. Based on this fact, subject andpatient samples can be queried for expression of the subset of INFrgenes.

Example 2 describes the analysis of gene expression in samples from SLEpatients. Pearson correlation was used to identify 15 different, pathwayor cell-type specific, gene clusters that were differentially expressedin patient samples during periods of disease quiescence versus periodswhen that patient was converting from quiescence to flare. Theseclusters are also shown and described in Table 1. Column 1 shows thenumber of the cluster; column 2, the array ID; column 3, the GenBank ID;column 4, the gene ID; and column 5, a short description of the gene.

To diagnose and monitor the status of a subject or patient, a samplefrom the subject or patient is analyzed for differential expression ofat least one gene selected from each of at least two different geneclusters shown in Table 1. Comparison of patient gene expression withreference profiles can also serve to monitor the status of SLE, topredict flare, and to assess treatment efficacy.

Prediction algorithms were developed using gene expression representingquiescent (QQ) versus flare (QF) samples. Multiple regression analysiswas used to associate gene expression with flare, and linear regressionwas used to examine individual genes. In general, prediction algorithmswere trained using 90% of the samples; and cross-validated, using 10% ofsamples in 100 iterations as explained in Example 3. Predictionalgorithms can be also used to assess patient prognosis—presence orlikelihood of developing premature carotid atherosclerosis orprogressing to end-stage organ damage—and to monitor treatment of SLEpatients. Of particular interest are samples and expression profilesfrom patients who responded to a given steroid or immunosuppressanttreatment regime versus samples or profiles from those same patientswhere the medication stopped working or from different patients who didnot respond or were resistant to a specific medication or treatmentregime.

Gene expression was analyzed using at least one statistical methodselected from analysis of variance, classification algorithms,classification and regression trees, Fisher's Exact Test, linearalgorithm, linear discriminatory analysis, linear regression, logisticalgorithm, multiple regression, nearest shrunken centroids classifier,Pearson correlation, prediction algorithm, significance analysis ofmicroarrays, one-tailed T-tests, two-tailed T-tests, voting algorithm,Wilcoxon's signed ranks test and the like. One or more of these methodswere used to process and evaluate the normal and patient samples and tochoose those samples used as reference profiles.

Example 4 describes the classification of SLE patients into type 1 SLEand type 2 SLE is based on IFNr score. A linear algorithm was used inthe analysis of the expression of at least two INFr genes selected fromTable 2. Expression of IFI27 was chosen as the basis to which all ofother genes expressed in SLE were compared, and Table 2 shows the 190features (probes on a microarray) that represent those INFr genespositively correlated with IFI27 (cutoff of ≧0.5 or <−0.5 using Pearsoncorrelation). Column 1 of Table 2 shows the feature ID on the HumanGenome CGH 44A microarrays (Agilent Technologies, Palo Alto Calif.)array; column 2, the name of probe; column 3, symbol or identifier forthe gene; column 5, description of the gene; and column 6, correlationwith IFI27. For purposes of demonstration, IFI27 and the two other INFrgenes highlighted in Table 2 were used to develop an exemplaryalgorithm, IFI27+IFI144*(1.1296)+OAS3*(1.8136), that can be used toproduce an INFr score.

The analysis and validation of data from paired, longitudinal samples asdescribed in Example 4 are summarized in Table 3. Exemplary data isshown for the first 25 of 81 patients. The data shows lack ofcorrelation with SLEDAI and the stability of IFNr score in individualpatients during periods of quiescence and flare. Regardless of diseaseactivity or flare, a high INFr score classified a patient as having type1 SLE, a condition characterized by more severe SLE symptoms such asincreased organ involvement and dysfunction, low complement levels, andhigh titer of anti-double-stranded DNA (dsDNA) antibodies; and a lowINFr score classified a patient as having type 2 SLE which is generallycharacterized by less severe symptoms. It is contemplated that manycombinations of at least two INFr genes and algorithms developed usingthem can be used to classify SLE patients.

Examples 5-8 describe how normal and patient samples were purified andhandled. Examples 9-11 describe the nucleic acid technologies(microarray and polymerase chain reaction) used to detect geneexpression and produce gene expression patient and reference profiles.

Methods are presented for screening subjects for SLE, for classifying apatient already diagnosed with SLE as having type 1 SLE or type 2 SLE,for predicting disease activity or flare, for selecting an effectiveimmunosuppressant and/or therapeutic agent for treatment of SLE, and foridentifying subjects with SLE from subjects with other rheumaticdiseases.

Useful reference profiles were derived from samples from at least onenormal subject and from at least one patient diagnosed with SLE andinclude but are not limited to a gene expression from one or morepatients with quiescent type 1 SLE, from one or more patients withquiescent type 2 SLE, from one or more patients with type I SLE showingincreased disease activity or flare, from one or more patients with type2 SLE showing increased disease activity or flare, from one or morepatients with type I SLE that had been treated with animmunosuppressant, from one or more patients with type 2 SLE that hadbeen treated with an immunosuppressant, from one or more patients withtype 1 SLE that had been treated with a therapeutic agent, and from oneor more patients with type 2 SLE that had been treated with atherapeutic agent.

Reagents used to establish a gene expression profile include but are notlimited to:

1) genes and their splice variants, primers, probe sets, peptide nucleicacids, locked nucleic acids and amplicons that can be used in nucleicacid technologies including but not limited to hybridization on arraysand amplification using quantitative RT-PCR; and 2) proteins and theirfragments, antibodies, and affinity reagents that can be used in proteintechnologies including but not limited to protein or antibody arrays andenzyme-linked immunosorbent assays (ELISAs). These reagents can be usedin assays or diagnostic kits to screen subjects for SLE.

Assays or diagnostic kits based on the primers and probe sets asdescribed in Example 9 can be used with a sample from a subject withsymptoms of a rheumatic disease to diagnose, classify or rule out SLE;and with a sample from a patient diagnosed with type 1 SLE or type 2 SLEto select a clinical trial, to predict flare, to detectimmunosuppressant responsiveness, to determine efficacy of a therapeuticagent, to design treatment regimes, to monitor the status of the patientor treatment regime. In one alternative, the diagnostic kit includes anarray of nucleic acid molecules or antibodies; in another, thediagnostic kit includes probe sets for use in quantitative RT-PCR.

Pharmacogenomics is the study of an individual's response to aparticular therapeutic agent, immunosuppressant or combinations ofagents. In this context, response refers to whether a particular agentor drug will work better for a particular type 1 SLE or type 2 SLEpatient. The methods disclosed provide for assigning a patient to aclinical trial based on classification as type 1 SLE or type 2 SLE anddisease status (quiescent or flare).

Pharmacogenomics is also important in determining the dosage of atherapeutic agent based on classification and disease status of thepatient. It is contemplated that a patient diagnosed with type 1 SLEwill respond differently to a particular immunosuppressant ortherapeutic agent than a patient diagnosed with type 2 SLE. Individualresponse must also be taken into account relative to the side-effects orinteractions of various immunosuppressant or therapeutic agents. Somepotentially useful therapeutic agents and immunosuppressants are listedin the definitions and claims.

The present invention contains many preferred embodiments and includesmaterial from patents, patent applications and other publicationsincorporated by reference in their entirety for all purposes, butespecially for details in practicing the invention and known to those inthe art.

EXAMPLES Example 1 Characterization of Patients and Samples

Patients who met the American College of Rheumatology (ACR) criteria forthe diagnosis of SLE (malar rash, discoid rash, photosensitivity, oralulcers, arthritis, serositis, renal disorder, neurologic disorder,hematologic disorder, immunologic disorder, and antinuclear antibody)were identified (cf. Tan et al (1982) Arthritis Rheum 25:1271-7). Afterinstitutional review and approval, patients gave informed consent andwere included in the Lupus Disease Activity Monitoring and RiskStratification Archive Discovery Microarray Study. The samples andclinical data were available via the Autoimmune Biomarkers CollaborativeNetwork (ABCoN).

Blood and/or tissue samples and clinical data have been collected frompatients managed at Johns Hopkins Medical Center (JHMC) within theHopkins Lupus Cohort. In this cohort, all SLE patients have beenfollowed according to protocol with visits at a minimum of every 3months. The table below has self-explanatory columns that showdemographic information for the patients in the SLE cohort.

Number (% of total cohort) Age at Entry into cohort (yrs) <30 304 (32%) 30 to 49 511 (53%)  50+ 148 (15%) Female 888 (92%) Race White 529 (55%)Black 403 (42%) Other 31 (3%) Education <12 yrs 124 (14%) High School281 (31%) Some College 497 (55%) Years in cohort  0 191 (19%)  1 to 3409 (41%)  4+ 391 (40%) Number of cohort visits  1 78 (8%)  2 to 8 320(32%)  9 to 44 492 (50%)  45+ 101 (10%) Years with SLE prior to cohortentry  0 304 (31%)  1 to 4 325 (33%)  5+ 362 (36%)

As seen above, the cohort was more or less racially balanced, and itsindividuals represented a broad socioeconomic spectrum. The patientsamples and clinical data used in this investigation were from SLEpatients who had been in the cohort for more than one year. In total,these patients visited the clinic 1782 times (an average of 5.9quarterly visits for each patient). In the alternative, samples fortraining and validating prediction algorithms were obtained from theAutoimmune Disease Registry of the Hospital for Special Surgery (HSS;New York City N.Y.).

Clinical data were examined for each patient in order to select samplesfor use in training or validation studies. Whereas additional samplescan be added to the training set, a completely unique set must be usedfor validation. Both clinical and existing expression data were analyzedfor 81 of the first 100 patients in the cohort and a subset of thesepatients was used for the training study. For the training study, thefollowing classes of samples (Q=quiescent, F=flare) were defined asfollows:

QF1: primary QF quiescent sample that proceeds to flare within 150 daysNo prior flare within 60 day 1 primary pair per patient only SLEDAI ≧4QF4: second QF1 A second, unique QF1|F from the same patient QF4precedes a distinct F from the QF1 Can be combined with QF1 for analysisQF5: earliest baseline additional, earlier QF for a given QF1|F F: highcurrent disease activity SLEDAI increases ≧4 from previous visit PGA(Physician's Global Assessment) = rating of disease activity as high orincreasing QQ: primary quiescent and stable SLEDAI ≦4 and no flares innext 150 days or more

Sample Characteristics

The table below shows the comparison between the various classes. Columnone lists the QF, F and QQ classes as defined above; column two, thegroups within the class; column three, the number of patients in theclass or group; column four, the average (avg) days (da) to flare;column five, the median days to flare; column six, the average (avg)increase in SLEDAI; column seven, the median (med) increase in SLEDAI;column eight, the average increase in SLEDAI at flare; and column nine,the number of visits prior to flare.

Class Group No. Avg da to F Med da to F SLEDAI avg SLEDAI med F SLEDAIVisits to F QF 1 30 87 87 5.7 4 7.6 1.1 4 3 78 84 6.7 4 8 1 5 12 227 186F 37 7.7 QQ 34 357 340

Sample Matching

One of the most important class comparisons was QQ vs. QF. Molecularcharacterization of the samples that do not progress in disease activityor proceed to flare were particularly important for assessing risk andefficacy of treatment regime, determining prognosis, and the like. Atypical subset of patients was characterized in the table below. In thatthe patients have similar clinical data, their samples showed thatobserved difference in class was due to activation at the molecularlevel (measured by gene expression) and not due to observabledifferences. Column one shows class or T-test; column two, number ofpatients (No), column three, physician's global assessment (PGA); columnfour, SLEDAI score, column five, prednisone treatment (Pred); columnsix, percent of patients on immunosuppressant treatment (Immuno); columnseven, percent of patients on intravenous treatment (IVS); and columnseven, percent of the patients who are female.

No PGA SLEDAI Pred Immuno IVS % Female QF1 30 0.79 1.87 6.96 47% 17% 97QQ 34 0.58 1.65 5.33 44% 12% 88 T-test 0.14 0.60 0.41 0.84 0.58 0.22QF1 + 4 33 0.78 1.82 7.75 45% 45% 97% QQ 34 0.58 1.65 5.33 44% 12% 88%T-test 0.17 0.68 0.26 0.91 0.69 0.18

Although none of the clinical variables was statistically significantbetween classes, there was a slight trend towards more severe disease inthe QF group. It must be noted that this trend was not clinicallyrelevant; and as samples are added to the study, it is expected thateven this slight trend will disappear.

The normal control sample was a pooled blood sample taken from equalnumbers of male and female Expression Genetics employees. These donorswere healthy at the time the sample was collected, and none had obviousdisease symptoms or diagnosis of SLE or any other rheumatic disease.

Example 2 Analyses of Gene Expression Profiles of SLE PatientsProceeding to Flare

The basis for diagnosing and monitoring the status of SLE in patientsinvolved detecting differential gene expression between quiescence (QQ)and flare (QF) samples. K-means clustering of gene using GeneSpring GX7.3 were done with the following criteria Number of clusters 15, Numberof iterations 200, Similarity Measure Pearson Correlation and genes inwhich half of the samples did not have data were not used Genes shown inTable 1 were defined as those with a p-value≦0.05 and a fold change≧1.2. The genes were clustered to group genes which represented aparticular pathway or cell type. The table below shows the number of thecluster as presented in Table 1, the average Radius between the clustersand an all clusters average. Average Radius is calculated by the rootmean square of the Euclidean distances between each gene and thecentroid.

Cluster No Cell Type Average Radius 1 Granulocytes & B cells 5.15 2 NKcells 6.02 3 Granulocytes 7.23 4 Granulocytes 6.82 5 Platelet 6.31 6 AllCell Types 6.32 7 B cells 4.39 8 All Cell Types 6.85 9 B cells 5.88 10 All Cell Types 8.81 11  All Cell Types 8.34 12  All Cell Types 3.67 13 Red Blood Cells 6.87 14  Red Blood Cells 4.98 15  All Cell Types 2.19All Clusters Ave 5.99

The genes shown in Table 1 were used with the statistical methodsdescribed below to diagnose and monitor the status of SLE patients, topredict flare and to assess treatment efficacy.

The various analyses were carried out using classification andprediction algorithms, software and programs including, but not limitedto, analysis of variance, classification and regression trees (Briemanet al. (1984) Classification and Regression Trees, Wadsworth, BelmontCalif.), linear discriminatory analysis (Statsoft, Tulsa Okla.),multiple additive regression trees (Friedman (2002) Stanford University,Stanford Calif.), nearest shrunken centroids classifier (Tibshirani etal. (2002) PNAS 99:6567-6572), significance analysis of microarrays(Tusher et al. (2001) PNAS 98:5116-5121), one and two tailed T-tests,Wilcoxon's signed ranks test, and the like. The statistical analysesapplied to both array and PCR expression data were also described in theDetailed Description of the Invention and in Example 5 of U.S. Pat. No.6,905,827 incorporated by reference herein in its entirety.

In addition to expression data, any piece of clinical data collectedfrom patients can be used in a correlation or classification analysis.Continuous variables including but not limited to albumin,autoantibodies, hemoglobin or other measures of organ function thatcontribute to SLEDAI score can be used for correlation analysis. In somecases, the logarithm of the values was used for the analysis. When thesevariables were included in the analysis, they were treated as another“gene”. For example, samples from kidney biopsies can be used to divideSLE patients into groups with or without renal disease. From theanalyses of clinical manifestations carried out in this study anddifferences in clinical manifestations reported by others, it iscontemplated that categorical variables such gender, ethnicity andsocioeconomic status can also contribute to classification, predictionof flare, and selection or modulation of effective therapeutics.

Example 3 Prediction Algorithms

After all the expression and clinical data were placed in a relationaldatabase, these data were used to build prediction algorithms. Theprediction algorithms were applied to gene expression profiles from SLEpatients converting from quiescence to flare to identify sets ofdifferentially expressed genes for monitoring the status of SLE,specifically for predicting flare or disease activity and effectivetreatment regimes.

Once a set of genes and expression criteria for those genes have beenestablished for classification, cross-validation was done. Validation ofthe algorithm by these means yielded an estimate of the predictive valueof the algorithm on the target population. For example, a 10-foldcross-validation analysis excluded 10% of the training samples from theanalysis, and the classification algorithm was built with the remaining90%. The 10% of the samples that were initially excluded were then usedas a test set for the algorithm. The process was repeated 10 times with10% of the samples being used as a test set each time. Through thisanalysis, it was possible to derive a cross-validation error whichhelped estimate the robustness of the algorithm for use on previouslyuntested samples (i.e., samples that were not included in the traininganalysis). Untested samples came from the JHMC or HSS archives In thealternative, the samples can come from a new clinical study.

Example 4 Classification of Patients as Type 1 SLE and Type 2 SLE

Another step toward better monitoring the status of SLE patients was toclassify them as having either type 1 SLE or type 2 SLE. A number ofcomparisons of data in the relational database were made and validatedas described below.

Gene Expression Patterns

One of the comparisons of gene expression patterns was to analyze genesthat were differentially expressed between paired QF1 and F samples fromthe same patient taken from about two to about six months apart. Thefirst sample was from a time period when the patient's disease activitywas low (SLEDAI 0-4), but the second sample from the same patient showedincreased disease activity and a SLEDAI≧4. In this process, examinationof some of the genes known to be expressed in inflammation or immunedisorders showed nearly parallel expression patterns in pairedquiescent/flare (QF) and flare (F) patient. The expression of one ofthose genes, IFI27, is shown in FIG. 1.

The x-axis of FIG. 1 represents patient number and the y-axis, the Log₁₀expression ratio for IFI27, FIG. 1 demonstrates that IFI27 was notdifferentially expressed according to disease activity or flare. Furtherexamination of longitudinal data showed that expression of INFr genesplaced SLE patients into at least two different groups.

INFr score

The relational database of SLE data was searched for genes whoseexpression correlated with IFI27≧0.5 or ≦−0.5 using Pearson correlation;these designated INFr genes are listed in Table 2. Longitudinal datafrom an initial group of 81 patients covering a period of up to twoyears (including extra time points available in the QF4 and QF5 classes)was used to examine IFNr gene expression.

Although many different algorithms were contemplated, one exemplaryalgorithm was developed to demonstrate how to use three INFr genes tocalculate an IFNr score. The genes that encode IFI27, IFI44 and OAS3,highlighted in Table 2, were used to develop the algorithm. The INFrscore based on these three genes reflects the Log₁₀ ratio of patientsample expression over reference sample expression on the microarrayafter normalization using Feature Extraction v 7.5 software (AgilentTechnologies). The standard deviation for each gene was normalized sothat each of the genes would have the same influence on IFNr score. Theexemplary algorithm is: IFI27+IFI144*(1.1296)+OAS3*(1.8136).

The genes used to derive INFr score are described as follows: 1) IFI27(also known as ISG12 and p27) maps to chromosome 14q32, the location ofthe serine protease inhibitor gene cluster. IFI27 is induced by alphainterferon and localizes to the nuclear membrane. Since IFI27 isexpressed in breast, head and neck carcinomas, it has been used topredict patient sensitivity to cisplatin and paclitaxel; 2) IFI44 (alsoknown as MTAP44) is induced by α and β interferons, but not by γinterferon and aggregates to form microtubular-like structures inhepatitus-C infected cells; and 3) OAS3 maps to chromosome 12q24.2 andis an interferon-induced protein that catalyzes the synthesis of 2′-5′oligomers of adenosine.

Table 3 presents longitudinal data for patients with SLE. Column oneshows patient number; column two, ABCoN ID followed by sample number;column three, sample designated as quiescent (QF) or flare (F); columnfour, date sample taken; column five, SLEDAI score; column six, IFNrscore (high or low); column seven, days from first sample; and INFrscore. The cutoff for distinguishing between high IFNr and low IFNrscores was the average of all INFr scores. Table 3 demonstrated: 1)longitudinal stability of INFr score in an individual over time, 2) theexistence of at least two types of SLE as defined by high and lowexpression of IFNr genes, and 3) lack of correlation between SLEDAI andIFNr scores as shown for patients 2, 4, 6, 9, and 15.

The change from high to low INFr score or from high to low to high INFrscore as seen in the data for patients 10 and 13, respectively, werefurther analyzed. A Fisher's Exact Test was used to calculate a p-valuefor hypothesized random discordant results. The conversion of one highto low and one low to high produced the p-value=0.000034 that the eventshappened at random.

Another way to look at IFNr score was to compare normal control andfirst visit patient samples. In FIG. 2, all samples were sorted low tohigh and plotted according to INFr score. The normal subjects arepresented on the left side of the graph, and the 81 SLE (lupus) patientsare presented on the right.

The x-axis shows the number assigned each normal subject or SLE patient,and the y-axis shows INFr score where the scale is fold. As shown onthis graph, INFr scores varied by as much as 500-fold. Although theyappeared healthy at the time of sampling, three of the normal subjectshad slightly elevated IFNr scores that were attributed to infection,allergies, or other sub-acute, non-SLE conditions.

Since the INFr scores of the SLE patients appeared as a continuous slopein the graph above, the data was parsed. The graph for IFI27, IFI44, andOAS3 (FIG. 3) clearly showed the bimodal distribution of SLE patients(type 2 SLE to the left of zero and type I SLE to the right, on thex-axis) when number of samples was graphed against log₁₀ of theexpression ratio.

Similar graphs or histograms can be plotted for any of the other INFrgenes shown in Table 2, and any of these INFr genes can be used todevelop an algorithm to classify SLE patients as type 1 SLE or type 2SLE.

In further support of the stability of type 1 and type 2 SLEclassification, a Fisher's Exact Test was applied to the hypothesis, “Dothe highs stay high and the lows stay low?” The data presented in thetable below produces a p-value=8.01e-13 that further demonstrates thevalidity of the bimodal distribution and the presence of at least twogroups, type I SLE and type 2 SLE.

First First high low Second high 48 4 Second low 4 25

Although SLEDAI scores are on average higher in type 1 SLE patients (whogenerally show more severe symptoms), SLEDAI did not correlate with highor low INFr score. The clinical manifestations that did associate withtype 1 SLE included low serum complement levels, high anti-doublestranded DNA antibodies, and more renal disease.

Example 5 Harvesting and Preparation of Blood Samples

One or more of the methods and/or procedures below were used to preparesamples from SLE patients and normal control subjects. In the firstmethod, two tubes of blood were drawn from each patient or normalcontrol subject using either a peripheral venous blood draw or directlyfrom a large-bore intra-arterial or intravenous catheter inserted in thefemoral artery or vein, subclavian vein or internal jugular vein. Carewas taken to avoid sample contamination with heparin since it interfereswith RNA preparation.

In the second method, 8 ml of blood was drawn into a VACUTAINER CPT tube(BD Biosciences (BD), San Jose Calif.) containing the anticoagulantsodium citrate, Ficoll Hypaque density fluid, and a thixotropicpolyester gel barrier permeable upon centrifugation to red blood cells(RBCs) and granulocytes but not to mononuclear cells. The blood wasmixed with the anticoagulant in the tube by inverting the tube 5-10times. Then, mononuclear cells and plasma were separated using thefollowing procedures.

In one procedure, the mononuclear cells and plasma moved to the top ofthe tube while the RBCs and the granulocytes were trapped beneath thegel barrier when the tube was centrifuged in a swinging bucket rotor at1750×g for 20 min at room temperature. After, the mononuclear cells andplasma were decanted into a 15 ml tube, 5 nil of phosphate-bufferedsaline (PBS) were added. The tubes was inverted 5 times and centrifugedfor 5 min at 1750×g to pellet the cells; the supernatant was discarded.

In a second procedure, the clear plasma layer that formed above themononuclear cell layer during centrifugation was aspirated anddiscarded. Then the mononuclear cell layer was aspirated, and all of themononuclear cells were washed from the surface of the gel barrier withPBS. Approximately 2 mls of mononuclear cell suspension were transferredto a microcentrifuge tube and centrifuged in a microcentrifuge for 3 minat 16,000 rpm to pellet the cells; the supernatant was discarded.

Following each of the methods and/or procedures above, 1.8 ml of RLTlysis buffer (Qiagen, Chatsworth Calif.) was added to the pellet, thecells and lysis buffer were pipetted up and down to ensure completelysis. Cell lysate was frozen and stored at −80° C. until total RNA wasisolated.

Example 6 RNA Preparation

RNA was prepared from the RNA samples from SLE patients or normalcontrols using one of the following protocols. In the first protocol: 1)samples were thawed, 2) 4 ml of chloroform were added to each tube, 3)tubes were vortexed prior to centrifugation at 2000×g for 5 min, and 5)the aqueous layer was moved to new tube and processed using the RNeasyMaxi kit (Qiagen) according to the manufacturer's instructions. RNAquality was assessed using spectrophotometry, A260/A280spectrophotometric ratios were considered to be acceptable when theyranged between 1.6 and 2.0, and/or gel electrophoresis, when 2 μl ofeach sample were run on an agarose gel in the presence of ethidiumbromide and no degradation of RNA and no DNA contamination were visible.

In the second protocol: 1) samples were thawed and held at roomtemperature for 5 min, 2) after adding 5 ml of chloroform, the sampleswere vortexed and incubated at room temperature for 3 min, 3) theaqueous layer was transferred to a new 50 ml tube and purified using theRNeasy Maxi kit (Qiagen), and 4) the columns were eluted twice with 1 mlRNAse free water and incubated for one min before each spin. RNAsisolated using the first and second protocols were combined when thenormal control cell preparations demonstrated reproducibility. The RNAswere mixed in a 50 ml tube, aliquoted into two 15 ml storage or 1.5 mlmicrocentrifuge tubes (100 μl per), and stored at −80° C.

In the third protocol: total RNA was purified using the RNeasy Miniprepkit (Qiagen) according to the protocol provided. Cells were homogenizedand DNAse treated on a QIASHREDDER columns (Qiagen) and purified RNA waseluted in 50 μl of water.

After the last two protocols, RNA using the Agilent 2100 bioanalyzer andRNA 6000 microfluidics chips (Agilent Technologies).

Example 7 cDNA Synthesis

cDNA was synthesized from RNA using reverse transcription with OLIGO-dTprimers/random hexamers (Invitrogen, Carlsbad Calif.) at a finalconcentration of 0.5 ng/μl and 3 ng/μl, respectively.

For the first strand reaction, 0.5 μg of mononuclear RNA or 2 μg ofwhole blood RNA and 1 μl of the OLIGO-dT/random hexamers (Invitrogen)were added to water in a reaction tube to a final volume of 11.5 μl. Thetube was incubated at 70° C. for 10 min, chilled on ice, centrifuged,and 88.5 μl of first strand buffer mix (Invitrogen) was added to thetube.

The first strand buffer mix contained 1×first strand buffer, 10 mM DTT(Invitrogen), 0.5 mM dATP (New England Biolabs (NEB), Beverly Mass.),0.5 mM dGTP (NEB), 0.5 mM dTTP (NEB), 0.5 mM dCTP (NEB), 200 U ofSUPERSCRIPT RNAse H reverse transcriptase (Invitrogen), and 18 U ofRNAGUARD inhibitor (GE Healthcare (GEH), Piscataway N.J.). After thereaction was incubated at 42° C. for 90 min, the enzyme washeat-inactivated at 70° C. for 15 min. After adding 2 U of RNAse H (NEB)to the reaction tube, it was incubated at 37° C. for 20 min.

For second strand synthesis, 40 U of E. coli DNA polymerase (Invitrogen)and 2 U RNaseH (Invitrogen) were added to the previous reaction to bringthe final volume to 150 μl Salts and nucleotides were added to a finalconcentration of 20 mM Tris-HCl (pH 7.0; Fisher Scientific, PittsburghPa.), 90 mM KCl (Teknova, Half Moon Bay Calif.), 4.6 mM MgCl₂ (Teknova),10 mM (NH₄)₂SO₄ (Fisher Scientific), 1×second strand buffer(Invitrogen), 0.266 mM dGTP, 0.266 mM dATP, 0.266 mM dTTP, and 0.266 mMdCTP.

After second strand synthesis for 150 min at 16° C., the cDNA waspurified away from the enzymes, dNTPs, and buffers usingphenol-chloroform extraction followed by ethanol precipitation in thepresence of glycogen. Alternatively, the cDNA was purified on a QIAQUICKsilica-gel column (Qiagen) followed by ethanol precipitation in thepresence of glycogen. The cDNA was centrifuged at >10,000×g for 30 min;and after the supernatant was aspirated, the pellet was washed with 150μl of 70% ethanol. Following recentrifugation, the supernatant wasremoved, and residual ethanol was evaporated at room temperature.Alternatively, the volume of column purified cDNA was reduced in avacuum evaporator to 7.4 μl.

Example 8 Arrays

Arrays were used to produce a gene expression profile for diagnosing andmonitoring the status of SLE in a patient. In one format, the arraycontains reagents specific for at least two genes or proteins, one thatbinds to a gene or protein of the invention, and one that binds to acontrol gene or protein.

Nucleic Acid Arrays

Human Genome CGH 44A microarrays (Agilent Technologies) were used todetermine differential gene expression. These Cy₃/Cy₅ chips contained41,675 probes (60-mers) that represented most the genes found in REFSEQdatabase (NCBI); additional genes on the chip represented variouscontrols. The chips were run as recommended by the manufacturer andscanned using an Agilent DNA microarray scanner. The data was extractedusing Feature Extraction v 7.5 software (Agilent Technologies).

In the alternative, Affymetrix U133A Human GeneChips (Affymetrix, SantaClara Calif.) with probe sets representing about 14,500 full lengthgenes and 22,000 features were used according to the manuals and productinserts supplied by the manufacturer. Affymetrix Microarray Suite (MAS)v 5.0 software was used to generate expression values for each gene. Tocorrect for slight differences in overall chip hybridization intensityand allow for comparison between samples, each chip was scaled to anoverall intensity of 1500.

In one alternative, the PAXgene Blood RNA system (PreAnalytix GmbH,Hombrechtikon Switzerland) was used for whole blood collection,stabilization, and RNA isolation from patient and/or normal samples.Five μg of total RNA was used to prepare biotinylated cRNA forhybridization using a standard protocol (Expression Analysis TechnicalManual, Affymetrix). For samples with low RNA yields, two or more roundsof amplification were performed. Fifteen micrograms of each labeled cRNAwas hybridized to Affymetrix U133A Human GeneChips.

In another alternative, a low density array containing ampliconsproduced using probe sets for genes selected from Table 1 and Table 2are harvested from PCR reactions, purified using Sephacryl-400 beads(GEH) and arrayed on a membrane. The membrane is UV irradiated, washedin 0.2% SDS at room temperature and rinsed three times in distilledwater, Non-specific binding sites on the array are blocked by incubationin 0.2% casein in PBS for 30 min at 60° C., and the arrays are washed in0.2% SDS and rinsed in distilled water.

In another alternative, purified amplicons are robotically arranged andimmobilized on polymer-coated glass slides using the procedure describedin U.S. Pat. No. 5,807,522 (which is hereby incorporated in itsentirety). Polymer-coated slides are prepared by cleaning glassmicroscope slides (Corning Life Sciences, Corning N.Y.) ultrasonicallyin 0.1% SDS and acetone, etching in 4% hydrofluoric acid (VWR ScientificProducts, West Chester Pa.), coating with 0.05% aminopropyl silane(Sigma-Aldrich) in 95% ethanol, and curing in a 110° C. oven. The slidesare washed extensively with distilled water between and aftertreatments.

Antibody Arrays

Monoclonal antibodies specific to at least two IFNr proteins and atleast two proteins selected from the clusters of Table 1 are immobilizedon a membrane, slide or dipstick or added to the wells of an ELISA plateusing methods well known in the art. The array is incubated in thepresence of serum or cell lysate until protein:antibody complexes areformed. The proteins encoded by genes or their splice variants areidentified by the known position and labeling of the antibody that bindsan epitope of that protein on the array. Quantification is normalizedusing the antibody:protein complex of various controls.

Example 9 Designing and Selecting Primers and Probe Sets

Primers and probe sets were designed and selected for each gene havingutility in the diagnosis and monitoring of SLE using the PRIMER3 program(Whitehead Research Institute (WRI), Cambridge Mass.). Default valueswere used for all parameters but melting temperature (Tm). Tm was setbetween 71.7 and 73.7° C.; amplicon size, between 50 and 150 bases inlength (optimum, about 100 bases); and primers or probes were allowed tobe 36 nucleotides in length. Salt concentration, a critical parameteraffecting the Tm of the probes and primers, was used at the defaultconcentration, 50 mM.

The C source code for the PRIMER3 program was downloaded from the WRIwebsite and complied on a Sun Enterprise 250 server (Sun Microsystems,Palo Alto Calif.) using the GCC compiler (Free Software Foundation,Boston Mass.). A subsequent version was compiled for machines runningthe Windows operating system (Microsoft, Redmond Wash.). The program wasrun from the command line which also dictated the use of an input filethat contained the sequences and the parameters for primer design asdescribed in the help files that accompanied the software. A script waswritten to input a number of sequences and automatically generate anumber of potential primers. The following batch approach was used todesign primers for the genes.

The first step in designing primers was to mask out repetitive sequencesin the mRNA using the REPEATMASKER program (Institute for SystemsBiology, University of Washington, Seattle Wash.). The second step wasto mask out all known SNPs for the genes as annotated in the SNPdatabase at NCBI (Bethesda Md.) that have an allelic heterozygosityhigher than 1%. The masked sequence was submitted to PRIMER3 usingparameters as outlined above, and the top eight sequences were selected.Alternatively, the Primer3 program was used on the MIT website(Massachusetts Institute of Technology, Cambridge Mass.) to examine aspecific region on the mRNA of a particular gene. The final step was totest several of the top pairs of primers for correct size andefficiency.

Primers were ordered from Integrated DNA Technologies (Coralville Iowa)or an alternative commercial source.

Example 10 Testing of Primers and Probe Sets for RT-PCR

Control genes: With both microarrays and RT-PCR, variation was monitoredby adding one or more genes from bacteria, plants, or animals in one ormore wells. Although human β-actin and β-GUS were used to validate thecontrol RNAs, several other genes were also tested for variabilitybetween samples, for expression in mononuclear and whole blood RNA fromcontrol subjects and SLE patients, on samples prepared using variousprotocols, and in the RT-PCR assays.

Based on criteria of low variability between control and patient samplesand high expression across samples, β-actin, β-GUS, 18s ribosomalsubunit, GAPDH, and β2-microglobulin were selected as the control genesand used in the various assays.

Primer Testing: Primers were tested once using RT-PCR protocol (withoutRox and Sybr green dyes) to see whether they produced an amplicon of thecorrect size without amplifying non-specific sequences. Each primerpair/probe set was tested on cDNA made from mononuclear cell control RNAdescribed in Example 2. The PCR reaction contained 1×RealTime-PCR buffer(Ambion, Austin Tex.), 2 mM MgCl₂ (ABI), 0.2 mM dATP (NEB), 0.2 mM dTTP(NEB), 0.2 mM dCTP (NEB), 0.2 mM dGTP (NEB), 0.625 U AMPLITAQ Goldenzyme (ABI), 0.3 μM of each primer to be used (Sigma Genosys, TheWoodlands Tex.), 5 μl of the reverse transcription reaction, and wateradded to a final volume of 19 μl.

Following 40 cycles of PCR, 101 of each product were combined with SybrGreen dye at a final dilution of 1:72,000. Melt curves for each PCRproduct were determined on a PRISM 7900HT Sequence detection system(ABI), and primer pairs yielding a product with one clean peak werechosen for further analysis. One μl of product from each probe set assaywas examined by agarose gel electrophoresis or using a DNA 1000 chip kitand an Agilent 2100 bioanalyzer (Agilent Technologies). From primerdesign and the genomic sequence, the expected size of the amplicon wasknown. Only primer pairs showing amplification of the single desiredproduct, and minimal amplification of contaminants, were used in assays.

Primers were tested a second time to determine their efficiency in anRT-PCR reactions. cDNA was synthesized as described above. A set of 5serial dilutions of cDNA in water: 1:10, 1:20, 1:40, 1:80, and 1:160 wastested using RT-PCR.

Example 11 RT-PCR Assays and Analysis

TAQMAN: PCR reactions were performed using the TAQMAN Universal PCRMaster mix (ABI). The master mix was aliquoted into light tight tubes,one for each gene. The primer pair for each gene was added to the tubeof PCR master mix labeled for that gene. A FAM/TAMRA dual labeled TAQMANprobe (Biosearch Technologies, Novato Calif.) was added to each tube.Alternatively, different combinations of commercially availablefluorescent reporter dyes and quenchers were used such that theabsorption wavelength for the quencher matches the emission wavelengthfor the reporter.

In one alternative, a Sybr green RT-PCR reaction can be performed usingthe TAQMAN PCR reagent kit (ABI). In the alternative, UniversalProbeLibrary (LNAs; Roche Diagnostics, Pleasanton Calif.), weresubstituted for Taqman probes.

RT-PCR Assays and Analysis: 18 μl of master mix were dispensed into eachwell of a 384 well plate (ABI), and 2 μl of the template sample weredispensed into triplicate wells for each primer pair. The finalconcentration of each reagent was: 1×TAQMAN Universal PCR Master Mix,300 nM each primer, 0.25 nM TAQMAN probe, and 21 μl of 1:10 dilutedtemplate. PCR reactions were run on the PRISM 7900HT Sequence Detectionsystem (ABI) with the following conditions: 10 min at 95° C.; 40 cyclesof 95° C. for 15 sec, 60° C. for 1 min.

Sequence detection system v2.0 software (ABI) was used to analyze thefluorescent signal from each reaction. Standard deviation (Stdev) andcoefficient of variation (CV) were calculated for triplicate wells. Ifthe CV was greater than 2, an outlier among the three wells wasidentified and deleted; and the average was recalculated. In each plate,the difference in CT (ΔCT) was calculated for each gene and controlcombination by subtracting the average CT of the gene from the averageCT of the control. The expression relative to the control was calculatedby taking two to the power of the ΔCT of the gene.

In each case, all plates were run in duplicate and analyzed in the samemanner. The percent variation was determined for each sample and genecombination (relative expression, RE) by taking the absolute value ofthe RE for the second plate from the RE for the first plate, anddividing that by the average. If more than a quarter of the variationcalculations on a plate were greater than 50%, then a third plate wasrun. The cycle number at which each amplification curve crossed CT wasrecorded, and the file was transferred to MS Excel for further analysis.CT values for triplicate wells were averaged, and data were plotted as afunction of the log₁₀ of the calculated starting concentration of RNA.The starting RNA concentration for each cDNA dilution was determinedbased on the original amount of RNA used in the reverse transcriptionreaction, the dilution of the reverse transcription reaction, and theamount used in the RT-PCR reaction (usually 5 μl). For each gene, alinear regression line was plotted through all points of the dilutionseries. The slope of the line was used to calculate efficiency of thereaction for each primer set using the equation, E=10^((−1/slope))−1.This efficiency equation was used to compare the expression of primersor probe sets for each gene, and a primer pair was considered successfulif the efficiency was reproducibly determined to be 0.85-1.2.

Since variation of RT-PCR assays can arise from unequal amounts of RNAstarting material, probe sets for control genes can be run in the samereaction as the probe set for the diagnostic gene to reduce variation.Different fluorescent dyes were used to amplify the control,differentiating their expression from that of the diagnostic gene.

Quantitative RT-PCR: RT-PCR was used to compare the expression of eachgene using the primers described above. cDNA was synthesized from normalcontrol, patient, and reference samples. Ten μl RT-PCR reactions wereperformed using a PRISM 7900 Sequence Detection system (ABI) usingFAM-TAMRA labeled probes and the standard TAQMAN protocols describedabove. RT-PCR amplification product was measured as CT (thresholdcycle=the point at which an amplification curve crosses a thresholdfluorescence value) during the PCR reaction to observe amplificationbefore any reagent became rate limiting. Threshold was set to a pointwhere all of the reactions were in their linear phase of amplification.A lower CT indicated a higher amount of starting material (greaterexpression in the sample) since an earlier cycle number meant thethreshold was crossed more quickly. A CT of less than 30 based onappropriate cDNA dilutions provided linear results for the blood samplesfrom SLE patients.

In the alternative, other labeling moieties or technologies can be usedto measure amplification product in RT-PCR. Molecular beacons(Invitrogen) use FRET technology, and fluorescence is measured when ahairpin structure is relaxed by the specific probe binding to theamplicon.

Other labeling moieties can be used for detection of an antibody,nucleic acid or protein in any of the assays or diagnostic kitsdescribed herein. These labeling moieties include fluorescent,chemiluminescent, or chromogenic agents, cofactors, enzymes, inhibitors,magnetic particles, radionuclides, reporters/quenchers, substrates andthe like that can be attached to or incorporated into the antibody,nucleic acid or protein. Visible labels and dyes include but are notlimited to anthocyanins, avidin-biotin, β glucuronidase, biotin,BIODIPY, Coomassie blue, Cy3 and Cy5, 4,6-diamidino-2-phenylindole(DAPI), digoxigenin, ethidium bromide, FAM/TAMRA, FITC, fluorescein,gold, green fluorescent protein, horseradish peroxidase, lissamine,luciferase, phycoerythrin, reporter/quencher pairs (HEX/TAMRA,JOE/TAMRA, ROX/BHQ2, TAMRA/BHQ2, TET/BHQ1, VIC/BHQ1, and the like),rhodamine, spyro red, silver, streptavidin, and the like. Radioactivemarkers include radioactive forms of hydrogen, iodine, phosphorous,sulfur, and the like.

Example 12 Protein Expression

Adapter sequences for subcloning are added at either end of a codingregion specific to a gene or a portion thereof and amplified using PCR.An epitope or affinity tag (6×his) or sequences for secretion from acell can be added to the adapter sequence to facilitate purificationand/or detection of the protein. The amplified cDNA is inserted into ashuttle or expression vector that can replicate in bacteria, insect,yeast, plant, or mammalian cells. Such vectors typically contain apromoter that operably links to the coding region, replication startsites, and antibiotic resistance or metabolite selection sequences.

The expression vector can be used in an in vitro translation system orto transfect cells. For example, Spodoptera frugiperda (Sf9) insectcells are infected with recombinant Autographica californica nuclearpolyhedrosis virus (baculovirus). The polyhedrin gene is replaced withthe cDNA by homologous recombination, and the polyhedrin promoter drivestranscription. The protein is synthesized as a fusion protein with anaffinity tag that enables purification.

Clones of transformed cells are analyzed to ensure that the insertedsequence is expressed. Once expression is verified, the cells are grownunder selective conditions; and the protein is isolated from cells, orif secreted, from the growth media using chromatography, size exclusionchromatography, immunoaffinity chromatography, or other methodsincluding cell fractionation, ion exchange, or selective precipitation.

The isolated and purified protein is then used as a reagent on an arrayor as an antigen to produce specific antibodies.

Example 13 Antibody Production and Testing

If antibodies are to be used as reagents, the sequence of the gene orsplice variant is analyzed to determine regions of high immunogenicity(LASERGENE software; DNASTAR, Madison Wis.), and an appropriateoligopeptide is synthesized and conjugated to keyhole lympet hemocyanin(KLH; Sigma-Aldrich, St Louis Mo.).

Immunization

Rabbits are injected with the oligopeptide-KLH complexes in completeFreund's adjuvant, and the resulting antisera is tested for specificrecognition of the protein or fragments thereof. Antisera that reactpositively with the protein are affinity purified on a column containingbeaded agarose resin to which the synthetic oligopeptide has beenconjugated (SULFOLINK kit; Pierce Chemical, Rockford Ill.). The columnis equilibrated using 12 ml IMMUNOPURE Gentle Binding buffer (PierceChemical). Three ml of rabbit antisera is combined with one ml ofbinding buffer and poured into the column. The column is capped (on thetop and bottom), and antisera is allowed to bind with the oligopeptideby gentle shaking at room temperature for 30 min. The column is allowedto settle for 30 min, drained by gravity flow, and washed with 16 mlbinding buffer (4×4 ml additions of buffer). The antibody is eluted inone ml fractions with IMMUNOPURE Gentle Elution buffer (PierceChemical), and absorbance at 280 nm is determined. Peak fractions arepooled and dialyzed against 50 mM Tris, pH 7.4, 100 mM NaCl, and 10%glycerol. After dialysis, the concentration of the purified antibody isdetermined using the BCA assay (Pierce Chemical), aliquoted, and frozen.

Electrophoresis and Blotting

Samples containing protein are mixed in 2×loading buffer, heated to 95°C. for 3-5 min, and loaded on 4-12% NUPAGE Bis-Tris precast gel(Invitrogen). Unless indicated, equal amounts of total protein areloaded into each well. The gel is electrophoresed in 1×MES or MOPSrunning buffer (Invitrogen) at 200 V for approximately 45 min on anXCELL II apparatus (Invitrogen) until the RAINBOW marker (GEH) resolvesand the dye front approaches the bottom of the gel. The gel is soaked in1×transfer buffer (Invitrogen) with 10% methanol for a few minutes; anda PVDF membrane (Millipore, Billerica Mass.) is soaked in 100% methanolfor a few seconds to activate it. The membrane, the gel, and supportsare placed on the TRANSBLOT SD transfer apparatus (Biorad, HerculesCalif.) and a constant current of 350 mA is applied for 90 min.

Conjugation with Antibody and Visualization

After the proteins are transferred to the membrane, it is blocked in 5%(w/v) non-fat dry milk in 1×phosphate buffered saline (PBS) with 0.1%Tween 20 detergent (blocking buffer) on a rotary shaker for at least 1hr at room temperature or at 4° C. overnight. After blocking, the bufferis removed, and 10 ml of primary antibody in blocking buffer is addedand incubated on the rotary shaker for 1 hr at room temperature orovernight at 4° C. The membrane is washed 3 times for 10 min each withPBS-Tween (PBST), and secondary antibody, conjugated to horseradishperoxidase, is added at a 1:3000 dilution in 10 ml blocking buffer. Themembrane and solution are shaken for 30 min at room temperature andwashed three times for 10 min with PBST.

The wash solution is carefully removed, and the membrane is moistenedwith ECL+chemiluminescent detection system (GEH) and incubated forapproximately 5 min. The membrane, protein side down, is placed on x-rayfilm (Eastman Kodak, Rochester N.Y.) and developed for approximately 30seconds. Antibody:protein complexes are visualized and/or scanned andquantified.

TABLE 1 Ratio cell type Clus- to all ter cells cell Type Array IDGenbank ID Gene ID Description Sequence 1 Granulocytes and B cells 1A_23_P113258 NM_005739 RASGRP1 Homo sapiens RAS guanyl releasing protein1 AGAAGAAAATAGAATCCCTCCAGCTTGAAAAA (calcium and DAG-regulated)(RASGRP1), mRNA AGCAATCATGTCTTAGCTCAAATGGAGC (SEQ ID NO: 1) 1A_23_P117599 NM_012111 AHSA1 Homo sapiens AHA1, activator of heat shockATTAGTGTGAGCCTTGCCAAAGATGAGCCTGA 90 kDa protein ATPase homolog 1 (yeast)CACAAATCTCGTGGCCTTAATGAAGGAA (SEQ (AHSA1), mRNA ID NO: 2) 1 A_23_P128230NM_002135 NR4A1 Homo sapiens nuclear receptor subfamily 4, groupAATGACAGATTCTGACATTTATATTTGTGTATTT A, member 1 (NR4A1), transcriptvariant 1, mRNA TCCTGGATTTATAGTATGTGACTTTT (SEQ ID NO: 3) 1 A_23_P134078NM_004824 CDYL Homo sapiens chromodomain protein, Y-likeAGGTACAGATACCTCAGATTCGGGAAACTCAA (CDYL), transcript variant 1, mRNAAATCAAAAGACTTAGCTTCTAGGATAAA (SEQ ID NO: 4) 1 A_23_P251686 NM_005160ADRBK2 Homo sapiens adrenergic, beta, receptor kinase 2GTCAAAATGGGTTAACTGTGTATATTGACTTTC (ADRBK2), mRNAATGTCGTCATGCATCTGTCATGAATGA (SEQ ID NO: 5) 1 A_23_P43580 NM_007018 CEP1Homo sapiens centrosomal protein 1 (CEP1),AACCTAGAAGGAGAATTGGAAAGCTTGAAAGA mRNA GAACCTTCCATTTACCATGAATGAGGGA (SEQID NO: 6) 1 A_23_P46781 NM_003638 ITGA8 Homo sapiens integrin, alpha 8(ITGA8), mRNA CCCATTATGGGTAATAATACTAGCAATACTTCTTGGATTGTTGGTTCTCGCCATTTTAAC (SEQ ID NO: 7) 1 A_23_P54170 NM_005466 MED6Homo sapiens mediator of RNA polymerase IIAGGCACCAGACTTGGGATCAGTTATAAACTCT transcription, subunit 6 homolog(yeast) (MED6), AGAGTGCTTACTGCAGTGCATGGTATTC (SEQ mRNA ID NO: 8) 1A_23_P64689 NM_014871 USP52 Homo sapiens ubiquitin specific peptidase 52CCAGATGGAAAGTAATTGGTATTCTTAATATCC (USP52), mRNATGGGTGACTAATATCCAGGCAGAGAAG (SEQ ID NO: 9) 1 3 Granulocyte A_24_P115932NM_004778 GPR44 Homo sapiens G protein-coupled receptor 44TGGATGAAATGTCAGTGGAAGAAGCAGATGAG (GPR44), mRNAAAACTCTTGAGATCTTGGTCCTGTGTTT (SEQ ID NO: 10) 1 A_24_P227585 NM_018559KIAA1704 Homo sapiens KIAA1704 (KIAA1704), mRNATGATGACACATCTGGAGATCGATCAATCTGGA CAGATACTCCAGCTGATAGGGAAAGGAA (SEQ IDNO: 11) 1 A_24_P229658 GAAGGGCGTAGTCACAGAACTCGAAGTAGGAGCCGAGATAAATCCCATAGGCATAAAAAA (SEQ ID NO: 12) 1 A_24_P312692 NM_006595API5 Homo sapiens apoptosis inhibitor 5 (API5), mRNATTGCTATTCAAATCAACTGCCTGAATGACATTT CTAGTAGTCTGATGTATTTTTCTGAGG (SEQ IDNO: 13) 1 A_24_P341489 AC003043 Homo sapiens chromosome 17, cloneATCTGAAGTCTGTCCAGGAACTCATTTTGAAAC HRPC1067M6, complete sequence.ATGGACAAGCCAAGATAAGGAATAAGA (SEQ ID NO: 14) 1 3 B cells A_24_P359165AC026250 Homo sapiens chromosome 11, clone RP11-TGGATAATTGAAGCCAGTGGTTTTTTAACCAAT 540A21, complete sequence.GTTATGTATCAGAATCACCTCACAAAG (SEQ ID NO: 15) 1 A_24_P4426 NM_014937INPP5F Homo sapiens inositol polyphosphate-5-TCTCATTTGATCCTAATTTTCCCCGTATTCTAC phosphatase F (INPP5F), transcriptvariant 1, TTGAACACATTAAAAATACTCTGCTGC (SEQ ID mRNA NO: 16) 1 A_24_P8140AK124166 Homo sapiens cDNA FLJ42172 fis, cloneAGCTACTTAGGGTGAGCCTGCCTTCTTCCATT THYMU2029676.CTATCCGAAGTCTCTTCTAAAGTTGCGG (SEQ ID NO: 17) 1 A_24_P861009 NM_001007246BRWD1 Homo sapiens bromodomain and WD repeatAGTCACAGATCCTACGTATGTGCTCTTCAGTA domain containing 1 (BRWD1), transcriptvariant GAGGATTTTCTGTGATCCTACAATGAAG (SEQ 3, mRNA ID NO: 18) 1A_24_P865672 AC018347 Homo sapiens chromosome 15 clone RP11-AAAGCACCGGTGAAGAAATCTATAAAGATGCT 410F2, complete sequence.CCAGCCGAAAATGCACAGAAGTCAAATC (SEQ ID NO: 19) 1 A_32_P90551 NM_014230SRP68 Homo sapiens signal recognition particle 68 kDaGACTTACATCAAGCTGTCAATGGCAATCAAGC (SRP68), mRNAGTAATGAGAGCATGGCCAAAGGTCTGCA (SEQ ID NO: 20) 1 A_32_P98683 AC006449 Homosapiens chromosome 17, clone TGAGGGGTGCCTTCATTCCCCTTTGTTCACTThCIT.58_E_17, complete sequence. TCTCCAGCTCAACTTGGGACTTGGGTGG (SEQ IDNO: 21) 2 NK cells 2 A_23_P10025 NM_006159 NELL2 Homo sapiens NEL-like 2(chicken) (NELL2), ACATCACCATGTAGAAGAATGGGCGTACAGTA mRNATATACCGTGACATCCTGAACCCTGGATA (SEQ ID NO: 22) 2 A_23_P103765 NM_002001FCER1A Homo sapiens Fc fragment of IgE, high affinity I,AGCTCCGCGTGAGAAGTACTGGCTACAATTTT receptor for, alpha polypeptide(FCER1A), mRNA TTATCCCATTGTTGGTGGTGATTCTGTT (SEQ ID NO: 23) 2A_23_P103775 NM_032270 LRRC8C Homo sapiens leucine rich repeatcontaining 8 AAACTCTGAAGATTGGAAAAAACAGCCTATCT family, member C (LRRC8C),mRNA GTACTTTCACCGAAAATTGGAAATTTGC (SEQ ID NO: 24) 2 A_23_P107283NM_002145 HOXB2 Homo sapiens homeo box B2 (HOXB2), mRNAATTAAACTCTAGGGGGACTTTCTTAAAAATAAC TAGAGGGACCTATTTTCCTCTTTTTTA (SEQ IDNO: 25) 2 A_23_P117662 NM_002112 HDC Homo sapiens histidinedecarboxylase (HDC), CCGAGGGTAGACAGGCAGCTTCTGTGGTTCA mRNAGCTTGTGACATGATATATAACACAGAAAT (SEQ ID NO: 26) 2 A_23_P119418 NM_003796C19orf2 Homo sapiens chromosome 19 open readingTCGCAAATCCATCCTGAAGTCTCGAAGTAGAG frame 2 (C19orf2), transcript variant1, mRNA AGAATAGTGTGTGTAGCGACACTAGTGA (SEQ ID NO: 27) 2 A_23_P12572NM_001227 CASP7 Homo sapiens caspase 7, apoptosis-relatedAGTTCTATAAGTGAGGAAGAGTTTATGGCAAA cysteine peptidase (CASP7), transcriptvariant GATTTTTGGGACTTTGTTTTCAAGATGG (SEQ alpha, mRNA ID NO: 28) 2A_23_P126057 NM_001007099 SCP2 Homo sapiens sterol carrier protein 2(SCP2), ACATTGGCAAATAGCGTGGGATAGATTTGTTT transcript variant 3, mRNACTTAATGGGTGTGACCAATCCTGTTTTT (SEQ ID NO: 29) 2 A_23_P127676 NM_014633CTR9 Homo sapiens SH2 domain binding protein 1TAAACCCAGATGCTAAATCATTCCTACAAAGGT (tetratricopeptide repeat containing)(SH2BP1), TTGACTGAAACTGTGGCAGATGTCTCA (SEQ mRNA ID NO: 30) 2A_23_P129128 NM_152334 TARSL2 Homo sapiens threonyl-tRNA synthetase-like2 TGACCCTTAAAAATGTATTTTTCTTAACATGTTA (TARSL2), mRNAGTACTTCTACGACTTTGGAGCCACTG (SEQ ID NO: 31) 2 A_23_P133543 NM_017415KLHL3 Homo sapiens kelch-like 3 (Drosophila) (KLHL3),TGGCTGTTAGGGACTGTATATCTTGTAAAAGA mRNA ACACTTGTCACATGCTTGATCAGTTACA (SEQID NO: 32) 2 A_23_P135857 NM_004836 EIF2AK3 Homo sapiens eukaryotictranslation initiation CCTCCAATAAAGGGAAAATGAAGCTTTTTATGT factor 2-alphakinase 3 (EIF2AK3), mRNA AAATTGGTTGAAAGGTCTAGTTTTGGG (SEQ ID NO: 33) 2A_23_P14543 NM_006020 ALKBH Homo sapiens alkB, alkylation repairTTGGCTGTAATGTATGTTGAGAAGTCAGTCCA homolog (E. coli)AGGAGGTATGTTCTTCCACAACAGCCTT (SEQ (ALKBH), mRNA ID NO: 34) 2 A_23_P14804NM_005724 TSPAN3 Homo sapiens tetraspanin 3 (TSPAN3), transcriptGGCTTTATAGGAGGAGTATAATGTATGCACTA variant 1, mRNACTGTTTTAAAAGAATTAGTGTGAGTGTG (SEQ ID NO: 35) 2 A_23_P152353 NM_133451KIAA1970 Homo sapiens KIAA1970 protein (KIAA1970),TGGCCAATCTTGTCTGAGTTCTTTGATGGCGA mRNA CACATGAACTACAGCCGTTTTGTTGTTG (SEQID NO: 36) 2 A_23_P200015 NM_012093 AK5 Homo sapiens adenylate kinase 5(AK5), transcript AATGCAGAGGGAACACCAGAGGACGTTTTTCT variant 2, mRNATCAACTCTGCACAGCTATTGACTCTATT (SEQ ID NO: 37) 2 A_23_P208477 NM_001419ELAVL1 Homo sapiens ELAV (embryonic lethal, abnormalGGAGGCGTAAAATGGCTCTGTATTTTAATAAC vision, Drosophila)-like 1 (Hu antigenR) ACAGAAACATTTGAGCATTGTATTTCTC (SEQ (ELAVL1), mRNA ID NO: 38) 2A_23_P213045 NM_016269 LEF1 Homo sapiens lymphoid enhancer-bindingfactor 1 AGCAGGAGCCAAAAAGACCTCACATTAAGAAG (LEF1), mRNACCTCTGAATGCTTTTATGTTATACATGA (SEQ ID NO: 39) 2 A_23_P214882 NM_019041MTRF1L Homo sapiens mitochondrial translational releaseCATAAAGTCAAAAAATCCTAAAACATAAGTTGG factor 1-like (MTRF1L), mRNATGACCATCTGTAATCATGATGTGGTGG (SEQ ID NO: 40) 2 A_23_P215566 NM_001621 AHRHomo sapiens aryl hydrocarbon receptor (AHR),AATGGCTTCGGACAAAATATCTCTGAGTTCTGT mRNA GTATTTTCAGTCAAAACTTTAAACCTG (SEQID NO: 41) 2 A_23_P215956 NM_002467 MYC Homo sapiens v-mycmyelocytomatosis viral TTCAAATGCATGATCAAATGCAACCTCACAACC oncogenehomolog (avian) (MYC), mRNA TTGGCTGAGTCTTGAGACTGAAAGATT (SEQ ID NO: 42)2 A_23_P217187 HS333E23 Human DNA sequence from clone RP3-333E23 onTTTTTCTAACAGGCAAGACAGTGTGAAGAATT chromosome Xq21.1 Contains the P2RY10gene GAAGCAATATGTGCATAAATTTCAGGAC (SEQ for purinergic receptor P2YG-protein coupled 10, ID NO: 43) complete sequence. 2 A_23_P25566NM_004951 EBI2 Homo sapiens Epstein-Barr virus induced gene 2CTGAAACGGCAAGTCAGTGTATCGATTTCTAG (lymphocyte-specific G protein-coupledreceptor) TGCTGTGAAGTCAGCCCCTGAAGAAAAT (SEQ (EBI2), mRNA ID NO: 44) 2 3NK A_23_P302018 NM_003328 TXK Homo sapiens TXK tyrosine kinase (TXK),mRNA GCTGAGAGTGCTTCCTTCTTGAAGACGAGTGT CATTCATCACTTCAGTGATCCATGCATA (SEQID NO: 45) 2 A_23_P31376 NM_018334 LRRN3 Homo sapiens leucine richrepeat neuronal 3 GCCTCTCTCCAGAAATGAACTGTGATGGTGGA (LRRN3), mRNACACAGCTATGTGAGGAATTACTTACAGA (SEQ ID NO: 46) 2 A_23_P33643 XM_937367IL7R PREDICTED: Homo sapiens interleukin 7 receptorGCAATGAGTGAACTGACTGTGGCTACATTCTT (IL7R), mRNAGAAGATATACGGGAGAGACGTATTATTA (SEQ ID NO: 47) 2 A_23_P338919 NM_005876APEG1 Homo sapiens aortic preferentially expressed geneGCAGGGGGCCACTGTAGTGAGCGTGGAGAAA 1 (APEG1), mRNATTTGGAAACACCTATTTCTTAACTCAAAT (SEQ ID NO: 48) 2 A_23_P343398 NM_001838CCR7 Homo sapiens chemokine (C-C motif) receptor 7AAGAGAGCAACATTTTACCCACACACAGATAA (CCR7), mRNAAGTTTTCCCTTGAGGAAACAACAGCTTT (SEQ ID NO: 49) 2 A_23_P345460 NM_015432PLEKHG4 Homo sapiens pleckstrin homology domainGACTTGATGCCTTTTGAATAACTTTCAATAGAA containing, family G (with RhoGefdomain) TTGTCTAAAATTATCTTACTGGTTGTT (SEQ ID member 4 (PLEKHG4), mRNA NO:50) 2 A_23_P354151 NM_005546 ITK Homo sapiens IL2-inducible T-cellkinase (ITK), TTGAACACTTCATGAGGAGGGACATTCCCTGA mRNATATAAGAGAGGATGGTGTTGCAATTGGC (SEQ ID NO: 51) 2 A_23_P384085 NM_014635GCC2 Homo sapiens GRIP and coiled-coil domainTCTCTTAAGCCTTCAGTTTATACTCTTAATTTAA containing 2 (GCC2), transcriptvariant 2, mRNA TTTTCTTTCTGAGCTGGAGAACTGGC (SEQ ID NO: 52) 2A_23_P404481 NM_001400 EDG1 Homo sapiens endothelial differentiation,GCTGAGGCCAAAGTTTCCATGTAAGCGGGATC sphingolipid G-protein-coupledreceptor, 1 CGTTTTTTGGAATTTGGTTGAAGTCACT (SEQ (EDG1), mRNA ID NO: 53) 2A_23_P436117 NM_018200 HMG20A Homo sapiens high-mobility group 20A(HMG20A), CACTTGACAGTGACTTGAAACATTTGCATATTC mRNAAGGAATGCATGAGATTTCAAGAGAGCC (SEQ ID NO: 54) 2 A_23_P45726 NM_005826HNRPR Homo sapiens heterogeneous nuclearGGGATAGATTACATAGGAGTATGGAGTATGCT ribonucleoprotein R (HNRPR), mRNAGTAAATAAAAATACAAGCTAGTGCTTTG (SEQ ID NO: 55) 2 A_23_P55682 NM_023926ZNF447 Homo sapiens zinc finger protein 447 (ZNF447),GCAAGTGGTCACCAGCATTACACAGCAATGAA mRNA GCAGAATAAAGTAGGCCAGAATGCATCA (SEQID NO: 56) 2 A_23_P68198 NM_015677 SH3YL1 Homo sapiens SH3 domaincontaining, Ysc84-like TGGAGACAGAATCACAGTTATATCAAAAACAG 1 (S.cerevisiae) (SH3YL1), mRNA ATTCACATTTTGATTGGTGGGAAGGAAA (SEQ ID NO: 57)2 A_23_P78268 NM_016080 C17orf25 Homo sapiens chromosome 17 open readingTAATCCCGACAGAACATCATGTGAGATTTCTTT frame 25 (C17orf25), mRNAAAAATGGATTAAACGATTTCTTCAGCC (SEQ ID NO: 58) 2 A_23_P83931 NM_005863 NET1Homo sapiens neuroepithelial cell transformingTCTTTGAAAGGGGGGAGGAGGAGTAAAAGCC gene 1 (NET1), mRNACGATTATAATGGTGATCAATTCAAGTCAG (SEQ ID NO: 59) 2 A_23_P91991 NM_138381MGC15763 Homo sapiens hypothetical protein BC008322ATGTACCCAAAGAACACATTTGCTTTGAGAAGT (MGC15763), mRNAGGTGGTAGGAGGCAGACAAAGGCAGAA (SEQ ID NO: 60) 2 A_23_P94889 AC103817 Homosapiens chromosome 8, clone CTD- TAAGTTTTGTAAAAAGGAGCATCTTGAATCCAC3083F21, complete sequence. TTAGATAAAGACAGACTGTGTGTGTAG (SEQ ID NO: 61)2 A_24_P108291 NM_018439 IMPACT Homo sapiens Impact homolog (mouse)AGAGCCTTTCTGAAGAGAATTATATCAAACTAA (IMPACT), mRNATTACAACCAAGAAATAATAGTATGAAG (SEQ ID NO: 62) 2 A_24_P117528 NM_002765PRPS2 mRNA CAAGGCCTAAAGCCAACTGACTTAAAGGTAAT CATTTCAGCTAAGATTAAATTTAAAGCC(SEQ ID NO: 63) 2 A_24_P12521 NM_138811 C7orf31 Homo sapiens chromosome7 open reading frame GGTGCACAAAAGCGTTTCCATAAATCAATTCTA 31 (C7orf31),mRNA GAAGACCATAAAGACCTCAGGGATAAT (SEQ ID NO: 64) 2 A_24_P136438NM_014915 ANKRD26 Homo sapiens ankyrin repeat domain 26ATGTTGATGAAGTGCACAAAAATAATAGAAGTG (ANKRD26), mRNAATATGATGTCCGCATTAGGATTAGGAC (SEQ ID NO: 65) 2 A_24_P157424 NM_007362NCBP2 Homo sapiens nuclear cap binding protein subunitCCCGTTAAACTGAGTGTAGAAATCTGAATTTTT 2, 20 kDA (NCBP2), mRNAAAAAGAGCTGTAACTAGTTGTAAGTGC (SEQ ID NO: 66) 2 A_24_P16361ACCAAAAAATTCATGAGAGATCCAATTAATTCT GGTGAAAAAGGATTGACCCTTGAAGGA (SEQ IDNO: 67) 2 A_24_P170103 AACGACAACAGAAAAACAATCTTATTCCAAGTCATTCCAGTAACTTTTTTGGGTACGTAC (SEQ ID NO: 68) 2 A_24_P170186 AL589796Human DNA sequence from clone RP13-469O16ATGCACAAAAGTCAAATCAGAATGGAGACTCA on chromosome 6 Contains anucleophosmin AAACCATCAAAGCTAAGATCAAAAGGTC (SEQ (nucleolarphosphoprotein B23, numatrin) ID NO: 69) (NPM1)(B23, NPM) pseudogene anda CpG island, complete sequence. 2 A_24_P202555 NM_015073 SIPA1L3 Homosapiens signal-induced proliferation- TGCAAAAACAGATCTATTTAATTTGAGGTTGATassociated 1 like 3 (SIPA1L3), mRNA GTTCTATCCAATGGCCGAAGATAGCAG (SEQ IDNO: 70) 2 A_24_P208345 NM_033102 SLC45A3 Homo sapiens solute carrierfamily 45, member 3 GTGCCGTTTGCAATAATGTCGTCTTATTTATTT (SLC45A3), mRNAAGCGGGGTGAATATTTTATACTGTAAG (SEQ ID NO: 71) 2 A_24_P212596 AC019288 Homosapiens chromosome 15, clone RP11- TTTTCAACAGTACAGAAAAATTGAAAAAAGGGG139F4, complete sequence. CTTTGCCTTTGTAACCTTTGATGACCA (SEQ ID NO: 72) 2A_24_P218970 NM_001417 EIF4B Homo sapiens eukaryotic translationinitiation TTTTTAAGCTTCCCTTGAGAGAATAAATGGTAA factor 4B (EIF4B), mRNATGGAGAGAACTATTTAACAAGGTCCTG (SEQ ID NO: 73) 2 A_24_P234921 NM_004367CCR6 Homo sapiens chemokine (C-C motif) receptor 6AAGCTTTAACTATATCTCTCTTTAAAATGCAAAA (CCR6), transcript variant 1, mRNATAATGTCTTAAGATTCAAAGTCTGTA (SEQ ID NO: 74) 2 A_24_P251381 NM_024782 XLFHomo sapiens XRCC4-like factor (XLF), mRNAACCTTGAAAGAAGCTTACATGGCAGCAATATTT CTAAAATAGTGATACAGTCAGAGGCCT (SEQ IDNO: 75) 2 A_24_P26073 NM_133259 LRPPRC Homo sapiens leucine-richPPR-motif containing AGAGAAAGATGTCACATCTGCTAAAGCACTGT (LRPPRC), mRNAATGAACATTTGACTGCAAAGAATACAAA (SEQ ID NO: 76) 2 A_24_P299911 NM_015148PASK Homo sapiens PAS domain containing ATCTTGCTGACTATACATGGGAAGAGGTGTTTserine/threonine kinase (PASK), mRNA CGAGTAAACAAGCCAGAAAGTGGAGAGTTC (SEQID NO: 77) 2 A_24_P302506 AL355145 Human DNA sequence from cloneRP5-831G13 AATTGGAGAATTGAATAATCAGCATATGTAAGC on chromosome 1GCACTAGAACCCTGTGTTGAAAACTGC (SEQ ID NO: 78) 2 A_24_P307384 XM_927265LOC643288 PREDICTED: Homo sapiens similar to 60 kDaCTAGTGAATATGAAAAGGAAAAACTGAATGAA heat shock protein, mitochondrialprecursor CTGGCAAAACTTTCAGATGGAGTAGCTG (SEQ (Hsp60) (60 kDa chaperonin)(CPN60) (Heat ID NO: 79) shock protein 60) (HSP-60) (Mitochondrialmatrix protein P1) (P60 lymphocyte protein) (HuCHA60) (LOC643288), mRNA2 A_24_P354451 AC104825 Homo sapiens BAC clone RP11-774O3 from 4,CATAACCTTATTAATTTGCACATAGATCATCTG complete sequence.AATGTCGTGGTTTAAGACTTAAGGAGG (SEQ ID NO: 80) 2 A_24_P366465GGATAAGATTGTCATTCAGAAATACCATCCTAA TGGCTACAACTTTGAAGTAAGAAAAGC (SEQ IDNO: 81) 2 A_24_P382113 NM_006107 CROP Homo sapiens cisplatinresistance-associated GCAGAGTGAAGACACAAACACTGAATCGAAGG overexpressedprotein (CROP), transcript variant AAAGTGATACTAAGAATGAGGTCAATGG (SEQ 2,mRNA ID NO: 82) 2 A_24_P385341 NM_014388 C1orf107 Homo sapienschromosome 1 open reading frame TTTCTATGAACTGCCGACATATCCACACTTTTA 107(C1orf107), mRNA CAGTGAAATCTGTAATATGCTGAGAGC (SEQ ID NO: 83) 2A_24_P388528 NM_003032 ST6GAL1 Homo sapiens ST6 beta-galactosamidealpha-2,6- ATGCAAATTATGATATGGACGTTATCATTGGTC sialytransferase 1(ST6GAL1), TGGTGAGATGTTTCATATTTGTGACAG (SEQ ID transcript variant 2,mRNA NO: 84) 2 A_24_P393838 NM_014765 TOMM20 Homo sapiens translocase ofouter mitochondrial CTAGCTGTGTCGAGTTAAGAAAAAATCAGCA membrane 20 homolog(yeast) (TOMM20), mRNA GTTTTTTCTCCCAGAAATGTAATTGCCA (SEQ ID NO: 85) 2A_24_P402690 NM_001012514 ITM2C Homo sapiens integral membrane protein2C ACTCTTAAATGCTTTGTATATTTTCTCAATTAGA (ITM2C), transcript variant 3,mRNA TCTCTTTTCAGAAGTGTCTATAGAAC (SEQ ID NO: 86) 2 A_24_P419300 AC010442Homo sapiens chromosome 5 clone CTD-2228K2,TTACAGAGTTCAATATACTGTGTACCATTGATC complete sequence.TTCTATTGTGAAAGCAAAGAATTTCAT (SEQ ID NO: 87) 2 A_24_P472455 HSM801157Homo sapiens mRNA; cDNA DKFZp564M0264 ACCCTCATGTTAAATCTTAAATGTAGTATTTCT(from clone DKFZp564M0264). AACTTGTGAAGACAGATTGGTAGGCAG (SEQ ID NO: 88)2 A_24_P4877 NM_033114 ZCRB1 Homo sapiens zinc finger CCHC-type and RNAGAAAAATTAATACTATCATGTTAATACTATTATT binding motif 1 (ZCRB1), mRNAGTCATCCCAAGAAAAAAGATATTTTA (SEQ ID NO: 89) 2 A_24_P542375 NM_002823 PTMAHomo sapiens prothymosin, alpha (gene sequenceACTATAAGTAGTTGGTTTGTATGAGATGGTTAA 28) (PTMA), mRNAAAAGGCCAAAGATAAAAGGTTTCTTTT (SEQ ID NO: 90) 2 A_24_P579826 AC090419 Homosapiens chromosome 17, clone CTD- GAAGAAAAGTATAAGAGTTGCTAGGTGTGACA2107B16, complete sequence. ATCTCAAGACTTTTCAACCACTACAAAT (SEQ ID NO: 91)2 A_24_P59239 CATCATCAACACCAAAAAAGGACAAGAATCCTTCAAAACAGGAAAAAACTCCTAAAACAC (SEQ ID NO: 92) 2 A_24_P595460 AK097398 Homosapiens cDNA FLJ40079 fis, clone AAATTGTATGTGATATTCCAACAGCAAGTTGGATESTI2001498, highly similar to DNA-BINDING TGCAATGTGTCATAAAAATGACCTCAG(SEQ ID PROTEIN NEFA PRECURSOR. NO: 93) 2 A_24_P6725 NM_001010914LOC400986 Homo sapiens protein immuno-reactive with anti-AATCTGGGACAGTGTCTCCTCAGAAACAATCA PTH polyclonal antibodies (LOC400986),mRNA GCCTGGAAGGTTATATTTAAAAAGAAAG (SEQ ID NO: 94) 2 A_24_P686992NM_001010914 LOC400986 Homo sapiens protein immuno-reactive with anti-TCCAGGAAAAGTGTCTTCTCAGAAACAACCAG PTH polyclonal antibodies (LOC400986),mRNA CTGAGAAGGCTACAAGTGACGACAAAGA (SEQ ID NO: 95) 2 A_24_P736638NM_002156 HSPD1 K (LOC646447), mRNA GTTGAGAAAATTATGCAAAGTTCCTCAGAAGTTGGTTATGATACTATGTTAGGAGATGTC (SEQ ID NO: 96) 2 A_24_P808100 AC011890 Homosapiens PAC clone RP4-655L22 from Xq23,TAAAAGTCAGGTTGCAGTTTCCATTGCATTCAA complete sequence.GAAAATCAGAAAAATAAATACAACTTT (SEQ ID NO: 97) 2 A_24_P82142 NM_003205TCF12 Homo sapiens transcription factor 12TCAGGATGATTCCTAACAAGTCAGTCATTTGTG (HTF4, helix-loop-helix transcriptionfactors 4) AACTTAGTGGACTTTTTGGTTACTTTA (SEQ ID (TCF12), transcriptvariant 3, mRNA NO: 98) 2 A_24_P832113 NM_001004419 CLEC2D Homo sapiensC-type lectin domain family 2, CTTTGAAATAACACCACCAGTAGTCTTACGGTT memberD (CLEC2D), transcript variant 2, mRNA GAAGTGTGGTTCAGGGCCAGTGCATAT (SEQID NO: 99) 2 A_24_P883109 AC073089 Homo sapiens BAC clone RP11-324F21from 7, GGGCAACTAGTCATCTACTAGTTAGCTTAGTA complete sequence.AGCTAAGCATTAAATCTAAGAAATAGCA (SEQ ID NO: 100) 2 A_24_P927189 NM_138381OXNAD1 oxidoreductase NAD-binding domain containing 1AGTGTGTTGTCGTTATTAATTTGCTATTCCTTG TCCTATTCAGAAAGGATTTCAAGAGGC (SEQ IDNO: 101) 2 A_24_P930963 AC009041 Homo sapiens chromosome 16 clone RP11-GCCCCATTTCAAGTATAACCAGGAGGGAAAAT 161M6, complete sequence.GGTGCTTGAAATAAGCATGCCACAAAGG (SEQ ID NO: 102) 2 A_24_P941188 XM_375697OTUD3 PREDICTED: Homo sapiens OTU domainCCACGGATTGTGTTCATCTGAACCATTTTATTT containing 3 (OTUD3), mRNATTTATTTACCAAAGTACTGTACTTGGC (SEQ ID NO: 103) 2 A_24_P943263 NM_006989RASA4 Homo sapiens RAS p21 protein activator 4TCCTGCATAGTCTATCTTTGTATATCTTTGAAC (RASA4), mRNATTTTCAAGAATAAAAAAGCTTAAAAAG (SEQ ID NO: 104) 2 A_32_P119604 AC090948Homo sapiens chromosome 3 clone RP11-415F23CAGAACTCTACTTCAGCAGACACTCAACTCAA map 3p, complete sequence.AAAGACTGGCAAATGGACATGTATTTAC (SEQ ID NO: 105) 2 A_32_P133213 AC006480Homo sapiens BAC clone RP11-166O4 from 7,TCAAGAGAGATCCTAAAGAAAGCAAAATCACT complete sequence.GTGGACTGAAATGAGCAGACAAGGTTTT (SEQ ID NO: 106) 2 A_32_P149492 XM_496391NBPF9 PREDICTED: Homo sapiens neuroblastomaTTCTGGATTGTTTTTTACATTCAGTGTTATAATA breakpoint family, member 9,transcript variant 1 TTTGATTATGCTGATTGGTTTTGGTG (SEQ ID (NBPF9), mRNANO: 107) 2 A_32_P155506 NM_152653 UBE2E2 Homo sapiensubiquitin-conjugating enzyme E2E 2 TGCAAACAATGTTGGAGCTGTAATAGTAAGAG(UBC4/5 homolog, yeast) (UBE2E2), mRNA CTTTCTTACAAAGCTTTGTATTACTGTG (SEQID NO: 108) 2 A_32_P159787 NM_005520 HNRPH1 Homo sapiens heterogeneousnuclear AAATAAAAGCATGTCTTTCAACATGCATCCAAA ribonucleoprotein H1 (H)(HNRPH1), mRNA ACAGTGTTCAATTTAACGTGGCAAAGG (SEQ ID NO: 109) 2A_32_P162306 NM_001004419 CLEC2D Homo sapiens C-type lectin domainfamily 2, GCTGACAAAGATGATCACTTTAAGGTGGATAA member D (CLEC2D), transcriptvariant 2, mRNA TGATGAAAATGAGCACCAGTTATCTTTA (SEQ ID NO: 110) 2A_32_P181548 AC087407 Homo sapiens 3 BAC CTC-269B10 (CalTechATATTCTTCCAATATGTAGGGGAAAAGACATAT Clone Library C) complete sequence.GAATAAGACAAATGAAAAATTGCATAT (SEQ ID NO: 111) 2 A_32_P187009 AC010260Homo sapiens chromosome 5 clone CTC-458l2,ATTCACATGAGTAAAATGATGGAAGAACTCTTT complete sequence.AAGGTAATCCTTTGGGATAAAGGATCC (SEQ ID NO: 112) 2 A_32_P193646 NM_002139RBMX Homo sapiens RNA binding motif protein, X-linkedGACTTGTACTGGTGTTGTAACTTTCCAAGTAAA (RBMX), mRNAAGTATCCCTAAAGGCCACTTCCTATCT (SEQ ID NO: 113) 2 A_32_P217510 NM_032168WDR75 Homo sapiens WD repeat domain 75 (WDR75),TTACCGAAAAAGTCCAGGATACAAGTAACACA mRNA GGTTTAGGAGAAGACATTATACATCAGT (SEQID NO: 114) 2 A_32_P225604 NM_000969 RPL5 Homo sapiens ribosomal proteinL5 (RPL5), AAGCACTTCATGGGCCAGAATGTTGCAGATTA mRNACATGCGCTACTTAATGGAAGAAGATGAC (SEQ ID NO: 115) 2 A_32_P34149 NM_005520HNRPH1 Homo sapiens heterogeneous nuclearTGAAGACTTAAGGCCCAGTATTTTTTAATAGAA ribonucleoprotein H1 (H) (HNRPH1),mRNA TACTCATCTAGGATGTAACAGTGAAGC (SEQ ID NO: 116) 2 A_32_P49423NM_002520 NPM1 Homo sapiens nucleophosmin (nucleolarAAACAGGAAAAAACTCCTAAAACACCTAAAAG phosphoprotein B23, numatrin) (NPM1),transcript GACCTAGTTCTGTAGAAGACATTAAAGC (SEQ variant 1, mRNA ID NO: 117)2 A_32_P63013 HUMYY74A12 Homo sapiens full length insert cDNA cloneCCCGGGAGTGTTGCAAGTTAAACTGATGAAAA YY74A12. GACGTTTAGTATTTAATTGCTCCTCATG(SEQ ID NO: 118) 2 A_32_P80068 NM_001004419 CLEC2D Homo sapiens C-typelectin domain family 2, TGAACTGCACATTGTTGAAGCAGAGGCCATGA member D(CLEC2D), transcript variant 2, mRNA ATTACGAAGGCAGTCCAATTAAAGTAAC (SEQID NO: 119) 3 Granulocytes 3 A_23_P11926 XR_001410 FLJ21272 PREDICTED:Homo sapiens hypothetical protein ATCTTCCTAATCTCGTGGGATCACAATATGAATFLJ21272 (FLJ21272), misc RNA AACAAGGATGAACATAAGACACATCTG (SEQ ID NO:120) 3 A_23_P135769 NM_001101 ACTB Homo sapiens actin, beta (ACTB), mRNATTTAAAAACTGGAACGGTGAAGGTGACAGCAG TCGGTTGGAGCGAGCATCCCCCAAAGTT (SEQ IDNO: 121) 3 A_23_P19590 NM_003379 VIL2 Homo sapiens villin 2 (ezrin)(VIL2), mRNA GATTATTCTCGAATCACCTCCTGTGTTGTGCTGGGAGCAGGACTGATTGAATTACGGAAA (SEQ ID NO: 122) 3 A_23_P20894 NM_024757EHMT1 Homo sapiens euchromatic histone-lysine N-TGATTTCAGACTCAGAAGCCGACGTTCGAGAG methyltransferase 1 (EHMT1), mRNAGAAGATTCTTACCTCTTTGATCTCGACA (SEQ ID NO: 123) 3 A_23_P257503 NM_003922HERC1 Homo sapiens hect (homologous to the E6-APTTTGGTCACTTTTGATAAGTTTGCATGAAACCA (UBE3A) carboxyl terminus) domain andRCC1 TTTTGGTGCATTTTTAGTTGGGAATGG (SEQ ID (CHC1)-like domain (RLD) 1(HERC1), mRNA NO: 124) 3 A_23_P259901 NM_012253 TKTL1 Homo sapienstransketolase-like 1 (TKTL1), GATGTCCTGTGCTGCTTGTGATGAGAGCCTCC mRNAACACTGTACTGTTCAAGTCAATGTTAAT (SEQ ID NO: 125) 3 A_23_P26759 NM_138793CANT1 Homo sapiens calcium activated nucleotidase 1AATGTTGCCTTTTTCTAGGAACTGTCAGAAATC (CANT1), mRNACTCATGCCTTTCAAGACTTCTGTGAAT (SEQ ID NO: 126) 3 A_23_P31686 NM_021174KIAA1967 Homo sapiens KIAA1967 (KIAA1967), transcriptAGAAAAAGGCTTTTCGAGTGTGGGACAAGGTC variant 1, mRNATGATGTCAGTGAACGGAATTGAAGAGCA (SEQ ID NO: 127) 3 A_23_P319895 XM_037523KIAA1076 PREDICTED: Homo sapiens KIAA1076 proteinTGCAACTGAGGAAATAATTTATTTTTCACATGA (KIAA1076), mRNAGGAAATGCGTAGCTTGTAGAGACGGCT (SEQ ID NO: 128) 3 A_23_P332190 NM_002163IRF8 Homo sapiens interferon regulatory factor 8GGGATGCCTTACTTTGCACTTAATTTAATAAGG (IRF8), mRNAGCATTCTCGGAGGAGTAGACGTTTAAT (SEQ ID NO: 129) 3 A_23_P359430 NM_015383NBPF14 Homo sapiens neuroblastoma breakpoint family,ACCCTGGTTTCAATGAACCTAACCTCATTCTTT member 14 (NBPF14), mRNAGTGTCTTCAGTGTTGGCTTGTTTTAGC (SEQ ID NO: 130) 3 A_23_P388681 NM_001419ELAVL1 Homo sapiens ELAV (embryonic lethal, abnormalAGATAATTAAGAGTGAAGGAGTTGAAACTTTTC vision, Drosophila)-like 1 (Hu antigenR) TTGTTAGTGTACAACTCATTTTGCGCC (SEQ ID (ELAVL1), mRNA NO: 131) 3A_23_P406330 NM_022733 SMAP1L Homo sapiens stromal membrane-associatedCAGCAGCCTAAAACTGTTGTGTTTTTCTTATGG protein 1-like (SMAP1L), mRNATTTAAAAAACGCCATGTCATTGATAAC (SEQ ID NO: 132) 3 A_23_P416434 NM_015288PHF15 Homo sapiens PHD finger protein 15(PHF15),ATATATTGAAAAGAGCAATTTTAAATTATTTTTG mRNA GCTTATGTTGCAATATTTATTTTCTT (SEQID NO: 133) 3 A_23_P417200 NM_005652 TERF2 Homo sapiens telomeric repeatbinding factor 2 TCCCTGGTAATCTGTAGAACCTTCTCCTAGGA (TERF2), mRNAAATGGTGAAGTCTATTAGGAGCCACTTG (SEQ ID NO: 134) 3 A_23_P44581 NM_001004060NOMO2 Homo sapiens NODAL modulator 2 (NOMO2),AATGTGATCACTTCCTCTGAATACCTTCCTACA transcript variant 1, mRNATTATGGGTCAAGCTTTACAAAAGCGAA (SEQ ID NO: 135) 3 A_23_P44734 NM_032557USP38 Homo sapiens ubiquitin specific peptidase 38GGATGCTATAACAAAAGACAATAAACTATATTT (USP38), mRNAACAGGAACAAGAGTTGAATGCTCGAGC (SEQ ID NO: 136) 3 A_23_P60354 NM_003070SMARCA2 Homo sapiens SWI/SNF related, matrixTATCATCATCGTCTATAAACTAGCTTTAGGATA associated, actin dependent regulatorof GTGCCAGACAAACATATGATATCATGG (SEQ chromatin, subfamily a, member 2(SMARCA2), ID NO: 137) transcript variant 1, mRNA 3 A_23_P73593NM_002444 MSN Homo sapiens moesin (MSN), mRNAGAAGCTTTCAGTATTAGTGATGTCATCTGTCAC TATAGGTCATACAATCCATTCTTAAAG (SEQ IDNO: 138) 3 A_23_P97770 NM_020216 RNPEP Homo sapiens arginylaminopeptidase ACCAGGAAGATTTCTGGAAAGTGAAGGAGTTC (aminopeptidase B)(RNPEP), mRNA CTGCATAACCAGGGGAAGCAGAAGTATA (SEQ ID NO: 139) 3A_24_P174257 NM_019044 CCDC93 coiled-coil domain containing 93AAAGAGAGGGAAGAACTACACTAATGTTAGAG ATAAGGTATGTTTTGGCTCAAAATGTGT (SEQ IDNO: 140) 3 A_24_P18190 NM_005347 HSPA5 Homo sapiens heat shock 70 kDaprotein 5 TTCTACAGCTTCTGATAATCAACCAACTGTTAC (glucose-regulated protein,78 kDa) (HSPA5), AATCAAGGTCTATGAAGGTGAAAGACC (SEQ mRNA ID NO: 141) 3A_24_P186030 NM_002760 PRKY Homo sapiens protein kinase, Y-linked(PRKY), CCAGTTTTCTCTGTACCTGTGTGTATAGAAATA mRNAGATCAGAGCACAGTTGAAATTCATGGA (SEQ ID NO: 142) 3 A_24_P187626 AC055811Homo sapiens chromosome 17, clone RP11- GAAGTGTGATGTGGACATCTGCAAAGACTTAT45M22, complete sequence. ATGCCAACGTGCTGTCTGGCGGCACCAC (SEQ ID NO: 143)3 A_24_P222599 NM_002613 PDPK1 Homo sapiens 3-phosphoinositide dependentGCTGGTAAAAGCCTCTATTACGACTGTAAGTA protein kinase-1 (PDPK1), transcriptvariant 1, AGTTGGATGTTGGCAAAATTAAATTGTT (SEQ mRNA ID NO: 144) 3A_24_P225325 NM_022733 SMAP1L Homo sapiens stromal membrane-associatedCATGTTCTCATGATTTATGGGAATGAAGCAAGT protein 1-like (SMAP1L), mRNAACTGAAATCAAATTAAATACTCCCTGG (SEQ ID NO: 145) 3 A_24_P226037 NM_001003810HNRPD Homo sapiens heterogeneous nuclearAGAAATACCACAATGTTGGTCTTAGTAAATGTG ribonucleoprotein D (AU-rich elementRNA binding AAATAAAAGTAGCCATGTCGAAGGAAC (SEQ protein 1, 37 kDa) (HNRPD),transcript variant 4, ID NO: 146) mRNA 3 A_24_P226554 NM_001101 ACTBHomo sapiens actin, beta (ACTB), mRNA GCACCCAGCACAATGAAGATCAAGATCATTGCTCCTCCTGAGCGCAAGTACTCCGTGTGG (SEQ ID NO: 147) 3 A_24_P238744 XM_292982LOC653269 PREDICTED: Homo sapiens similar to proteinTGTGGCATCCACGAAACTACCTTCAACTCCAT expressed in prostate, ovary, testis,and CATGAAGTCGGATGTGGACATCTACAAA (SEQ placenta 15, transcript variant 1ID NO: 148) (LOC653269), mRNA 3 A_24_P255786 AL359844 Human DNA sequencefrom clone RP11-314J18 GTCCTCCTGGGAGAAGAGCTATGAGCTGTCA on chromosome 10GATGGCCAGGTCATCACCAGCAGCAACAA (SEQ ID NO: 149) 3 A_24_P261169 NM_006378SEMA4D Homo sapiens sema domain, immunoglobulinAACTTCCTTTTGCTAAATGCATTCTTTCTGCTTT domain (Ig), transmembrane domain(TM) and TAGAAATGTAGACATAAACACTCCCC (SEQ ID short cytoplasmic domain,(semaphorin) 4D NO: 150) (SEMA4D), mRNA 3 A_24_P273666 NM_000516 GNASHomo sapiens GNAS complex locus (GNAS), CCCCGAGTGATTTTGCGAAACCCCCTTTTCCCtranscript variant 1, mRNA TTCAGCTTGCTTAGATGTTCCAAATTTA (SEQ ID NO: 151)3 A_24_P287272 XM_498427 NBPF1 PREDICTED: Homo sapiens neuroblastomaACCTAACCTCATTCTTTGTATCTTCAGTGTTGA breakpoint family, member 1,transcript variant 1 ATTGTTTTAGCTGATCCATCTTTAACG (SEQ ID (NBPF1), mRNANO: 152) 3 A_24_P325333 NM_002600 PDE4B Homo sapiens phosphodiesterase4B, cAMP- ACTTCTACACAGATAAGCTTTCAAAGTTGACAA specific (phosphodiesteraseE4 dunce homolog, ACTTTTTTGACTCTTTCTGGAAAAGGG (SEQ ID Drosophila)(PDE4B), mRNA NO: 153) 3 A_24_P331998 NM_203447 DOCK8 Homo sapiensdedicator of cytokinesis 8 (DOCK8), CCTACATACAGATCACTTTTGTGGAGCCCTACmRNA TTTGATGAGTATGAGATGAAAGACAGGG (SEQ ID NO: 154) 3 A_24_P354724NM_054114 TAGAP Homo sapiens T-cell activation GTPase activatingGGCCATACGCCATGCCATAGCTTGTGCTATCT protein (TAGAP), transcript variant 2,mRNA GTAAATATGAGACTTGTAAAGAACTGCC (SEQ ID NO: 155) 3 A_24_P369154NM_002721 PPP6C Homo sapiens protein phosphatase 6, catalyticAATATTGCTTCGATCATGGTCTTCAAAGATGTA subunit (PPP6C), mRNAAATACAAGAGAACCAAAGTTATTCCGG (SEQ ID NO: 156) 3 A_24_P375076 AL390237Human DNA sequence from clone RP11-278J20GACAATATTATGCAAGTGTGGCAAATGGCAGA on chromosome 6 Contains aretinoblastoma GAACATTTACAACAATGAAGACCCTGAA (SEQ binding protein 4(RBBP4) pseudogene and a ID NO: 157) KIAA0797 pseudogene, completesequence. 3 A_24_P383901 HSBA12M9 Human DNA sequence from cloneRP11-12M9 on CATGTACCCTGGCATCACCAACAGGATGCAGA chromosome 22, completesequence. AGAAGATCACCGCCCTAGCACCCAGCAT (SEQ ID NO: 158) 3 A_24_P391568NM_001668 ARNT Homo sapiens aryl hydrocarbon receptor nuclearGGCTTTGGCCAGTAGCTAAAGTGCAAGACTGA translocator (ARNT), transcript variant1, mRNA ATTAATGAGAAGATATATTAAATGTAGT (SEQ ID NO: 159) 3 A_24_P393151AC009892 Homo sapiens chromosome 19 clone CTB-83J4,AAGAAATCTTATCATTCGCCATCTACCCTGTAG complete sequence.AATAAAGAAATCTTATCATTCACCGTC (SEQ ID NO: 160) 3 A_24_P401090 AL354702Human DNA sequence from clone RP11-334L9 onTTTTCTACAGCTTTTGATAATCAAGTTACAATC chromosome 1 Contains a heat shock 70kDa AAGGTCTATGAAGGTAAACAACCCCTG (SEQ protein 5 (glucose-regulatedprotein, 78 kDa) ID NO: 161) (HSPA5) pseudogene, complete sequence. 3A_24_P408424 NM_002473 MYH9 Homo sapiens myosin, heavy polypeptide 9,non- CTGGTCTACACTGGTTGCCGAATTTACTTGTAT muscle (MYH9), mRNATCCTAACTGTTTTGTATATGCTGCATT (SEQ ID NO: 162) 3 A_24_P410017 NM_001017421FKSG30 Homo sapiens actin-like protein (FKSG30), mRNAATGAAACTACCTTCAACTCCATCATGAAGTCTG ATGTGGACATCCGCAAAGACCTGTACA (SEQ IDNO: 163) 3 A_24_P42517 NM_006854 KDELR2 Homo sapiens KDEL(Lys-Asp-Glu-Leu) CATCCTATACTGTGACTTCTTCTACTTGTACAT endoplasmicreticulum protein retention TACAAAAGTACTCAAGGGAAAGAAGCT (SEQ receptor 2(KDELR2), mRNA ID NO: 164) 3 A_24_P47182 NM_003373 VCL Homo sapiensvinculin (VCL), transcript ATGGGGTTCAAGAGAGTAATGGGTTTCATATT variant 2,mRNA TCTTATCACCACAGTAAGTTCCTACTAG (SEQ ID NO: 165) 3 A_24_P475115AC097103 Homo sapiens 3 BAC RP11-319G6 (Roswell ParkACTGACTACTTCATGAAGATCCTCATGGAGTG Cancer Institute Human BAC Library)complete CAGCTACCGTTTCACCACCATGGCTGAG (SEQ sequence ID NO: 166) 3A_24_P63118 NM_013374 PDCD6IP Homo sapiens programmed cell death 6TAGTTTTTGCACGGAAGACAGAAAGAGATGAA interacting protein (PDCD6IP), mRNACTCTTAAAGGACTTGCAACAAAGCATTG (SEQ ID NO: 167) 3 3 GranulocyteA_24_P63136 NM_023914 P2RY13 Homo sapiens purinergic receptor P2Y,G-protein ATGCCAGATTTTCTTGGTATCTCCCATAATACG coupled, 13 (P2RY13),transcript variant 1, mRNA ACCTACAGTCCATGGTCTACAGATGTT (SEQ ID NO: 168)3 A_24_P63827 NM_005494 DNAJB6 Homo sapiens DnaJ (Hsp40) homolog,subfamily CAACTTCAACTAAAATGGTTAATGGCAGAAAAA B, member 6 (DNAJB6),transcript variant 2, TCACTACAAAGAGAATTGTCGAGAACG (SEQ mRNA ID NO: 169)3 A_24_P643587 NM_024095 ASB8 Homo sapiens ankyrin repeat and SOCS box-GCTCTGTAATAACAGTAATAAATAGCTCTGAAA containing 8 (ASB8), mRNATAACAGTCCTAAGAACTCCTAAAGTCC (SEQ ID NO: 170) 3 A_24_P681011 HSM807522Homo sapiens mRNA; cDNA DKFZp686K02111 GTGTTAATCCATGTTAATCTGTGTGAAAATTAT(from clone DKFZp686K02111). TGCGTGCAACAGTATTTTCTCGTGTAC (SEQ ID NO:171) 3 A_24_P68649 NM_020216 RNPEP Homo sapiens arginyl aminopeptidaseGCAACAGGAGAGAAGCTTTTTGGACCTTATGT (aminopeptidase B) (RNPEP), mRNATTGGGGAAGGTATGACTTGCTCTTCATG (SEQ ID NO: 172) 3 A_24_P693321ATCACAACTATGCCAAATAATCAATCCTACAAT GTCCAAAATTTTACTTTAAAACTGGAA (SEQ IDNO: 173) 3 A_24_P714134 XR_019310 LOC646447 PREDICTED: Homo sapienssimilar to AGAGTGCATAAAATTATCCTTGATCTTATATCT heterogeneous nuclearribonucleoprotein GAGTCTCCTACAGAGGATGTGCACAGA (SEQ ID NO: 174) 3A_24_P787897 XM_001125986 LOC283824 PREDICTED: Homo sapiens hypotheticalprotein TGAACTATCTGAAATTGACCAGTAATCAAAGTT LOC283824CCAATCATCTGAATGCTTTTCCTTGAG (SEQ ID NO: 175) 3 A_24_P79617 NM_014656KIAA0040 Homo sapiens KIAA0040 (KIAA0040), mRNATGAAAATGAAAAGTCTTGATGTAGTCAGATGG TTACTCTCTTAACATTAGGTATTACCCC (SEQ IDNO: 176) 3 A_24_P7974 AF161369 Homo sapiens HSPC106 mRNA, partial cds.GTTGCTTTATGTAGCAAATTCTCCGTTTGGAG CTTTTAAAATAGGATTATTTGCCAGAAC (SEQ IDNO: 177) 3 A_24_P808534 NM_001357 DHX9 Homo sapiens DEAH(Asp-Glu-Ala-His) box GGAAAAGACAAAGATTCTCACCACTGAAGGGT polypeptide 9(DHX9), transcript variant 1, mRNA GTAATGCACTTATCCACAAATCATCTGT (SEQ IDNO: 178) 3 A_24_P940059 NM_015553 PIP3-E Homo sapiensphosphoinositide-binding protein CCCAGGGTTTTGTAATACATAATTGAAAATAAAPIP3-E (PIP3-E), mRNA AGTCCCTGAAACTAAATGTTTGCAGCC (SEQ ID NO: 179) 3A_32_P11359 AACTAAAAAGCATTAATTAAAAAGTACTTAACTCAGAAATTATAAAAATAGGAGACATCA (SEQ ID NO: 180) 3 A_32_P144920 NM_015509NECAP1 Homo sapiens NECAP endocytosis associated 1TTGAGTTTGAATTGTGTAACATCTTTGATCAGT (NECAP1), mRNAGGGTGTATCTGTAATGAAGGAGGTTCA (SEQ ID NO: 181) 3 A_32_P155776 NM_001017421FKSG30 Homo sapiens actin-like protein (FKSG30), mRNAATAGTGAAGTCTGATGTGGACATCCGCAAAGA CCTGTACACCAACACAGTGCTGTCTGGC (SEQ IDNO: 182) 3 A_32_P221958 NM_133446 CTGLF1 Homo sapiens centaurin,gamma-like family, ATGGGAAAAATAAGGATAACTCAGAATTTCAAA member 1 (CTGLF1),mRNA AGGAAATCACAAATTCAGCTAGTAATA (SEQ ID NO: 183) 3 A_32_P60551 HS661I20Human DNA sequence from clone RP4-661I20 onGCAGAAGTACAAGCTTTAGGGTGTATCTATTC chromosome 20q11.23-12 Contains theRPL12L2 ATCTATTCCTAGTACATAAAATTTAGCC (SEQ gene for ribosomal proteinL12-like 2 pseudogene, ID NO: 184) the 5′ end of the CHD6 gene forchromodomain helicase DNA binding protein 6 and two CpG islands,complete sequence. 3 A_32_P79434 NM_002847 PTPRN2 Homo sapiens proteintyrosine phosphatase, TCTCTACATGGTATTGTAATGAATATCTGCTTT receptor type, Npolypeptide 2 (PTPRN2), AATATAGCTATCATTTCTTTTCCAAAA (SEQ ID transcriptvariant 1, mRNA NO: 185) 3 A_32_P8666 NM_002140 HNRPK Homo sapiensheterogeneous nuclear GGTCTGCAGATTAAACAAATCCGTCATGAGTC ribonucleoproteinK (HNRPK), transcript GGGAGCTTCGATCAAAATTGATGAGCCT (SEQ variant 1, mRNAID NO: 186) 4 Granulocytes 4 A_23_P113762AGACGCTGGACGAAGATGGGGATGGGGAGTG TGACTTCCAGGAGTTTATGGCCTTCGTCT (SEQ IDNO: 187) 4 A_23_P117992 NM_014861 KIAA0703 Homo sapiens KIAA0703 geneproduct TCCATCACCGGATCAGTTTTTCCTCTTAGGAAA (KIAA0703), mRNAGCTGCAGGAACCTCGTGGGCTCCAGGG (SEQ ID NO: 188) 4 A_23_P119222 NM_020415RETN Homo sapiens resistin (RETN), mRNA CAATAAGCAGCATTGGCCTGGAGTGCCAGAGCGTCACCTCCAGGGGGGACCTGGCTACTT (SEQ ID NO: 189) 4 2 GranulocyteA_23_P121622 NM_014465 SULT1B1 Homo sapiens sulfotransferase family,cytosolic, GAAATAGAGATTGTCTGTAGTTGATTGAAACG 1B, member 1 (SULT1B1), mRNAAGGGCAGTTATGAATTGATTTGGGCAAT (SEQ ID NO: 190) 4 8 GranulocyteA_23_P121716 NM_005139 ANXA3 Homo sapiens annexin A3 (ANXA3), mRNATGGACATTCGAACAGAGTTCAAGAAGCATTAT GGCTATTCCCTATATTCAGCAATTAAAT (SEQ IDNO: 191) 4 A_23_P122924 NM_002192 INHBA Homo sapiens inhibin, beta A(activin A, AAACATCATCAAAAAGGACATTCAGAACATGAT activin AB alphapolypeptide) (INHBA), mRNA CGTGGAGGAGTGTGGGTGCTCATAGAG (SEQ ID NO: 192)4 A_23_P123645 AATGGTTTTGTGCAGTGAACAACACATGGCGAGGTACTAACTGAGAAACTTTTTCATGCT (SEQ ID NO: 193) 4 A_23_P126278 NM_003465CHIT1 Homo sapiens chitinase 1 (chitotriosidase)GGGCCACCAAACAGAGAATCCAGGATCAGAA (CHIT1), mRNAGGTGCCCTACATCTTCCGGGACAACCAGT (SEQ ID NO: 194) 4 A_23_P130961 NM_001972ELA2 Homo sapiens elastase 2, neutrophil (ELA2),AACGGCTACGACCCCGTAAACTTGCTCAACGA mRNA CATCGTGATTCTCCAGCTCAACGGGTCG (SEQID NO: 195) 4 4 Granulocyte A_23_P131785 NM_001725 BPI Homo sapiensbactericidal/permeability-increasing GACTCAGATTCAGAAATGATCTAAACACGAGGprotein (BPI), mRNA AAACATTATTCATTGGAAAAGTGCATGG (SEQ ID NO: 196) 4A_23_P140384 NM_001911 CTSG Homo sapiens cathepsin C (CTSG), mRNATGTGACTGACTCTTCTTCTCGGGGACACAGGC CAGCTCCACAGTGTTGCCAGAGCCTTAA (SEQ IDNO: 197) 4 A_23_P141173 NM_000250 MPO Homo sapiens myeloperoxidase(MPO), nuclear CCTGTTCTGGGTGCAGCTGAGAAAATGAGTGA gene encodingmitochondrial protein, mRNA CTAGACGTTCATTTGTGTGCTCATGTAT (SEQ ID NO:198) 4 A_23_P149301 NM_002105 H2AFX Homo sapiens H2A histone family,member X GGCGCGCGACAACAAGAAGACGCGCATCATC (H2AFX), mRNACCGCGCCACCTGCACCTGGCCATCCGCAA (SEQ ID NO: 199) 4 A_23_P151637 NM_002934RNASE2 Homo sapiens ribonuclease, RNase A family, 2GTGGTAACCCAAATATGACCTGTCCTAGTAAC (liver, eosinophil-derived neurotoxin)(RNASE2), AAAACTCGCAAAAATTGTCACCACAGTG (SEQ mRNA ID NO: 200) 4 3Granulocyte A_23_P156180 NM_003059 SLC22A4 Homo sapiens solute carrierfamily 22 (organic AAACAAGAGACTCAATGGAGACAGAAGAAAAT cation transporter),member 4 (SLC22A4), mRNA CCCAAGGTTCTAATAACTGCATTCTGAA (SEQ ID NO: 201) 4A_23_P161428 NM_144590 ANKRD22 Homo sapiens ankyrin repeat domain 22AATCCTTGTGACCACACCGATGGAGATACAGA (ANKRD22), mRNAAAAAGTTAACGACTGGATTCTATCTTCA (SEQ ID NO: 202) 4 A_23_P163025 NM_002934RNASE2 Homo sapiens ribonuclease, RNase A family, 2AGCCACAGCTCAGAGACTGGGAAACATGGTTC (liver, eosinophil-derived neurotoxin)(RNASE2), CAAAACTGTTCACTTCCCAAATTTGTCT (SEQ mRNA ID NO: 203) 4 4Granulocyte A_23_P166848 NM_002343 LTF Homo sapiens lactotransferrin(LTF), mRNA ATATTTGGGACCACAGTATGTCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCCCC (SEQ ID NO: 204) 4 A_23_P168014 NM_003509HIST1H2AI Homo sapiens histone 1, H2ai (HIST1H2AI),TGAGGAGCTCAACAAGCTTCTGGGCAAACTCA mRNA CCATCGCACAGGGTGGCGTCCTGCCCAA (SEQID NO: 205) 4 A_23_P169437 NM_005564 LCN2 Homo sapiens lipocalin 2(oncogene 24p3) GCTATGGTGTTCTTCAAGAAAGTTTCTCAAAAC (LCN2), mRNAAGGGAGTACTTCAAGATCACCCTCTAC (SEQ ID NO: 206) 4 A_23_P170233 NM_005213CSTA Homo sapiens cystatin A (sterin A) (CSTA), mRNAAACTGGCTACTGAGTCATGATCCTTGCTGATA AATATAACCATCAATAAAGAAGCATTCT (SEQ IDNO: 207) 4 A_23_P19543 NM_003137 SRPK1 Homo sapiens SFRS protein kinase1 (SRPK1), CTGTCAAATTGCCACGATCTCACTAAAGGATTT mRNACTATTTGCTGTCAGTTAAAATAAAGC (SEQ ID NO: 208) 4 A_23_P200507 NM_014184CNIH4 Homo sapiens cornichon homolog 4 (Drosophila)TGGTTGAAGTCAGCCTACACTACAGTGCACAG (CNIH4), mRNA TTGAGGAGCCAGAGACTTAAATCAT(SEQ ID NO: 209) 4 A_23_P206760 NM_005143 HP Homo sapiens haptoglobin(HP), mRNA GATAAGATGTGGTTTGAAGCTGATGGGTGCCA GCCCTGCATTGCTGAGTCAATCAATAAA(SEQ ID NO: 210) 4 3 Granulocyte A_23_P218442 NM_002483 CEACAM6 Homosapiens carcinoembryonic antigen-relatedACACTCATCTGACTCATTCTTTATTCTATTTTAG cell adhesion molecule 6(non-specific cross TTGGTTTGTATCTTGCCTAAGGTGCG (SEQ ID reacting antigen)(CEACAM6), mRNA NO: 211) 4 A_23_P23048 NM_002965 S100A9 Homo sapiensS100 calcium binding protein A9 GAGCTGGTGCGAAAAGATCTGCAAAATTTTCT(calgranulin B) (S100A9), mRNA CAAGAAGGAGAATAAGAATGAAAAGGTC (SEQ ID NO:212) 4 A_23_P25235 NM_080387 CLEC4D Homo sapiens C-type lectin domainfamily 4, CATTTAACCCACGCAGAGTATTCTGGCATAAG member D (CLEC4D), mRNAAATGAACCCGACAACTCTCAGGGAGAAA (SEQ ID NO: 213) 4 18 GranulocyteA_23_P253791 NM_004345 CAMP Homo sapiens cathelicidin antimicrobialpeptide GAATTGTCCAGAGAATCAAGGATTTTTTGCGG (CAMP), mRNAAATCTTGTACCCAGGACAGAGTCCTAGT (SEQ ID NO: 214) 4 A_23_P258493 NM_005573LMNB1 Homo sapiens lamin B1 (LMNB1), mRNAAATATTAACCTAATCACCATGTAAGCACTCTGG ATGATGGATTCCACAAAACTTGGTTTT (SEQ IDNO: 215) 4 3 Granulocyte A_23_P259506 NM_032412 ORF1-FL49 Homo sapiensputative nuclear protein ORF1- TGGGATTCTAGATTAATGGGGGTTGCTACTGT FL49(ORF1-FL49), mRNA TTAATTCAGTGACTTGATCTTTTTAATG (SEQ ID NO: 216) 4A_23_P302470 NM_014465 SULT1B1 Homo sapiens sulfotransferase family,cytosolic, TGTCTAAGTCACAAATCTGAAGAAATAAGAGAT 1B, member 1 (SULT1B1),mRNA TGTCTGTAGTTGATTGAAACGAGGGCA (SEQ ID NO: 217) 4 A_23_P306941NM_153615 Rgr Homo sapiens Ral-GDS related protein Rgr (Rgr),CCATGGGACTTTTGTGAGTCAGGCGGGAGAC mRNA CATTTTATGTTTATTTTCTTTAGTGTATA (SEQID NO: 218) 4 2 Granulocyte A_23_P309381 NM_003516 HIST2H2AA Homosapiens histone 2, H2aa (HIST2H2AA), CGACTTTCCCGATCGCCAGGCAGGAGTTTCTCmRNA TCGGTGACTACTATCGCTGTCATGTCTG (SEQ ID NO: 219) 4 A_23_P312932NM_175857 KRTAP8-1 Homo sapiens keratin associated protein 8-1GGCTATGGCTTCGGCTATGGCTACAACGGCT (KRTAP8-1), mRNAGTGGGGCTTTCGGCTACAGGAGATACTCG (SEQ ID NO: 220) 4 24 GranulocyteA_23_P31816 NM_004084 DEFA1 Homo sapiens defensin, alpha 1 (DEFA1), mRNAGAGAACGTCGCTATGGAACCTGCATCTACCAG GGAAGACTCTGGGCATTCTGCTGCTGAG (SEQ IDNO: 221) 4 13 Granulocyte A_23_P326080 NM_001925 DEFA4 Homo sapiensdefensin, alpha 4, corticostatin AGAGCTACAGGAAATGGTTGTTTCTCCTATACT(DEFA4), mRNA TTGTCCTTAACATCTTTCTTGATCCTA (SEQ ID NO: 222) 4A_23_P330561 NM_174918 MCEMP1 Homo sapiens mast cell-expressed membraneCTGTCTCCCTGTTTGTGTAAACATACTAGAGTA protein 1 (MCEMP1), mRNATACTGCGGCGTGTTTTCTGTCTACCCA (SEQ ID NO: 223) 4 A_23_P332042 NM_004259RECQL5 Homo sapiens RecQ protein-like 5 (RECQL5),CTTTCTGCTTGCAAAGCCTATAGACCCTTCTCA transcript variant 1, mRNAGAGCGGTCCTCATGGCTGGGTTTTCTG (SEQ ID NO: 224) 4 A_23_P344973 NM_021019MYL6 Homo sapiens myosin, light polypeptide 6, alkali,CCTATGAGGATTATGTCGAAGGACTTCGGGTG smooth muscle and non-muscle (MYL6),transcript TTTGACAAGGAAGGAAATGGCACCGTCA (SEQ variant 1, mRNA ID NO: 225)4 2 Granulocyte A_23_P370635 NM_138799 OACT2 Homo sapiensO-acyltransferase (membrane TTGTTCCTAAATGGTATTTTCAAGTGTAATATT bound)domain containing 2 (OACT2), mRNA GTGAGAACGCTACTGCAGTAGTTGATG (SEQ IDNO: 226) 4 A_23_P371495 XM_928461 LOC653626 PREDICTED: Homo sapienssimilar to ARG99 ACCAGACTAAGTGCCAGTATATATATGACTGAT protein (LOC653626),mRNA ATTTTCGTGACTCATAGAAGGTGTCCA (SEQ ID ID NO: 227) 4 5 GranulocyteA_23_P380240 NM_001816 CEACAM8 Homo sapiens carcinoembryonicantigen-related TAGTCCACCCAATGGCTGACAGTAACAGCATC cell adhesion molecule8 (CEACAM8), mRNA TTTAACACAACTCTTTGTTCAAATGTAC (SEQ ID NO: 228) 4A_23_P395438 NM_053044 HTRA3 Homo sapiens HtrA serine peptidase 3(HTRA3), AAGGGGCATTTGTGAGCTTTGCTGTAAATGGA mRNATTCCCAGTGTTGCTTGTACTGTATGTTT (SEQ ID NO: 229) 4 A_23_P4096 NM_000717 CA4Homo sapiens carbonic anhydrase IV (CA4),TAATATCCCCAAACCTGAGATGAGCACTACGA mRNA TGGCAGAGAGCAGCCTGTTGGACCTGCT (SEQID NO: 230) 4 A_23_P41114 NM_005213 CSTA Homo sapiens cystatin A (stefinA) (CSTA), mRNA AAACAAATGAGACTTATGGAAAATTGGAAGCTGTGCAGTATAAAACTCAAGTTGTTGCTG (SEQ ID NO: 231) 4 A_23_P421493 NM_020995HPR Homo sapiens haptoglobin-related protein (HPR),GGGGACAAAGTGACAACTTTAAACTTACTGAC mRNA CATCTGAAGTATGTCATGCTGCCTGTGG (SEQID NO: 232) 4 A_23_P434809 NM_002964 S100A8 Homo sapiens S100 calciumbinding protein A8 AAAGCCATGAAGAAAGCCACAAAGAGTAGCTG (calgranulin A)(S100A8), mRNA AGTTACTGGGCCCAGAGGCTGGGCCCCT (SEQ ID NO: 233) 4A_23_P60248 NM_003329 TXN Homo sapiens thioredoxin (TXN), mRNAGGACAAAAGGTGGGTGAATTTTCTGGAGCCAA TAAGGAAAAGCTTGAAGCCACCATTAAT (SEQ IDNO: 234) 4 A_23_P63390 NM_000566 FCGR1A Homo sapiens Fc fragment of IgG,high TTTAGTGAACACTGTTCTCTGGGTGACAATAC affinity Ia, receptor (CD64)(FCGR1A), mRNA GTAAAGAACTGAAAAGAAAGAAAAAGTG (SEQ ID NO: 235) 4 4Granulocyte A_23_P67847 NM_024572 GALNT14 Homo sapiensUDP-N-acetyl-alpha-D- AAGCCTTCTTTTTCACTAGGCCAGGACTACATTgalactosamine:polypeptide N- GAGAGATGAAGAATGGAGGTTGTTTCC (SEQacetylgalactosaminyltransferase 14 (GalNAc-T14) ID NO: 236) (GALNT14),mRNA 4 A_23_P74001 NM_005621 S100A12 Homo sapiens S100 calcium bindingprotein A12 TGAAGGCTTTTTACCCAGCAATGTCCTCAATG (calgranulin C) (S100A12),mRNA AGGGTCTTTTCTTTCCCTCACCAAAACC (SEQ ID NO: 237) 4 3 B cellsA_23_P85250 NM_013230 CD24 Homo sapiens CD24 antigen (small cell lungCTGCCTCGACACACATAAACCTTTTTAAAAATA carcinoma cluster 4 antigen) (CD24),mRNA GACACTCCCCGAAGTCTTTTGTTTGTA (SEQ ID NO: 238) 4 A_23_P85903NM_003268 TLR5 Homo sapiens toll-like receptor 5 (TLR5), mRNAAACAGTAGAAAGATCGTTTGTCTTGTGAGCAG ACACTTCCTTAGAGATGGCTGGTGCCTT (SEQ IDNO: 239) 4 A_23_P94230 NM_015364 LY96 Homo sapiens lymphocyte antigen 96(LY96), TGAAGCTATTTCTGGGAGCCCAGAAGAAATGC mRNATCTTTTGCTTGGAGTTTGTCATCCTACA (SEQ ID NO: 240) 4 3 GranulocyteA_23_P99253 NM_004664 LIN7A Homo sapiens lin-7 homolog A (C. elegans)TTGAGGGAAAGCTACTTGATCAAACATCCGAT (LIN7A), mRNAAGTCACAAATTTGAAACCGTGCTTCAGA (SEQ ID NO: 241) 4 A_24_P145066 NM_183416KIF1B Homo sapiens kinesin family member 1B (KIF1B),TAGCTAGAACAGTTGAAGTCTTCAACTGAGGT transcript variant 2, mRNATTTATAGCAGATTAGACATGGGTAAATG (SEQ ID NO: 242) 4 33 GranulocyteA_24_P181254 NM_006418 OLFM4 Homo sapiens olfactomedin 4 (OLFM4), mRNATTTTTCCTTTGATGTTCAAGTCCTAGTCTATAG GATTGGCAGTTTAAATGCTTTACTCCC (SEQ IDNO: 243) 4 A_24_P252996 NM_000804 FOLR3 Homo sapiens folate receptor 3(gamma) CCTGCAAAAGCAACTGGCACAAAGGCTGGAAT (FOLR3), mRNATGGACCTCAGGGATTAATGAGTGTCCGG (SEQ ID NO: 244) 4 A_24_P273143 NM_052871MGC4677 Homo sapiens hypothetical protein MGC4677ACAGGAAGCTCTATGACACACTTGATCGAATA (MGC4677), mRNATGACAGACACCGAAAATCACGACTCAGC (SEQ ID NO: 245) 4 A_24_P52004 NM_015200SCC-112 Homo sapiens SCC-112 protein (SCC-112),TGCATTGATAGGGACCTTTGTCTCTTCCTCCC mRNA TTTGATTAATTGCCCGGCATCACAGTTT (SEQID NO: 246) 4 A_24_P649624 BC063684 Homo sapiens cDNA clone IMAGE:4395035, CTGTTAGAGCCAAAATTGTGATGAGCAATACT partial cds.GATAATTGTCCAGTTTATGTCATCTTTC (SEQ ID NO: 247) 4 A_24_P6921 NM_052871MGC4677 Homo sapiens hypothetical protein MGC4677CAGGAAGCTCTATGACACACTTGATCGAATAT (MGC4677), mRNAGACAGACACTGAAAATCACGACTCATCC (SEQ ID NO: 248) 4 A_24_P759747 CNS01RGEHuman chromosome 14 DNA sequence BAC R- GGAGGAGCCCCACCTTCTGCTACTATTATGTT300J18 of library RPCI-11 from chromosome 14 ofCTTCAGATGAGTAGAAGAGAGTGGGGAG Homo sapiens (Human), complete sequence.(SEQ ID NO: 249) 4 A_24_P8151 AK098403 Homo sapiens cDNA FLJ25537 fis,clone ATCTAGCAGGCGACTGAGTGCCGAGAAAATAC CBR09136.CTGGCAGAGGTGGGCACAAGGCGGGGTC (SEQ ID NO: 250) 4 A_24_P86389 NM_003514HIST1H2AM Homo sapiens histone 1, H2am (HIST1H2AM),CTTGGTAAAGTTACCATCGCTCAGGGCGGTGT mRNA TCTGCCTAACATCCAGGCCGTACTGCTC (SEQID NO: 251) 4 A_32_P112452 NM_002965 S100A9 Homo sapiens S100 calciumbinding protein A9 CGTGGGAGGTGTTGATGATGGTCTCTATGTTG (calgranulin B)(S100A9), mRNA CGTTCCAGCTGCGACATTTTGCAAGTCA (SEQ ID NO: 252) 4A_32_P113646 NM_005544 IRS1 Homo sapiens insulin receptor substrate 1(IRS1), CAGTCTCTTCCTCTCTGGGAGCTGGCTGGAG mRNACTGGGATGGACACCTGACAGAAGGAAATT (SEQ ID NO: 253) 4 A_32_P143589 AC018758CD177 Homo sapiens chromosome 19, BAC CTB-61I7AGCTTGGATGGTAGCAGAGACTTCAGGGTGC (BC52850), complete sequence.TCCAGCCAAACGTATTTGGGCATCACCAT (SEQ ID NO: 254) 4 A_32_P146815 AC007528Homo sapiens 12 BAC RP11-473N11 (RoswellTACCTTTTGCATATGCTTTTCTTGGCCTTAGGA Park Cancer Institute Human BACLibrary) TAGTACTGGACTTTGTTGTCCTCTGCT (SEQ ID complete sequence. NO: 255)4 2 Granulocyte A_32_P198223 AC022784 Homo sapiens chromosome 8, cloneRP11-10A14, CAGGAATCACGGGAGTGAATCACATTCCAGAC complete sequence.ACTTGCTTGGACTTCATCACATCCTCAG (SEQ ID NO: 256) 4 26 GranulocyteA_32_P228455 AC073172 Homo sapiens chromosome 11, clone RP11-AGTTACTTGCCTCCAGATATCTTGGTGTGTGA 531H8, complete sequence.GAACATTAAATCTGTATGTGTCTAAATC (SEQ ID NO: 257) 4 A_32_P41604 HS86F14Human DNA sequence from clone RP1-86F14 onGATCTGGAAAATACTTGTTTGGGGATCAATAAT chromosome 1q23-24 Contains the F5gene for ATGTTTGGGCTATTATCTAATGCTGTG (SEQ ID coagulation factor V(proaccelerin NO: 258) labile factor) and the 3′ end of the SELP genefor selectin P (granule membrane protein 140 kDa antigen CD62), completesequence. 4 A_32_P47754 HSM803756 Homo sapiens mRNA; cDNA DKFZp434F1129TTCACGTCAACTTCTGGCTCCTCAGTTTGGCA (from clone DKFZp434F1129).GTAAGGCAGGGAAGTTGTTTTCCTATTT (SEQ ID NO: 259) 4 A_32_P9753 AC004686 Homosapiens chromosome 17, clone ATTGGATAGGAAGAGGAATAAAATATAAAAATChRPC.1073_F_15, complete sequence. AGAGAACTGCTGAAATTCTGTGACCCC (SEQ IDNO: 260) 5 Platelet 5 A_23_P104624 XM_290546 KIAA0830 PREDICTED: Homosapiens KIAA0830 protein, GGAGAGAACACATGGTACAATCGTAACACATG transcriptvariant 1 (KIAA0830), mRNA AAGGACAAGTAAGTGCTGCAGTAAAGGT (SEQ ID NO: 261)5 A_23_P118313 NM_007285 GABARAPL2 Homo sapiens GABA(A)receptor-associated TGAGGTAGGTGCGGTATTAAAGTGAAAGGGAA protein-like 2(GABARAPL2), mRNA GGTGATGCATTTATTCTGGGTTATGCTT (SEQ ID NO: 262) 5A_23_P131646 NM_144563 RPIA Homo sapiens ribose 5-phosphate isomerase AACTTTTGCTAAGATCTGGGGGTTTCTTCATATT (ribose 5-phosphate epimerase) (RPIA),mRNA CCTGCTGTTGGAAGCAGTTGACCAGAA (SEQ ID NO: 263) 5 A_23_P134925NM_004331 BNIP3L Homo sapiens BCL2/adenovirus E1B 19 kDaATTTGGGGACAAAAAGGCAGGCTTCATTTTTC interacting protein 3-like (BNIP3L),mRNA ATATGTTTGATGAAAACTGGCTCAAGAT (SEQ ID NO: 264) 5 A_23_P137434NM_014372 RNF11 Homo sapiens ring finger protein 11 (RNF11),TGTAGTATCCATATGTTGCTTAAATTTCCTTAT mRNA GAGCCCCATGATGGAAAGACTTAAAGA (SEQID NO: 265) 5 A_23_P140256 NM_000270 NP Homo sapiens nucleosidephosphorylase (NP), CTACTAGCTCTTTGAGATAATACATTCCGAGG mRNAGGCTCAGTTCTGCCTTATCTAAATCACC (SEQ ID NO: 266) 5 A_23_P141764 NM_003826NAPG Homo sapiens N-ethylmaleimide-sensitive factorCATGCCATTTCAAGGACTTGGGAATAGATTAG attachment protein, gamma (NAPG), mRNAGGATATCCGTACTTCATTACAGTCATGA (SEQ ID NO: 267) 5 A_23_P144145 AC092953Homo sapiens 3 BAC RP11-531F16 (Roswell ParkTCTTTAGTGAATATCATCTGCATATCTCTGTAA Cancer Institute Human BAC Library)complete GTTCAATTGTGTTTCTTACAGTCCCTG (SEQ ID sequence. NO: 268) 5A_23_P145114 NM_001498 GCLC Homo sapiens glutamate-cysteine ligase,catalytic AGAATGCCTGGTTTTCGTTTGCAATTTGCTTGT subunit (GCLC), mRNAGTAAATCAGGTTGTAAAAAGGCAGATA (SEQ ID NO: 269) 5 2 Platelet A_23_P157795NM_003798 CTNNAL1 Homo sapiens catenin (cadherin-associatedGGATAGTAAAACTTGAGAAGCTTTTGGGGTCA protein), alpha-like 1 (CTNNAL1), mRNAGATCTCTGGAACATCATGTGATGAAGCT (SEQ ID NO: 270) 5 A_23_P160359 NM_004437EPB41 Homo sapiens erythrocyte membrane protein bandAGAGCAAGAGCAGTATGAAAGTACCATCGGAT 4.1 (elliptocytosis 1, RH-linked)TCAAACTTCCCAGTTACCGAGCAGCTAA (SEQ (EPB41), transcript variant 3, mRNA IDNO: 271) 5 A_23_P203558 NM_000518 HBB Homo sapiens hemoglobin, beta(HBB), mRNA GTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAAT (SEQ ID NO: 272) 5 A_23_P209426 NM_015049TRAK2 Homo sapiens trafficking protein, kinesinAGAAAATGTTGTGCTGTATGTTCTTGATTTGAC binding 2 (TRAK2), mRNAATAAATGAATAGACTTTGGCAAGGGAG (SEQ ID NO: 273) 5 A_23_P21785 NM_022072NSUN3 Homo sapiens NOL1/NOP2/Sun domain family,ACGGTAACATCATGCCTATGGACATTAAAGGA member 3 (NSUN3), mRNAATAGCAAGGACTTGCTCCCACGACTTCA (SEQ ID NO: 274) 5 A_23_P383377 NM_006563KLF1 Homo sapiens Kruppel-like factor 1 (erythroid)GGACCCGGGACGGTGGGCACTGGACTCGGG (KLF1), mRNAGGGACTGCAGAGGATCCAGGTGTGATAGCC (SEQ ID NO: 275) 5 A_23_P38757 NM_015865SLC14A1 Homo sapiens solute carrier family 14 (ureaGTATTAAAAATTAAACCCCCATAAACCCAACCT transporter), member 1 (Kidd bloodgroup) AAGCCTATGGAATCCACAGTCACAAAAA (SEQ (SLC14A1), mRNA ID NO: 276) 5A_23_P397999 NM_003468 FZD5 Homo sapiens frizzled homolog 5 (Drosophila)GGGGCTTTACAATCCTAAGGTTGGCGTTGTAA (FZD5), mRNATGAAGTTCCACTTGGTTCAGGTTTCTTT (SEQ ID NO: 277) 5 2 Platelet A_23_P45304NM_021083 XK Homo sapiens X-linked Kx blood group (McLeodGCTTTCGTTGACTGCTTCTCTGCAGTCGTTGA syndrome) (XK), mRNATGCTAATAAATATTGTCCTGTTTCTTCA (SEQ ID NO: 278) 5 A_23_P55578 NM_003831RIOK3 Homo sapiens RIO kinase 3 (yeast) (RIOK3),CTTTAGTGGGTAGAACAAATGGAAATTTGGTTT transcript variant 1, mRNACAGAATGGCTGACAGAAATCGACATAA (SEQ ID NO: 279) 5 A_23_P60324 NM_016172UBADC1 Homo sapiens ubiquitin associated domainTTTAGCATCTGACAGGTGTTTACAAAAAAGTG containing 1 (UBADC1), mRNAGTTGTCGCACTGGGAAGTGGAGTGATGG (SEQ ID NO: 280) 5 A_23_P63547 XM_931256CR1L PREDICTED: Homo sapiens complement AACACCTGTTTGTGACAGTGAGTTGAAATATGcomponent (3b/4b) receptor 1-like, transcriptCATTCCTATTTCTTTTACCGATACATTC (SEQ ID variant 3 (CR1L), mRNA NO: 281) 5A_23_P67708 NM_003200 TCF3 Homo sapiens transcription factor 3 (E2ACGGAGAAATGGAAACATATCACTCAAGGGGGA immunoglobulin enhancer binding factorsTGCTGTGGAAACCTGGCTTATTCTTCTA (SEQ E12/E47) (TCF3), mRNA ID NO: 282) 5A_23_P69695 NM_001008388 LOC493856 Homo sapiens similar to RIKEN cDNAATTTGTGTCTTACTAAAGCAGCTTATTGTAGGT 1500009M05 gene (LOC493856), mRNAGTTGGCGTTCTAAAACGTTTCCTGCCT (SEQ ID NO: 283) 5 A_23_P70843 NM_001724BPGM Homo sapiens 2,3-bisphosphoglycerate mutaseTAGTAGAATTCCTCTTTGGCCACAAGAATAAG (BPGM), transcript variant 1, mRNACAGCAAATAAACAACTATGGCTGTTGAG (SEQ ID NO: 284) 5 A_24_P132039 NM_004290RNF14 Homo sapiens ring finger protein 14 (RNF14),GGGTGTTAGAACCTAGATTCAAAATGGCTTGT transcript variant 1, mRNACTTTGCTACTTTTGTTCCACATTCTCTC (SEQ ID NO: 285) 5 A_24_P173823 HSM800166Homo sapiens mRNA; cDNA DKFZp586J2118 ATGATACTAACACGGTGTAGGTTTTACAGTCTC(from clone DKFZp586J2118). CTAATTTGTACTGGTAATGCATATTCC (SEQ ID NO: 286)5 A_24_P285880 NM_003262 TLOC1 Homo sapiens translocation protein 1(TLOC1), AAGGTATTTTTCCTTTTCCCTCTTACTGGATTT mRNATTCAATTTTCAAACCATATGGCCTAGG (SEQ ID NO: 287) 5 A_24_P32790 NM_018566YOD1 Homo sapiens YOD1 OTU deubiquinating enzymeCTAGGGATCTAATTAAGGACATTAAAGTACAAT 1 homolog (yeast) (YOD1), mRNATCTTGAGCTACTAACCATCAGCTCTTC (SEQ ID NO: 288) 5 A_24_P335620 NM_003486SLC7A5 Homo sapiens solute carrier family 7 (cationicTTTCAGTCGTTGTGCTTTTTTGTTTTGTGCTAA amino acid transporter, y+ system),member 5 CGTCTTACTAATTTAAAGATGCTGTCG (SEQ ID (SLC7A5), mRNA NO: 289) 5A_24_P483083 NM_007111 TFDP1 Homo sapiens transcription factor Dp-1(TFDP1), AAACAGAAACAGTCTCAACTTCAAAACTTATTC mRNATACAGCAAATTGCCTTCAAGAACCTGG (SEQ ID NO: 290) 5 A_24_P503866 XM_930101LOC647087 PREDICTED: Homo sapiens hypothetical proteinTATACCTTTTCACATTAAAAAAGGTATTTATATT LOC647087 (LOC647087), mRNAATTACTTTGTAGTGATTGTCTTAAGA (SEQ ID NO: 291) 5 A_24_P570806TCTCAGAAGACAGAGGGTTTTCTTTTGAGGTA AATTTGATAGTACATTTTGATAGTACGG (SEQ IDNO: 292) 5 A_24_P599496 CNS01DVX Human chromosome 14 DNA sequence BAC C-GGCGGAAAACAAGTTTAGTCACAGAAGACTAC 2555C10 of library CalTech-D fromchromosome TCCATGTTTGAGCTTCTGTTTCAAGGGA (SEQ 14 of Homo sapiens (Human),complete ID NO: 293) sequence. 5 A_24_P673786 AL513128 Human DNAsequence from clone RP11-301N24 GTCTATAACAAACAGTCTGTTCATTTATTTCTG onchromosome 10 TTGATAAACCATTTGGACAGAGTGAGG (SEQ ID NO: 294) 5 A_24_P67946NM_019094 NUDT4 Homo sapiens nudix (nucleoside diphosphateGAACTCAGATTTGCAAACCAGGTTTCTGAAAC linked moiety X)-type motif 4 (NUDT4),transcript TTTGGGTAAGGTGTATGCTTTTAACTTT (SEQ variant 1, mRNA ID NO: 295)5 A_24_P886515 AC124287 Homo sapiens chromosome 17, clone RP13-CGTTGCCTGTCTTGCTGGATAACTGCATATATT 991F5, complete sequence.GTGTTCAGTTGTGTATTTGTTTTGCTT (SEQ ID NO: 296) 5 A_24_P926507 AC087685Homo sapiens chromosome 18, clone RP11- GAATAAACAGAAATAGGGAAGTAAACCTACAA618K16, complete sequence. ATATTTTAGGGAGAAGCTCACTTCTTCC (SEQ ID NO: 297)5 A_24_P935893 NM_017709 FAM46C Homo sapiens family with sequencesimilarity 46, TTCACATGCAAGTTCTAATCTAAAGTTAAGCAG member C (FAM46C), mRNATCTCTTATTTGTTTCGGGACTCTGATT (SEQ ID NO: 298) 5 4 Platelet A_32_P109653AF163864 Homo sapiens SNCA isoform (SNCA) gene,TGTGGTTTGGTATTCCAAGTGGGGTCTTTTTC complete cds, alternatively spliced.AGAATCTCTGCACTAGTGTGAGATGCAA (SEQ ID NO: 299) 5 A_32_P11181 AC034102Homo sapiens 12 BAC RP11-603J24 (Roswell GGCATGCTGTCCCAGGAAACTAGGGCTCCCAPark Cancer Institute Human BAC Library) CTAACTTATGAGGTTTTTAAACACATTGA(SEQ complete sequence. ID NO: 300) 5 A_32_P122715 AC025300 Homo sapienschromosome 11, clone RP11- GAAAGTTCACATACAGGGGAAAGTGTACGATT 573E11,complete sequence. TCATCTACTGTTTATCTTCTAACCTCAC (SEQ ID NO: 301) 5A_32_P133840 NM_014858 TMCC2 Homo sapiens transmembrane and coiled-coilCTTCCATTCCATTTAGCCTTTGGATCATCCTGG domain family 2 (TMCC2), mRNACTGGGAGAAGTGGGACCGAGCCACCCA (SEQ ID NO: 302) 5 A_32_P159651 NM_003884PCAF Homo sapiens p300/CBP-associated factorGAGTGGTGTCTAGATTTCTAATGAAGAATCAT (PCAF), mRNAGATACAGTTTGGATTAAGTATCTTGGAC (SEQ ID NO: 303) 5 A_32_P165297 HSJ842K24Human DNA sequence from clone RP5-842K24 onGAGGGGTATTTAGGGCCACTGTATTTTTGGTG chromosome Xq25-26.3 Contains the3′ end of the CCACAATTTTCTACATTGTTGGCATTTT (SEQ MBNL3 gene formuscleblind-like 3 (Drosophila) ID NO: 304) and a novel gene, completesequence. 5 A_32_P1712 NM_002934 RNASE2 Homo sapiens ribonuclease, RNaseA family, 2 TCCAGGTGCCTTTAATGTACTGTAACCTCACAA (liver, eosinophil-derivedneurotoxin) (RNASE2), CTCCAAGTCCACAGAATATTTCAAACT (SEQ ID mRNA NO: 305)5 A_32_P175183 AC019227 ZBTB44 Homo sapiens BAC clone RP11-567O18 from11, CAGTCAAGCTGTGGATGAAATGACCAGGAACG complete sequence.GAGAATGAAGTATGTAAATCCCAGCTTC (SEQ ID NO: 306) 5 A_32_P178945 NM_018566YOD1 Homo sapiens YOD1 OTU deubiquinating enzymeTTGCCAGCATTTTTTGAAGTAATACACTGCTGC 1 homolog (yeast) (YOD1), mRNATACCTGGAAGATGTCTAACTTCATTTT (SEQ ID NO: 307) 5 A_32_P192480 HSJ842K24Human DNA sequence from clone RP5-842K24 onTAGTGCTGTAGTGCTTGTTTATGTTTAAAAGTG chromosome Xq25-26.3 Contains the3′ end of the CACATTATGCAGCTCATTTTAGTATGC (SEQ ID MBNL3 gene formuscleblind-like 3 (Drosophila) NO: 308) and a novel gene, completesequence. 5 A_32_P204048 HSJ842K24 Human DNA sequence from cloneRP5-842K24 on GGGTGGGAAAGCATAAGATGGGGACTAAGAC chromosome Xq25-26.3Contains the 3′ end of the TTTGCCTTTAACCTTCATGACATGAAGAA (SEQ MBNL3 genefor muscleblind-like 3 (Drosophila) ID NO: 309) and a novel gene,complete sequence. 5 A_32_P23795 XM_929854 LOC646890 PREDICTED: Homosapiens hypothetical protein GATGAAGAATTTGCCTTACTTTGTTGTTCGCTC LOC646890(LOC646890), mRNA AGTTCCTAAGACTGTGAGTTGTCAAAT (SEQ ID NO: 310) 5A_32_P36694 NM_175061 JAZF1 Homo sapiens juxtaposed with another zincfinger CAGGTAAGGATGGGAATATTTTGTTATACTGT gene 1 (JAZF1), mRNAGTATAGTGAATGTATTGTACTGTGTCTG (SEQ ID NO: 311) 5 A_32_P465742NM_001031687 PIP5K1B Homo sapiens phosphatidylinositol-4-phosphate 5-TTCCTATGGACTTTTGCATTATTTCATTGTGCA kinase, type I, beta (PIP5K1B),TGCATCCAGTGATTATACATAAGCAAC (SEQ ID transcript variant 1, mRNA NO: 312)6 all cell types 6 A_23_P109133 NM_000490 AVP Homo sapiens argininevasopressin (neurophysin CGAGAGCTGCGTGACCGAGCCCGAGTGCCGC II,antidiuretic hormone, diabetes insipidus, GAGGGCTTTCACCGCCGCGCCCGCGCCAGneurohypophyseal) (AVP), mRNA (SEQ ID NO: 313) 6 A_23_P15174 NM_005949MT1F Homo sapiens metallothionein 1F (functional)TGCCAGGACAACCTTTCTCCCAGATGTAAACA (MT1F), mRNAGAGAGACATGTACAAACCTGGATTTTTT (SEQ ID NO: 314) 6 A_23_P157943 NM_016219MAN1B1 Homo sapiens mannosidase, alpha, class 1B,AGCTATGACAACAGCAAGAGTTGGCGGCGGC member 1 (MAN1B1), mRNAGCTCGTGCTGGAGGAAATGGAAGCAACTG (SEQ ID NO: 315) 6 A_23_P159191 NM_000805GAST Homo sapiens gastrin (GAST), mRNA AGCCTATGGATGGATGGACTTCGGCCGCCGCAGTGCTGAGGATGAGAACTAACAATCCTA (SEQ ID NO: 316) 6 A_23_P16483 NM_000455STK11 Homo sapiens serine/threonine kinase 11CCGTGGCCTCGTGCTCCGCAGGGCGCCCAGC (STK11), mRNAGCCGTCCGGCGGCCCCGCCGCAGACCAGC (SEQ ID NO: 317) 6 A_23_P208900GGGTCTCCGAGGTGCCGGTTAGGAGTTTGAA CCCCCCCCACTCTGCAGAGGGAAGCGGGG (SEQ IDNO: 318) 6 A_23_P211345 NM_080647 TBX1 Homo sapiens T-box 1 (TBX1),transcript variant TGTAGATACTGTAGATACTGTAGATACCGCCC C, mRNACGGCGCCGACTTGATAAACGGTTTCGCC (SEQ ID NO: 319) 6 A_23_P25790 NM_022478CDH24 Homo sapiens cadherin-like 24 (CDH24),CGAGACGTGTTGCCCCGGGCCCGGGTGTCGC transcript variant 1, mRNAGCCAGCCCAGACCCCCCGGCCCCGCCGAC (SEQ ID NO: 320) 6 A_23_P3413 NM_130901OTUD7 Homo sapiens OTU domain containing 7GCCGACGCGCCGACCGCGCGCTCGAACGGT (OTUD7), mRNAGAGTGCGGCCGTGGCGGCCCGGGGCCGGTG (SEQ ID NO: 321) 6 A_23_P346309 NM_004324BAX Homo sapiens BCL2-associated X protein (BAX),CCCGCGCGGACCCGGCGAGAGGCGGCGGCG transcript variant beta, mRNAGGAGCGGCGGTGATGGACGGGTCCGGGGAG (SEQ ID NO: 322) 6 A_23_P35534 NM_020999NEUROG3 Homo sapiens neurogenin 3 (NEUROG3), mRNACATTCAAAGAATACTAGAATGGTAGCACTACC CGGCCGGAGCCGCCCACCGTCTTGGGTC (SEQ IDNO: 323) 6 A_23_P401626 NM_174919 LOC201175 Homo sapiens hypotheticalprotein LOC201175 GCAGCGACTCAGAGAACGTCTACGAGGTCAT (LOC201175), mRNACCAGGACTTGCACGTCCCGCCGCCGGAGG (SEQ ID NO: 324) 6 A_23_P431346 NM_175887LOC222171 Homo sapiens hypothetical protein LOC222171CCCCAAACCAGACAAGTTATACGGGGACAAAT (LOC222171), mRNACCGGCAGCAGCCGCCGCAATTTGAAGAT (SEQ ID NO: 325) 6 A_23_P96072 NM_000832GRIN1 Homo sapiens glutamate receptor, ionotropic, N-CAGGGTGCAGGCGCGCACCGCCCAACCCCCA methyl D-aspartate 1 (GRIN1), transcriptvariant CCTCCCGGTGTATGCAGTGGTGATGCCTA NR1-1, mRNA (SEQ ID NO: 326) 6A_24_P108738 NM_153334 SCARF2 Homo sapiens scavenger receptor class F,CAGCGCCGCTGCAGCTGGCCGTGCGCCCTCA member 2 (SCARF2), transcript variant 1,mRNA CCACCGCCGCCAGGCTCCGAGGCCGCGCC (SEQ ID NO: 327) 6 A_24_P112803NM_005986 SOX1 Homo sapiens SRY (sex determining region Y)-GCTGGGCTCTCTGGTGAAGTCGGAGCCCAGC box 1 (SOX1), mRNAGGCAGCCCGCCCGCCCCAGCGCACTCGCG (SEQ ID NO: 328) 6 A_24_P113725 NM_005634SOX3 Homo sapiens SRY (sex determining region Y)-GCCGCCCGCCATCGCATCGCACTCTCAGCGC box 3 (SOX3), mRNAGCGTGCCTCGGCGACCTGCGCGACATGAT (SEQ ID NO: 329) 6 A_24_P11737 XR_015426LOC731268 PREDICTED: Homo sapiens similar to zinc fingerGTGAGAAGTTCTGCAGATGTATGTGGCGCACA protein 499 (LOC731268),GCCTCTACAGCCGCCGACTCCGACTCCT (SEQ ID NO: 330) 6 A_24_P117782 NM_033129SCRT2 Homo sapiens scratch homolog 2, zinc fingerCTTCAAGCACTACCGCTGCCGCCAGTGCGAC protein (Drosophila) (SCRT2), mRNAAAGAGCTTCGCGCTCAAGTCCTACCTCCA (SEQ ID NO: 331) 6 A_24_P127719 NM_201589MAFA Homo sapiens v-maf musculoaponeuroticGTTCGAGGTGAAGAAGGAGCCTCCCGAGGCC fibrosarcoma oncogene homolog A (avian)GAGCGCTTCTGCCACCGCCTGCCGCCAGG (MAFA), mRNA (SEQ ID NO: 332) 6A_24_P144465 NM_022107 GPSM3 Homo sapiens G-protein signalling modulator3 CAGACTGAACTCCTTCTGGACCTGGTGGCTGA (AGS3-like, C. elegans) (GPSM3), mRNAAGCCCAGTCCCGCCGCCTGGAGGAGCAG (SEQ ID NO: 333) 6 A_24_P253293 NM_014360NKX2-8 Homo sapiens NK2 transcription factor related,GCGAGGTGGGAACCGCCGCGGCCCAGGAGA locus 8 (Drosophila) (NKX2-8), mRNAAGTGCGGCGCCCCTCCAGCCGCCGCCTGCC (SEQ ID NO: 334) 6 A_24_P273378 NM_006549CAMKK2 Homo sapiens calcium/calmodulin-dependentCCGGGCCGCCCCCCAGGATGAGCTGGGGGG protein kinase kinase 2, beta (CAMKK2),TAGGGGCAGCAGCAGCAGCGAAAGCCAGAA transcript variant 1, mRNA (SEQ ID NO:335) 6 A_24_P280660 NM_178174 TREML1 Homo sapiens triggering receptorexpressed on GAGGGGTGCCAGCCCCTGGTGTCCTCAGCTG myeloid cells-like 1(TREML1), mRNA TGGATCGCAGAGCTCCAGCGGGCAGGCGT (SEQ ID NO: 336) 6A_24_P315500 NM_014223 NFYC Homo sapiens nuclear transcription factor Y,TCAGGAGTCCAGGAAGAGCAGGAGCCGCCCC gamma (NFYC), mRNACGCGCTCCTACGGAGTCGGGCAATGCAGA (SEQ ID NO: 337) 6 A_24_P328446 NM_016170TLX2 Homo sapiens T-cell leukemia homeobox 2ACGGAGCCTCGGGCTACGGTCCCGCCGGCTC (TLX2), mRNAACTTGCCCCGCTGCCCGGCAGCTCCGGAG (SEQ ID NO: 338) 6 A_24_P376451 NM_000514GDNF Homo sapiens glial cell derived neurotrophicAACAGCAATGGTGCCGCCGCCGGACGGGACT factor (GDNF), transcript variant 1,mRNA TTAAGATGAAGTTATGGGATGTCGTGGCT (SEQ ID NO: 339) 6 A_24_P37665NM_022042 SLC26A1 Homo sapiens solute carrier family 26 (sulfateTTATTTGAACAAGGGTCCCCCGCCATCATGCA transporter), member 1 (SLC26A1),transcript GCCTCCAAGGTGCCAAGAGGACTCCCTA (SEQ variant 1, mRNA ID NO: 340)6 A_24_P40775 XM_290842 LRFN1 PREDICTED: Homo sapiens leucine richrepeat AGGGGGCGCGGCCGGGGAGGATGGAGACCT and fibronectin type III domaincontaining 1 GGGGCTGGGCTCCGCCAGGGCGTGCCTGGC (LRFN1), mRNA (SEQ ID NO:341) 6 A_24_P416595 NM_174945 ZNF575 Homo sapiens zinc finger protein575 (ZNF575), CAAGCTGGCCACGCACCGCTTAGCACACGGA mRNAGGCGCCCGACCCCACCCATGCCCAGACTG (SEQ ID NO: 342) 6 A_24_P471099TGCAGGTTTTTGCCCCCGCCGTTGCGGCTGTT TTCCCCCCGTCAGCGAGGCTTTTTGTTG (SEQ IDNO: 343) 6 A_24_P535483 NM_207349 LOC284739 Homo sapiens hypotheticalprotein LOC284739 AGGAGGCCCGCCCTCCACGCGCCGAAGGCCT (LOC284739), mRNACAATAAACGGAGCTGGCGCTGCGGGTCCG (SEQ ID NO: 344) 6 A_24_P600087GGGGGTTTCCCCCCCGGGAGGACCCCCCCTG GGGGCCCCCCTGTTTGTTACACGGCGGGT (SEQ IDNO: 345) 6 A_24_P75183 NM_199046 TEPP Homo sapienstestis/prostate/placenta-expressed TCAGCGGCTACGCGGTGCGGTACTTGAAGCCprotein, isoform 2 (TEPP), transcript variant 1,CGACGTGACCCAGACCTGGCGGTACTGCC mRNA (SEQ ID NO: 346) 6 A_24_P780709AGGCAGCCGCCGGGCCAGGTCGAGGCCGCC GCCGCCCGGCCAGAGCACGCCAGGGAGCAG (SEQ IDNO: 347) 6 A_24_P920135 CAAGTGGAAAAAAATATTAAAAAACTGATAATGGCCTCGGTTGGCCTCAGCGGCGGAACT (SEQ ID NO: 348) 6 A_32_P138359 NM_012331MSRA Homo sapiens methionine sulfoxide reductase ATGCGGCTCCGCTGCCGGTAGCGCCGTCCCCC (MSRA), mRNAGGGACCACCCTTCGGCTGGCGCCCTCCCA (SEQ ID NO: 349) 6 A_32_P336712 NM_173573C11orf35 Homo sapiens chromosome 11 open readingAGCCCCAAGGGCGAGGTCCTCAGTGAGCACC frame 35 (C11orf35), mRNAGGATCCCACGCCGCGAGACTCCGGCCCCG (SEQ ID NO: 350) 6 A_32_P509169 NM_207322NLF1 Homo sapiens nuclear localized factor 1 (NLF1),CCCCGCCTGGCCTTGGCTGCGCTCCGGAATT mRNA CTTGGGTCGAAGAAGCAGGGATGGACGAG (SEQID NO: 351) 7 B cells 7 4 B cells A_23_P158817 NM_001040070 ELK2P1 ELK2,member of ETS oncogene family, ATGCATGAGGCTCTGCACAACCACTACACGCApseudogene 1 GAAGAGCCTCTCCCTGTCTCCGGGTAAA (SEQ ID NO: 352) 7 4 B cellsA_23_P158868 ACACCTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCAT (SEQ ID NO: 353) 7 A_23_P168229 NM_022085TXNDC5 Homo sapiens thioredoxin domain containing 5ATACGCAAGGGGATGTGGATACTTGGCCCAAA (TXNDC5), transcript variant 2, mRNAGTAACTGGTGGTAGGAATCTTAGAAACA (SEQ ID NO: 354) 7 7 B cells A_23_P21260TAGGAGACAGAGTCACCATCACTTGCCGGGC AAGTCAGACCATTAGCAGCTATTTAAATT (SEQ IDNO: 355) 7 4 B cells A_23_P350782 XM_942302 LOC652694 PREDICTED: Homosapiens similar to Ig kappa GCAGCCTGCAGCCTGAAGATATTGCAACATAT chain V-Iregion HK102 precursor (LOC652694), TACTGTCAACAGTATGATAATCTCCCTC (SEQmRNA ID NO: 356) 7 5 B cells A_23_P361654 AC073416 Homo sapiens BACclone RP11-136K15 from 2, TCAGGGTATTAGCAGCTGGTTAGCCTGGTATC completesequence. AGCAGAAACCAGAGAAAGCCCCTAAGTC (SEQ ID NO: 357) 7 9 B cellsA_23_P435390 AGACAGCACTGGTTCTTATTTGCTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCA (SEQ ID NO: 358) 7 3 B cells A_23_P44053AGCTCCTGATCTACGATGCATCCACTTTGGAA ACCGGGGTCCCATCAAGGTTCAGTGCAC (SEQ IDNO: 359) 7 7 B cells A_23_P61042 S55735 Homo sapiens immunoglobulinA1-A2 lambda GAGTTGAAGACCCCACTAACCGCCAACATCAC hybrid GAU heavy chainmRNA, partial cds. AAAATCCGGAAACACATTCCGGCCCGAG (SEQ ID NO: 360) 7 8 Bcells A_23_P61068 GCCTGAAGATCTTGCAGTATATTACTGTCAGCAGTATAGTAGTCCACCTCGGACTTTTGG (SEQ ID NO: 361) 7 A_23_P72330AGATGGTGCAGCCACAGTTCGTTTGATCTCCA GCTCGAGCCGCTGCGTGTTTTCCTCTTG (SEQ IDNO: 362) 7 5 B cells A_23_P84596 NM_016459 PACAP Homo sapiensproapoptotic caspase adaptor GGACATGTTTGCACTACTTGGGGGAGTTTGGA protein(PACAP), mRNA GAAGACCAGATCTATGAAGCCCACCAAC (SEQ ID NO: 363) 7 4 B cellsA_24_P100684 ATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTC (SEQ ID NO: 364) 7 5 B cells A_24_P144346GTGGCACATACTATGCAGACTCCGTGAAGGG CCGATTCACCATCTCCAGAGACAATGCCA (SEQ IDNO: 365) 7 6 B cells A_24_P15388 GCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTAT (SEQ ID NO: 366) 7 2 B cells A_24_P15550GCAGGGTGGAGGCTGAGGATGTTGGGGTTTA TTACTGCATGCAAGGTACACACTGGCCTC (SEQ IDNO: 367) 7 A_24_P169713 S80758 Ig VL = platelet glycoprotein IIIaCATAGTTATAACCAACGTCACTGCTGGTT leucine-33 form-specific antibody lightCCAGTGCAGGAGATGGTGATCGACTGTC (SEQ chain variable region [human, ID NO:368) plasma, mRNA Partial, 329 nt]. 7 13 B cells A_24_P169873 HSM806780Homo sapiens mRNA; cDNA DKFZp686O16217 GTAAACCCACCCACATCAATGTGTCTGTTGTC(from clone DKFZp686O16217). ATGGCGGAGGCGGATGGCACCTGCTACT (SEQ ID NO:369) 7 A_24_P204374 AGCCTGATGCCTGAACAGTGGAGATCCCGCAGCAGCTACAACTGCTGGGCCATGCATAAA (SEQ ID NO: 370) 7 4 B cells A_24_P204574HUMIGLVE Homo sapiens Ig germline lambda-chain geneGAGGATGAGGCTGATTATTACTGTGCAGCATG variable region myeloma subgroup I(IGLV), GGATGACAGCCTGAGTGGTCCCACAGTG complete exon. (SEQ ID NO: 371) 7 5B cells A_24_P212024 TGATCTATGCTGCATCCAGTTTGCAGTCGGGGGTCCCATCTCGGTTCAGTGGCAGTGGAT (SEQ ID NO: 372) 7 5 B cells A_24_P239076NM_001013618 LOC91353 Homo sapiens similar to omega proteinAACAAGGCCACACTGGTGTGTCTCATGAATGA (LOC91353), mRNACTTCTATCTGGGAATCTTGACGGTGACC (SEQ ID NO: 373) 7 4 B cells A_24_P24371CACAAGCCCAGCAACACCAAGGTGGACAAGA GAGTTGAGTCCAAATATGGTCCCCCATGC (SEQ IDNO: 374) 7 7 B cells A_24_P272146 TCACTATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAACA (SEQ ID NO: 375) 7 3 B cells A_24_P315854ATCAGTAGACACGTCCAAGAACCAGTTCTCCC TGAAGCTGAGCTCTGTGACCGCTGCGGA (SEQ IDNO: 376) 7 4 B cells A_24_P33341 XM_370973 LOC388255 PREDICTED: Homosapiens similar to Ig heavy CCGTATCTGCAAATGAACAGCTTGAGAGCTGA chain V-IIIregion VH26 precursor (LOC388255), GGACACGGCTGTGTATTACTGTGTGAAA (SEQmRNA ID NO: 377 7 7 B cells A_24_P357847CCATCAGCAGCCTGCAGTCTGAAGATTTTGCA GTTTATTACTGTCAGCAGTATAATAACT (SEQ IDNO: 378) 7 4 B cells A_24_P465799 AF063695 Homo sapiens clone BCPBLL11immunoglobulin CTGTCAGGTGTGGGATAGTACTAGTGATCATT lambda light chainvariable region mRNA, partial ATGTCTTCGGAACTGGGACCAAGGTCGC (SEQ cds. IDNO: 379) 7 6 B cells A_24_P488083 HSA519285 Homo sapiens partial mRNAfor IgM CAATTCCAAGAACACGCTGTATCTGCAAGTGA immunoglobulin heavy chainvariable region (IGHV ACAGCCTGAGAGTCGAGGACACGGCCCT gene), cloneANBPM204. (SEQ ID NO: 380) 7 6 B cells A_24_P490109AGCAGCCTGCAGCCTGAAGATTTTGCAACCTA TTACTGTCAACAGAGTGACAACACAAGA (SEQ IDNO: 381) 7 7 B cells A_24_P510357 S76132 Ig V lambda II = IgG rheumatoidfactor [human, CATCACTGGTCTCCAGGCTGAGGACGAGGCT hybridoma AEE111F, mRNAPartial, 315 nt]. GATTATTACTGCAGCTCATATACAAGCAG (SEQ ID NO: 382) 7 9 Bcells A_24_P605563 S42404 Ig lambda chain = anti-Rh(D) antibody [human,AAGATAGCAGCCCCGTCAAGCGGGAGTGGAG mRNA Partial, 642 nt].ACCACCACACCCTCCAAACAAAGCAACAA (SEQ ID NO: 383) 7 5 B cells A_24_P608268CCAGAGATGATTCCAAGAACACGGCGTATCTG CAAATGAACAGCCTGAAAACCGAGGACA (SEQ IDNO: 384) 7 5 B cells A_24_P626951 GACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGAATTAGCAATTATTTAGCCTGGTTT (SEQ ID NO: 385) 7 3 B cells A_24_P66578GCAGATTACACTCTCACCATCCGCAGCCTGCA GCCTGAAGATTTTGCAAATTATTACTGT (SEQ IDNO: 386) 7 6 B cells A_24_P702749 ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGGTGT (SEQ ID NO: 387) 7 4 B cells A_24_P76868HSZ74662 H. sapiens mRNA for immunoglobulin, light chain,TGGGCATCACCGGACTCCAGACTGGGGACGA V-J region.GGCCGATTATTACTGCGGAACATGGAATA (SEQ ID NO: 388) 7 6 B cells A_24_P83102NM_001013618 LOC91353 Homo sapiens similar to omega proteinTCCAAGCCAACAAGGCTACACTGGTGTGTCTC (LOC91353), mRNAATGAATGACTTTTATCCGGGAATCTTGA (SEQ ID NO: 389) 7 3 B cells A_24_P852001HSA234192 Homo sapiens mRNA for Ig heavy chain variableAGTTTGGGCTGAGCTGCCTTTTTCTTGTGGCT region, clone C2.ATTTTAAAAGGTGTCCAGTGTGAGGTGC (SEQ ID NO: 390) 7 6 B cells A_32_P148118CAGCAGCCTGCAGCCTGAAGATTTTGCAGCTT ATTACTGTCAACAGAGTGACAGTACCCC (SEQ IDNO: 391) 7 3 B cells A_32_P157927 AC096579 Homo sapiens BAC cloneRP11-601N4 from 2, GGCCACCATCAACTGCAAGTCCAGCCAGAGT complete sequence.GTTTTATACAGCTCCAAGAATAAGAACTA (SEQ ID NO: 392) 7 6 B cells A_32_P159192AGCAGCCTGCAGCCTGAAGATTTTGCAGTTTA TTACTGTCAGCAGGATIATMCTTACCT (SEQ ID NO:393) 7 13 B cells A_32_P200144 XM_939003 LOC649923 PREDICTED: Homosapiens similar to Ig gamma- CGTGAGGATGCTTGGCACGTACCCCGTGTAC 2 chain Cregion (LOC649923), mRNA ATACTTCCCAGGCACCCAGCATGGAAATA (SEQ ID NO: 394)7 7 B cells A_32_P39440 GTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAG (SEQ ID NO: 395) 7 4 B cells A_32_P43664NM_144646 IGJ Homo sapiens immunoglobulin J polypeptide,TCTGTCATAAGTGTAGCAGGTCTCTGTAGCAC linker protein for immunoglobulin alphaand mu TGTCTTCATCACAGATATTGCTCTGGGT (SEQ polypeptides (IGJ), mRNA ID NO:396) 7 3 B cells A_32_P722809 XM_940969 LOC651751 PREDICTED: Homosapiens similar to Ig kappa GATTTTACACTGAAAATCAGCAGAGTGGAGGC chain V-IIregion RPMI 6410 precursor TGAGGATGTTGGGGTTTATTACTGCATG (SEQ(LOC651751), mRNA ID NO: 397) 8 all cell types 8 A_23_P148473 NM_000206IL2RG Homo sapiens interleukin 2 receptor, gammaCTTTCCTGTTTGCATTGGAAGCCGTGGTTATC (severe combined immunodeficiency)(IL2RG), TCTGTTGGCTCCATGGGATTGATTATCA (SEQ mRNA ID NO: 398) 8A_23_P21057 NM_052838 SEPT1 Homo sapiens septin 1 (SEPT1), mRNAATTTCCTGAACCTGCGACGGATGCTGGTGCAG ACACACCTGCAGGACCTGAAAGAGGTGA (SEQ IDNO: 399) 8 A_23_P213424 NM_003633 ENC1 Homo sapiens ectodermal-neuralcortex (with BTB- GTTGGAGGATACTTTGGCATTCAGCGATGCAA like domain) (ENC1),mRNA GACTTTGGACTGCTACGATCCAACATTA (SEQ ID NO: 400) 8 A_23_P25069XM_927026 LOC440080 PREDICTED: Homo sapiens similar to cDNATTTACTCCAACCATGTCATCCATTGAAGAGCTT sequence BC048546, transcript variant2 GAAAACAAGGGCCAAGTGATGAAGACT (SEQ (LOC440080), mRNA ID NO: 401) 8A_23_P26810 NM_000546 TP53 Homo sapiens tumor protein p53 (Li-FraumeniCTGTGAGGGATGTTTGGGAGATGTMGAAATG syndrome) (TP53), mRNATTCTTGCAGTTAAGGGTTAGTTTACAAT (SEQ ID NO: 402) 8 A_23_P301925 MIHSXX H.sapiens mitochondrial genome. CTACGTTGTAGCCCACTTCCACTATGTCCTATCAATAGGAGCTGTATTTGCCATCATAGG (SEQ ID NO: 403) 8 A_23_P315252 HUMMTCGHuman mitochondrion, complete genome. CATCGCTGGGTCAATAGTACTTGCCGCAGTACTCTTAAAACTAGGCGGCTATGGTATAAT (SEQ ID NO: 404) 8 A_23_P337726 MIHSXX H.sapiens mitochondrial genome. CATGGCCATCCCCTTATGAGCGGGCACAGTGATTATAGGCTTTCGCTCTAAGATTAAAAA (SEQ ID NO: 405) 8 A_23_P402751 MTHSCOXIIHomo sapiens mitochondrial coxII mRNA forGACTCCTTGACGTTGACAATCGAGTAGTACTC cytochrome C oxidase II subunit.CCGATTGAAGCCCCCATTCGTATAATAA (SEQ ID NO: 406) 8 A_23_P70095 NM_001025158CD74 Homo sapiens CD74 antigen (invariant polypeptideAAGATCAGAAGCCAGTCATGGATGACCAGCG of major histocompatibility complex,class II CGACCTTATCTCCAACAATGAGCAACTGC antigen-associated) (CD74),transcript variant 3, (SEQ ID NO: 407) mRNA 8 A_23_P86943 NM_003139 SRPRHomo sapiens signal recognition particle receptorGCTAGGCTGGAGTGATTTGTTACAAATGAGCA (‘docking protein’) (SRPR), mRNAAAAGATGAGTCCTTGCTTCCCTCAGAAA (SEQ ID NO: 408) 8 A_23_P98884 NM_005785RNF41 Homo sapiens ring finger protein 41 (RNF41),TTCCAGATGAGCTCTTCTTTCCTACAAGTTTTC transcript variant 1, mRNAATAATTAGGGAATGCCAGGGTTTAGGG (SEQ ID NO: 409) 8 A_24_P202319 NM_005173ATP2A3 Homo sapiens ATPase, Ca++ transporting,CAACTTCTACCAGCTGAGGAACTTCCTGAAGT ubiquitous (ATP2A3), transcript variant1, mRNA GCTCCGAAGACAACCCGCTCTTTGCCGG (SEQ ID NO: 410) 8 A_24_P204334CTAGCCAIGGCCATCCCCTTAAGCGGGGTGAT TATAGGCTTTCGCTCTAAGATTAAAAAT (SEQ IDNO: 411) 8 A_24_P350200 AAGGCCACCACACACCACCTGTCCAGAAAGGCCTTCGATACGGGATAATCCTATTTATTA (SEQ ID NO: 412) 8 A_24_P381224 NM_032431SYVN1 Homo sapiens synovial apoptosis inhibitor 1,AAGTTTAGAATTGGAATTACTTCCTTACTAGTG synoviolin (SYVN1), transcript variant1, mRNA TCTTTTGGCTTAAATTTTGTCTTTTGA (SEQ ID NO: 413) 8 A_24_P416728NM_001130 AES Homo sapiens amino-terminal enhancer of splitACGGCTTGAACATCGAGATGCACAAACAGGCT (AES), transcript variant 2, mRNAGAGATCGTCAAAAGGCTGAACGGGATTT (SEQ ID NO: 414) 8 A_24_P551842CTCCGATCCGTCCCTAAACAAACTAGGAGGCG TCCTTTGCCCTATTATATCCATCCTCAT (SEQ IDNO: 415) 8 A_24_P700170 NM_014225 PPP2R1A Homo sapiens proteinphosphatase 2 (formerly ACGGCTGAACATCATCTCTAACCTGGACTGTG 2A), regulatorysubunit A (PR 65), alpha isoform TGAACGAGGTGATTGGCATCCGGTCAGC (SEQ(PPP2R1A), mRNA ID NO: 416) 8 A_24_P710024TTAGCATCATCCCTCTACTATTTTTTAGCCAAA TCAACAACAACCTATTTTAGCTGTTCC (SEQ IDNO: 417) 8 A_24_P713185 AATATGACTAGCTTACACAATAGCTCACATAGTACAGATACTCTTTACGGACTCCACTTA (SEQ ID NO: 418) 8 A_24_P910169TTACATGGGTTTTCATGATCAGCCGCGAAACT GAGAACGTCAGGTCAGCGAGGAGATTGG (SEQ IDNO: 419) 9 B cells 9 5 B cells A_23_P10356 NM_021777 ADAM28 Homo sapiensADAM metallopeptidase domain 28 CTTAGAAGCTTCGAACTGAAAATCATGGAAAG(ADAM28), transcript variant 3, mRNA GTTTTAAGATTTGAGGTTGGTTTTAGGG (SEQID NO: 420) 9 9 B cells A_23_P113572 NM_001770 CD19 Homo sapiens CD19antigen (CD19), mRNA TACATGCCAGTGACACTTCCAGTCCCCTTTGTATTCCTTAAATAAACTCAATGAGCTCTT (SEQ ID NO: 421) 9 6 B cells A_23_P116371NM_021950 MS4A1 Homo sapiens membrane-spanning 4-domains,GAGCTCACACACCATATATTAACATATACAACT subfamily A, member 1 (MS4A1),transcript variant GTGAACCAGCTAATCCCTCTGAGAAAA (SEQ 3, mRNA ID NO: 422)9 6 B cells A_23_P121657 NM_005114 HS3ST1 Homo sapiens heparan sulfate(glucosamine) 3-O- GGCAGAACATTTGACTGGCACTGATTTGCAAT sulfotransferase 1(HS3ST1), mRNA AAGCTAAGCTCAGAAACTTTCCTACTGT (SEQ ID NO: 423) 9A_23_P125618 NM_000808 GABRA3 Homo sapiens gamma-aminobutyric acid(GABA) TGCATGCCTGCCCACTGAAGTTTGGAAGCTAT A receptor, alpha 3 (GABRA3),mRNA GCCTATACAACAGCTGAAGTGGTTTATT (SEQ ID NO: 424) 9 4 B cellsA_23_P149368 NM_052938 FCRL1 Homo sapiens Fc receptor-like 1 (FCRL1),mRNA AAACAAGATGGAATAAAAGAAATTGGGATCTT GGGTTGGAGGGACAGTGAAGCTTAGAGC (SEQID NO: 425) 9 A_23_P151166 NM_032369 MGC15619 Homo sapiens hypotheticalprotein MGC15619 TCTAGAAAAGTCTCTTATTTTCAAGCTGTTCTA (MGC15619), mRNAAATAGCTTCGTCTCAGTTTCCCCAAAA (SEQ ID NO: 426) 9 9 B cells A_23_P160751NM_030764 FCRL2 Homo sapiens Fc receptor-like 2 (FCRL2),GAGGAATCAGAAGGGAAGATCAACAGCAAGG transcript variant 2, mRNAATGGGGCATCATTAAGACTTGCTATAAAA (SEQ ID NO: 427) 9 4 B cells A_23_P207201NM_000626 CD79B Homo sapiens CD79B antigen (immunoglobulin-CGCTGAAGGATGGTATCATCATGATCCAGACG associated beta) (CD79B), transcriptvariant 1, CTGCTGATCATCCTCTTCATCATCGTGC (SEQ mRNA ID NO: 428) 9 7 Bcells A_23_P209055 NM_001771 CD22 Homo sapiens CD22 antigen (CD22), mRNAGCCTCAGGCACAAGAAAATGTGGACTATGTGA TCCTCAAACATTGACACTGGATGGGCTG (SEQ IDNO: 429) 9 4 B cells A_23_P250245 NM_001782 CD72 Homo sapiens CD72antigen (CD72), mRNA TGCTCAAAGCTCAAAATGTAACAAGGTACATAAAACTTGGTCATGGTGGACACTGGAGTC (SEQ ID NO: 430) 9 A_23_P307382 NM_080552SLC32A1 Homo sapiens solute carrier family 32 (GABACCAGCTTGCCTGCCGGTTTTCAGGAATCTAAA vesicular transporter), member 1(SLC32A1), CTCTCATCTTGTGCAATTTATCAGGTGT (SEQ mRNA ID NO: 431) 9 5 Bcells A_23_P31725 NM_001715 BLK Homo sapiens B lymphoid tyrosine kinase(BLK), TCGCACGGTCATCCGGAGTACTAAGCCCCAGT mRNAAAGGTGTTCAGGACTGGTAAGCGACTGT (SEQ ID NO: 432) 9 5 B cells A_23_P357717NM_021966 TCL1A Homo sapiens T-cell leukemia/lymphoma 1ATTTCCCCCCTTTATAGATGGTCACGCACCTGG (TCL1A), mRNAGTGTTACAAAGTTGTATGTGGCATGAAT (SEQ ID NO: 433) 9 A_23_P398294 NM_003959HIP1R Homo sapiens huntingtin interacting protein 1GTTAGCATTTCCTCCTGAAGTGTTCTGTTGGC related (HIP1R), mRNAAATAAAATGCACTTTGACTGTTTGTTGT (SEQ ID NO: 434) 9 A_23_P76402 NM_024549FLJ21127 Homo sapiens tectonic (FLJ21127), mRNAGCTTTGGTTATAGAAGTGAAGTGGACTAAATA CGGATCCCTGCTGAATCCACAGGCCAAA (SEQ IDNO: 435) 9 2 B cells A_23_P904 NM_024603 C1orf165 Homo sapienschromosome 1 open reading frame CATCGTCAGAGAGTGTTTGTATGACAGAATAG 165(C1orf165), mRNA CACAAGAAACTGTGGATGAAACTGAAAT (SEQ ID NO: 436) 9 4 Bcells A_24_P203056 NM_001024808 BCL7A Homo sapiens B-cell CLL/lymphoma7A (BCL7A), TCGCCAAGAACCTGGTTAGAGGCATAAAGACC transcript variant 2, mRNATTTTTTCACCGTTACCTAATTTTTTCCC (SEQ ID NO: 437) 9 4 B cells A_24_P252945NM_001716 BLR1 Homo sapiens Burkitt lymphoma receptor 1, GTPTTTTCTTTTTAATAAAAAGGCACCTATAAAACA binding protein (chemokine (C-X-Cmotif) receptor GGTCAATACAGTACAGGCAGCACAGAG (SEQ 5) (BLR1), transcriptvariant 1, mRNA ID NO: 438) 9 A_24_P254106AACACTATTGTAGGTAGTGATATGTGTGTTAG GAAAAAAATAAGGCCGAGAGAGGGGAGT (SEQ IDNO: 439) 9 A_24_P305067 NM_024015 HOXB4 Homo sapiens Homo box B4(HOXB4), mRNA GATCAACTCAAACTATGTCGACCCCAAGTTCCCTCCATGCGAGGAATATTCACAGAGCGA (SEQ ID NO: 440) 9 3 B cells A_24_P324838HSIGCMUDE Human immunoglobulin C(mu) and C(delta) heavyAGATGGTGCAGTGGTTAGAGCTGAGGCTTATC chain genes (constant regions).CCACAGAGAACCCTGGCGCCTTGGTCAA (SEQ ID NO: 441) 9 4 B cells A_24_P413126NM_020182 TMEPAI Homo sapiens transmembrane, prostate androgenAAGAAACTGCTTGTTGTGTATCAGTAATCATTA induced RNA (TMEPAI), transcriptvariant 1, GTGGCAATGATGACATTCTGAAAAGCT (SEQ mRNA ID NO: 442) 9 8 B cellsA_24_P417352 HSIGCMUS Human C mu gene for IgM heavy chain exons CH1TGACCACCTATGACAGCGTGACCATCTCCTGG 4, secretory.ACCCGCCAGAATGGCGAAGCTGTGAAAA (SEQ ID NO: 443) 9 8 B cells A_24_P621701HS250D10 Human DNA sequence from clone CTA-250D10TGGTAAGTTTCTCTCTCTTTAGAGACTCCACAA on chromosome 22TAAAGTTTTCAACATGGTAAGGTTTTC (SEQ ID NO: 444) 9 7 B cells A_24_P64344NM_013314 BLNK Homo sapiens B-cell linker (BLNK), mRNATAAGCGAGTATATAATATTCCTGTGCGATTTAT TGAAGCAACAAAACAATATGCCTTGGG (SEQ IDNO: 445) 9 A_24_P916364 AC007172 Homo sapiens chromosome 9, cloneGGGTGAATGTTTGAAAATCATGAATCAGCCAC hRPK.538_E_7, complete sequence.CATTATTAATTGAAGAGCTGGGAATACC (SEQ ID NO: 446) 9 7 B cells A_24_P940348NM_173544 BCNP1 Homo sapiens B-cell novel protein 1 (BCNP1),AGACAAGCTTTTACCGACTTCCTCTGCTTGCC mRNA AGCAAAGTCATCTGCTAACTGGATATTG (SEQID NO: 447) 9 A_24_P95723 NM_014792 KIAA0125 Homo sapiens KIAA0125(KIAA0125), mRNA CCATTTTAAAGATGGCTACTTAGGACCATATGGATGTTGTACTGATGTCATTTGACCACG (SEQ ID NO: 448) 9 A_32_P107002NM_001012391 LOC400509 Homo sapiens similar to FLJ12363 proteinTGTGAAAAGCATCGATGATGAAGATGTGGATG (LOC400509), mRNAAAAACGAAGATGACGTGTATGGAAACTC (SEQ ID NO: 449) 9 3 B cells A_32_P13337AC006230 Homo sapiens chromosome 4 clone C0287J14ATCCTCCATGGTATCTGAATCCCAGAATCCTA map 4p16, complete sequence.CAATCCTGCATGGTATCTGAAACATACT (SEQ ID NO: 450) 9 3 B cells A_32_P137819AL450344 Human DNA sequence from clone RP11-136K14CTGCAGATCTTTATTACTGGCAAGAAAGTCCC on chromosome 6 Contains three novelgenes, the AGAAGTTCTTTTCTCTAACTTATGACTA (SEQ 5′ end of a novel gene(contains FLJ31738 and ID NO: 451) KIAA1209) and a CpG island, completesequence. 9 4 B cells A_32_P356316 NM_002119 HLA-DOA Homo sapiens majorhistocompatibility complex, TGGAAAGGTGTTTCTCTCATCTCTGTCCTAAG class II,DO alpha (HLA-DOA), mRNA GCTTGATAAAGTCATTAAAATTGTGTTC (SEQ ID NO: 452) 93 B cells A_32_P57013 NM_018014 BCL11A Homo sapiens B-cell CLL/lymphoma11A (zinc ATAATACAAAGATGGCGCAGGGAAGATGAATT finger protein) (BCL11A),transcript variant 2, GTGGGAGAGCCGTCATGGCTTTTTTTTA (SEQ mRNA ID NO: 453)9 A_32_P64016 CTCTGAGGCTAAGATTACTGGTGTACTCATTGGGACCAGTTTGGTCTCAGTGACTGAAAA (SEQ ID NO: 454) 9 9 B cells A_32_P71876AL356276 Human DNA sequence from clone RP11-367J7 onGAAGTTTGAACTTCTTTGTATTGTATGATCATC chromosome 1CCTTTACCTTAATACTCACATGAAATG (SEQ ID NO: 455) 9 A_32_P8813GACGGGACATCATGCTGGGCAACACAGCTAA AATGCGGGTGAAGACCAGATTTCTTGCAC (SEQ IDNO: 456) 10 all cell types 10 A_23_P117480 CNS06C82 Human chromosome 14DNA sequence BAC C- ATTGTCGGCATCTTCCATGCTCTGAGTCAGTT 2335L22 of libraryCalTech-D from chromosome AGCATTTACAGTGAATCTGCCCTTCTGT (SEQ 14 of Homosapiens (Human), complete ID NO: 457) sequence. 10 A_23_P153827NM_005934 MLLT1 Homo sapiens myeloid/lymphoid or mixed-lineageTACACCGGAGGCTGATGGCGCTGCGGGAGCG leukemia (trithorax Homolog,Drosophila); CAACGTGCTGCAGCAGATTGTGAATCTGA translocated to, 1 (MLLT1),mRNA (SEQ ID NO: 458) 10 A_23_P170464 NM_031297 DKFZP761H1 Homo sapienshypothetical protein TGGCCCCAGAGGATGAGGTCATTGTGAATCAG 710 DKFZp761H1710(DKFZP761H1710), mRNA TACGTGATTCGGCCTGGCCCCTCGGCCT (SEQ ID NO: 459) 10A_23_P258887 NM_012190 ALDH1L1 Homo sapiens aldehyde dehydrogenase 1family, TTCGGGCCTGTCATGATCATCTCTGGGTTTGC member L1 (ALDH1L1), mRNATGATGGGGACTTGGATGCCGTGCTGTCT (SEQ ID NO: 460) 10 A_23_P30805 NM_003541HIST1H4K Homo sapiens histone 1, H4k (HIST1H4K), mRNAAAGCGCCAGGGCCGCACCCTCTACGGTTTCG GTGGTTGAGCGTCCCTTTCTATCAATAAA (SEQ IDNO: 461) 10 A_23_P390504 NM_001453 FOXC1 Homo sapiens forkhead box C1(FOXC1), mRNA CCTTCCAGCCAGTCTCTGTACCGCACGTCCGGAGCTTTCGTCTACGACTGTAGCAAGTTT (SEQ ID NO: 462) 10 A_23_P407695 NM_147161ACOT11 Homo sapiens acyl-CoA thioesterase 11AGCGGACCTCAGGGCGGAGGCTTCCCACGG (ACOT11), transcript variant 2, mRNAGGAGGCAGGAAGAAATAAAGGTCTTTGGCT (SEQ ID NO: 463) 10 A_23_P432506NM_152757 FLJ30313 Homo sapiens hypothetical protein FLJ30313GTGGGGAGGGTTTCTTGGGTTTCTTGAAGCCA (FLJ30313), mRNAGTATTTCCCATAGTATCTTACGTCCCAG (SEQ ID NO: 464) 10 A_23_P46894 NM_020549CHAT Homo sapiens choline acetyltransferase (CHAT),TAGCCTCCTCGGCAGAAAAACTTCAACGAATA transcript variant M, mRNAGTAAAGAACCTTGACTTCATTGTCTATA (SEQ ID NO: 465) 10 A_23_P57089 NM_020182TMEPAI Homo sapiens transmembrane, prostate androgenGCCGGGCTGGGGCTGCGTAGGTGAAAAGGCA induced RNA (TMEPAI), transcript variant1, GAACACTCCGCGCTTCTTAGAAGAGGAGT mRNA (SEQ ID NO: 466) 10 A_23_P69652NM_080819 GPR78 Homo sapiens G protein-coupled receptor 78GCTCGTGCCCTTCGTCACCGTGAACGCCCAG (GPR78), mRNATGGGGCATCCTCAGCAAGTGCCTGACCTA (SEQ ID NO: 467) 10 A_23_P75283 NM_006744RBP4 Homo sapiens retinol binding protein 4, plasmaTCAGTTCCCATAAAACCTTCATTACACATAAAG (RBP4), mRNAATACACGTGGGGGTCAGTGAATCTGCT (SEQ ID NO: 468) 10 A_23_P93217 NM_006672SLC22A7 Homo sapiens solute carrier family 22 (organicAGTGAACTTCTCCTATTACGGCCTGAGTCTGG anion transporter), member 7 (SLC22A7),ATGTGTCGGGGCTGGGGCTGAACGTGTA transcript variant 1, mRNA (SEQ ID NO: 469)10 A_24_P187539 ACGAATATGCGTTCGACAAGCCGGTCCCGAAAGACATGGTCATCTGGAATCGTGAACGGG (SEQ ID NO: 470) 10 A_24_P297539 NM_007019UBE2C Homo sapiens ubiquitin-conjugating enzyme E2CTTGTCTTTTAAATTAAGCCTCGGTTGAGCCCTT (UBE2C), transcript variant 1, mRNAGTATATTAAATAAATGCATTTTTGTCC (SEQ ID NO: 471) 10 A_24_P302172 NM_000959PTGFR Homo sapiens prostaglandin F receptor (FP)CCCATTCAAATTGTCCTAGGTCTATCAGAAATT (PTGFR), mRNAAGGGAAGGTAGTCCTGCTTTATAATAG (SEQ ID NO: 472) 10 A_24_P322229 NM_033315RASL10B Homo sapiens RAS-like, family 10, member BTGGGGGAAGGGTCGTGGGTGGGGAATTTATC (RASL10B), mRNAACCAACATCCATTGTAGGGGGAATCTATG (SEQ ID NO: 473) 10 A_24_P396489 HSM807143Homo sapiens mRNA; cDNA DKFZp686E15252 AGCTTTGCTTTGCAAAGATTGATGACAGACTG(from clone DKFZp686E15252). GTTCCTCAGAGGCCTAGGCTACCCGTCA (SEQ ID NO:474) 10 A_24_P418176 NM_001007238 HRES1 Homo sapiens HTLV-1 relatedendogenous GCGGGCTGGGCGCTCTGGCGGTGTGCGCTG sequence (HRES1), mRNAAGGTGGGCAGAGCGGCAGGTGGGGGCGTTG (SEQ ID NO: 475) 10 A_24_P636974NM_001013665 LOC399744 Homo sapiens hypothetical LOC399744GTGGGAGGGGCCGGTGTGAGGCAAGGCTCA (LOC399744), mRNACGCTGACCTCTCTCGGCGTGGGAGGGGCCG (SEQ ID NO: 476) 10 A_24_P741378 AC027682Homo sapiens chromosome 16 clone CTD- CACAGAAACATACAAGGAAGGCACCCCCGCTC2012K14, cemplete sequence. TGTGGGCGAGACAAAGCAGCAATCCTCT (SEQ ID NO:477) 10 A_24_P810084 AC016394 Homo sapiens chromosome 10 clone RP11-GGAATTGGCTCTTCCTATTTCCCTACTTCATGA 152N13, complete sequence.AAACTCCAGTAGAAGACCTTAGAACCT (SEQ ID NO: 478) 10 A_24_P8298 AC026740 Homosapiens chromosome 5 clone CTD- TTTAAACACACGTGGTCCCCCGTCTAGAAGCC2589H19, complete sequence. TCTGCATTTAAGCACACGTGGTCCCCCG (SEQ ID NO:479) 10 A_32_P138032 NM_006365 C1orf61 Homo sapiens chromosome 1 openreading frame ATGGCTAAGTTGGGAGACCAAAAAGAAGAATG 61 (C1orf61), mRNATACTTCATCTGGTTGGGCTGGATTCCCT (SEQ ID NO: 480) 10 A_32_P187571 NM_004588SCN2B Homo sapiens sodium channel, voltage-gated,TGTGACTCGACTGCTGGGATGTATCTGCTTTT type II, beta (SCN2B), mRNAGGGAGCAGACTGAGTTTCTTTTGCAATT (SEQ ID NO: 481) 10 A_32_P219148NM_001013725 LOC441268 Homo sapiens hypothetical gene supported byTCCCCGTCCACGTTACCGCATTCAGAGCTTGG BC044942 (LOC441268), mRNAGTCACCTGGACACTGAACTCAGGTGAAT (SEQ ID NO: 482) 10 A_32_P222149 XM_499058LOC442512 PREDICTED: Homo sapiens similar to U2 smallTACAGAGCAGTCGCCGGGCAGTTGAAGATCA nuclear ribenucleoprotein A (U2 snRNP-A)GCTAAAGATATGTGGCCACAGGAGGGATG (LOC442512), mRNA (SEQ ID NO: 483) 10A_32_P52386 AC004080 Homo sapiens PAC clone RP1-170O19 from 7p15-p21,AAATGTGGCGCTCTCGCCAAGAAAAAGCTTGG complete sequence.GGACTGAATTCTTGAGATTTATGGTGCA (SEQ ID NO: 484) 10 A_32_P71710 NM_000577IL1RN Homo sapiens interleukin 1 receptor antagonistAAGATTTTATTGTAAAACAGAGCTGAAGTCACA (IL1RN), transcript variant 3, mRNAGGAAGTAGGGAACTTTGCACCCAACAT (SEQ ID NO: 485) 11 all cell types 11A_23_P128974 NM_006399 BATF Homo sapiens basic leucine zippertranscription TATTAAGAAAGATGCTCAAGTCCCATGGCACA factor, ATF-like (BATF),mRNA GAGCAAGGCGGGCAGGGAACGGTTATTT (SEQ ID NO: 486) 11 A_23_P218731NM_005111 CRYZL1 Homo sapiens crystallin, zeta (quinoneAAGATGATGAACCAGCTGTAAAACTACAACTA reductase)-like 1 (CRYZL1), transcriptCTACCACATAAACATGATATCATCACAC (SEQ variant 1, mRNA ID NO: 487) 11A_23_P42514 NM_030939 C6orf62 Homo sapiens chromosome 6 open readingframe TCCTTTGGAGTAAAACTAGTGCTTACCAGTTTC 62 (C6orf62), mRNACAATTGTATTTAGCTTCTGGTTGGAAT (SEQ ID NO: 488) 11 A_23_P92967 NM_004531MOCS2 Homo sapiens molybdenum cofactor synthesis 2AAGCATATCTACCCATGGCGGAAAATGAAGTC (MOCS2), transcript variant 3, mRNAAGAAAGATTTGTAGTGACATTAGGCAGA (SEQ ID NO: 489) 11 A_32_P160615 AC016554Homo sapiens chromosome 5 clone CTC-340H12,ACTGCAATGAACACATATACATATACATCCAAA complete sequence.CATTCCTCCATTCGTCTATTAATCTGC (SEQ ID NO: 490) 11 A_32_P37461CATCAACTGGTAAACAAAAAACTGTGAGAACG GATCCTGAATCTTGCGCTTACCAGGGGA (SEQ IDNO: 491) 12 all cell types 12 A_23_P100711 NM_000304 PMP22 Homo sapiensperipheral myelin protein 22 TGTGCCTCCAAGGACTGTCTGGCAATGACTTG (PMP22),transcript variant 1, mRNA TATTGGCCACCAACTGTAGATGTATATA (SEQ ID NO: 492)12 A_23_P135730 NM_145295 ZNF627 Homo sapiens zinc finger protein 627(ZNF627), ACTCCCCTAGTCTGTAGACGGAATTGGCATAC mRNAGGTCTAATTTGTGTAGTAAGCACCTTTG (SEQ ID NO: 493) 12 A_23_P307968 NM_022124CDH23 Homo sapiens cadherin-like 23 (CDH23),CCATCTGACGCTACAGTCACCACGACCTTCAA transcript variant 1, mRNATATCCTGGTTATTGACATCAATGACAAT (SEQ ID NO: 494) 12 A_23_P411162 NM_003894PER2 Homo sapiens period Homolog 2 (Drosophila)TCCTCCTGAAAAGAGAATTTTTACAACCACCCA (PER2), transcript variant 2, mRNATACACCAAATTGTTTGTTCCAGGATGT (SEQ ID NO: 495) 12 A_23_P63343 NM_006786UTS2 Homo sapiens urotensin 2 (UTS2), transcriptAGAATCTGGAAACCATACAAGAAACGTGAGAC variant 2, mRNATCCTGATTGCTTCTGGAAATACTGTGTC (SEQ ID NO: 496) 12 A_23_P64879 NM_004982KCNJ8 Homo sapiens potassium inwardly-rectifyingCTTCCCTCATGGTACCAAAGGTGCAATTTATG channel, subfamily J, member 8 (KCNJ8),mRNA ACTCCAGAAGGAAATCAAAACACATCGG (SEQ ID NO: 497) 12 A_24_P45620NM_006786 UTS2 Homo sapiens urotensin 2 (UTS2), transcriptAGAAAGTTTCAGGATTTCTCTGGACAAGATCC variant 2, mRNATAACATTTTACTGAGTCATCTTTTGGCC (SEQ ID NO: 498) 12 A_24_P614702 AC091320Homo sapiens BAC clone RP11-447A2 from 7,CCTTCCTCATTTTGGAACTTAAGGTTGTGTACA complete sequenceGAACAGTCTTACAATGACAGTGTTTAG (SEQ ID NO: 499) 12 A_32_P31144TTCTATACCTCTAAGCTGTTCTTTTCTGAACCA TGAATCGGGAGAATTATTGTCACTCAT (SEQ IDNO: 500) 12 A_32_P427222 XM_291007 LOC339766 PREDICTED: Homo sapienshypothetical protein TCTCTACCGCTTCTTGCTAGAAACAATGGCCT LOC339766(LOC339766), mRNA ATGTTAAAAATAACTTGTCAAGAATCAG (SEQ ID NO: 501) 13 RedBlood cells 13 A_23_P109322 NM_006198 PCP4 Homo sapiens Purkinje cellprotein 4 (PCP4), CCCTCCTAGTCCACCTGAAAACACCAAATTCA mRNAACCATCATCTGTCAAGAAATTAAAAGAA (SEQ ID NO: 502) 13 3 RBC A_23_P11408NM_001002758 PRY2 Homo sapiens PTPN13-like, Y-linked 2 (PRY2),ACCTCCTTCTCTTCTGGACATGTCCAGGAGTG mRNA GCCGTTGCTACAAGTCACCTGGTGCTAC (SEQID NO: 503) 13 A_23_P135568 AC026315 Homo sapiens 3 BAC RP11-114D6(Roswell Park AGCAAGATATCCTCCTCATGGTCCCTTTAGCT Cancer Institute HumanBAC Library) complete CTCAAAAGCAATGAAATCCTCCTGTTCT (SEQ sequence. ID NO:504) 13 A_23_P161474 NM_018518 MCM10 Homo sapiens MCM10 minichromosomeCCTCCTGTGACTCTGGAAAGCAAAGGATTGGC maintenance deficient 10 (S.cerevisiae) (MCM10), TGTGTATTGTCCATTGATTCCTGATTGA (SEQ transcriptvariant 2, mRNA ID NO: 505) 13 A_23_P204998 NM_005766 FARP1 Homo sapiensFERM, RhoGEF (ARHGEF) and TCCTCCTGCAACTGTGGTTTGAAACTGCGCAT pleckstrindomain protein 1 (chondrocyte-derived) TCTCTAGTAGTATATATCGTGCCTGTCT (SEQ(FARP1), transcript variant 1, mRNA ID NO: 506) 13 3 RBC A_23_P205637NM_015163 TRIM9 Homo sapiens tripartite motif-containing 9CCTCCTCGACTTAAATAGAAAAAACTTGACATT (TRIM9), transcript variant 1, mRNATTTTATCAACGATGAACAACAAGGTCC (SEQ ID NO: 507) 13 A_23_P215549 NM_000940PON3 Homo sapiens paraoxonase 3 (PON3), mRNAGCACCTCTGTGGCTTCTGTGTACCATGGGAAA ATTCTCATAGGCACCGTATTTCACAAAA (SEQ IDNO: 508) 13 A_23_P254626 NM_003919 SGCE Homo sapiens sarcoglycan,epsilon (SGCE), ACTGGTCCTTTTTCTAATACTTGCTTATATCAT mRNAGTGCTGCCGACGGGAAGGCGTGGAAAA (SEQ ID NO: 509) 13 A_23_P26582 NM_020988GNAO1 Homo sapiens guanine nucleotide binding proteinTTGTACTGACCTCTTGTCCTGTATAGCAACCTA (G protein), alpha activating activityTTTGACTGCTTCACGGACTCTTTGCTG (SEQ ID polypeptide O (GNAO1), transcriptvariant 1, mRNA NO: 510) 13 A_23_P303803 NM_152474 C19orf18 Homo sapienschromosome 19 open reading CAGCTCGAGTCACTTTATAAGAACCTCAGGAT frame 18(C19orf18), mRNA ACCGTTATTAGGAGATGAAGAAGAGGGC (SEQ ID NO: 511) 13A_23_P309278 NM_173158 NR4A1 Homo sapiens nuclear receptor subfamily 4,group CTCCCTTGCCACCCAAATGTTAGAAAAATAGCT A, member 1 (NR4A1), transcriptvariant 3, mRNA GTGAACAGAGAGCGCTTTTGTCTGCAA (SEQ ID NO: 512) 13A_23_P326844 NM_174913 C14orf21 Homo sapiens chromosome 14 open readingACTCCTGGTCTTGTACTTCGAAGTCTGGGTGC frame 21 (C14orf21), mRNACTTGACGGGACCACAGCTTCTGTCCCTT (SEQ ID NO: 513) 13 A_23_P44648 NM_030955ADAMTS12 Homo sapiens ADAM metallopeptidase withCAGACCTCCAGAATTCAAAAAATGCAACCAGC thrombospondin type 1 motif, 12(ADAMTS12), AGGCCTGCAAGAAAAGTGCCGATTTACT (SEQ mRNA ID NO: 514) 13A_23_P68234 NM_006794 GPR75 Homo sapiens G protein-coupled receptor 75ATCCTCCCATCATGAAACAAACTCTGCCTACAT (GPR75), mRNAGTTATCTCCAAAGCCACAGAAGAAATT (SEQ ID NO: 515) 13 A_23_P78795 NM_001009813MEIS3 Homo sapiens Meis1, myeloid ecotropic viralCCTCCCAGACCAGAATAATATGTGGATTCGAG integration site 1 homolog 3 (mouse)(MEIS3), ACCATGAGGATAGTGGGTCTGTACATTT (SEQ transcript variant 2, mRNA IDNO: 516) 13 A_23_P80122 NM_004627 WRB Homo sapiens tryptophan rich basicprotein CCTGGTAGCCTTTCCTACTAGAGTAGCAGGTG (WRB), mRNAGTGTTGGAATTACCTGTTGGATTTTAGT (SEQ ID NO: 517) 13 A_24_P126587 NM_181489ZNF445 Homo sapiens zinc finger protein 445 (ZNF445),GCTCCTACAGGAGATGACCTCCAGAGTAAAAC mRNA AAACAAATTCATCTTAAATCAGGAACCT (SEQID NO: 518) 13 A_24_P136299 AC103975 Homo sapiens chromosome 15, cloneRP11- TCAATTGCTTCCTCCTCAATCTGGCAGCCACT 1001M11, complete sequence.GACCTGCAGTTTGTGCTAACGCTGCCCT (SEQ ID NO: 519) 13 A_24_P200250 HSU37055Human hepatocyte growth factor-like protein gene,CCTTCCATTAGCAACTACTCTGTACCACCCTTC complete cds.CCAAGAGTATGTCTGGAGGACTAGTGT (SEQ ID NO: 520) 13 A_24_P312594 AL133215Human DNA sequence from clone RP11-108L7 onTTCTTCCCTCCATACATTTGCTTCCAAGTGAAT chromosome 10TTGCATAAGCAGTGCTCAGACTGCACC (SEQ ID NO: 521) 13 A_24_P31875 NM_152577ZNF645 Homo sapiens zinc finger protein 645 (ZNF645),CTCCTTCAACCCTACATGGTCGATCACATCATT mRNA CACACCAGAGAAGACATAGACGGTATT (SEQID NO: 522) 13 2 RBC A_24_P341116 NM_207378 SERPINA13 Homo sapiensserpin peptidase inhibitor, clade A CTTCCTGGTGATGACTTTCCACACGGAAACAG(alpha-1 antiproteinase, antitrypsin), member 13GAAGCATGCTTTTTCTGGAGAAGATTGT (SEQ (SERPINA13), mRNA ID NO: 523) 13A_24_P365349 AC008440 Homo sapiens chromosome 19 clone CTC-CCTGGCTCTGTTATTTACCGTGTATCATATGTA 331H23, complete sequence.AATATCGACAGAAACTTCAATAAACTT (SEQ ID NO: 524) 13 A_24_P409451 NM_018651ZNF167 Homo sapiens zinc finger protein 167 (ZNF167),AAGAACTATCCTCCTGTCTGCGAAATCTTCCG transcript variant 1, mRNAGCTACACTTCAGGCAATTGTGTTACCAC (SEQ ID NO: 525) 13 4 RBC A_24_P59735BC041372 Homo sapiens similar to seven in absentia 2,TCCTGGTTTTTGAGACTCAACCACTTTGAAAGC mRNA (cDNA clone IMAGE: 5273845),partial cds. ATTTGTGTAGCATCACAGGTGCTCCAG (SEQ ID NO: 526) 13A_24_P607751 HSU91328 Human hereditary haemochromatosis region,CCTTCTTGGGTCAGTTAGGCCATTGGTTTCTTT histone 2A-like protein gene,hereditary TTAAAGGTTTTCAAATTTATTTGCATC (SEQ ID haemochromatosis (HLA-H)gene, RoRet gene, NO: 527) and sodium phosphate transporter (NPT3) gene,complete cds. 13 A_24_P666035 AC055716 Homo sapiens 12 BAC RP11-641A6(Roswell Park AGTTGTACTGTCAAGGGGCAGCATTTCTGGTA Cancer Institute HumanBAC Library) complete TTTCTATAATAAATTTTTCTGTGATCTC (SEQ ID sequence. NO:528) 13 A_24_P915376 NM_006757 TNNT3 Homo sapiens troponin T type 3(skeletal, fast) AGAAACCGAGACCCAAACTCACTGCTCCTAAG (TNNT3), mRNAATCCCAGAAGGGGAGAAAGTGGACTTCG (SEQ ID NO: 529) 13 A_24_P920555 NM_198486RPL7L1 Homo sapiens ribosomal protein L7-like 1GGCATTCACTGATCCCAGCAGGTCTCCATCTA (RPL7L1), mRNATTTGTACCAGCCTCCTCTATTCCTCCCA (SEQ ID NO: 530) 13 A_24_P927404 AC084033Homo sapiens 12q BAC RP11-58A17 (RoswellGCCCTTTTTTGTCACTCACTGTTGTGACAGATC Park Cancer Institute Human BACLibrary) CTCCGATTTCTTACATAAGTTATGCAG (SEQ ID complete sequence. NO: 531)13 A_32_P114483 NM_153344 C6orf141 Homo sapiens chromosome 6 openreading frame GAGCCCAACTACCCTTCTGTCTTTCAACGAGA 141 (C6orf141), mRNAAAAGCGAATTTCTGGCAGGCGTGTAGCC (SEQ ID NO: 532) 13 3 RBC A_32_P133106AP005433 Homo sapiens genomic DNA, chromosome 18CTAATGGACTAGATTGCTGACCTTTTAATACCT clone: RP11-945C19, complete sequence.TTGGTTTTCATTGAACATACAATCACC (SEQ ID NO: 533) 13 A_32_P181638 NM_007073BVES Homo sapiens blood vessel epicardial substanceAATCCTGGTTTCCTAACCTCCTCTTGTAGTAAT (BVES), transcript variant A, mRNATCTCAACTCAACTCAAAGTCCCAAGAA (SEQ ID NO: 534) 13 A_32_P354945 AC011503Homo sapiens chromosome 19 clone CTB-92J24,CCCTCCTGATGATGAAGGACCTGTCATTGGAG complete sequence.AATCGACCAAAACTGACAGTGATAACTT (SEQ ID NO: 535) 13 2 RBC A_32_P5057AC010798 Homo sapiens , clone RP11-470B24, completeCCCTGAACCTACATAGACATTTTATATCAGCAT sequence. ACAGAAAAGTAAAATCCTCCTTCAGTC(SEQ ID NO: 536) 13 A_32_P51005 BX629352 Human DNA sequence from cloneWI2-80267E6 ATTCCTTTCTGGTCTCCATCCTGTCTGTAGATA on chromosome 9, completesequence. TGTAGATCTCTTTGAAACGAAGTAAGC (SEQ ID NO: 537) 13 A_32_P524904GGCTGAGCACTCTGTGCTGAAAACCTTTGAAC CTCACGGTGTCCTGATGAAGGAAGCAGA (SEQ IDNO: 538) 14 Red Blood cells 14 A_23_P153351 NM_000713 BLVRB Homo sapiensbiliverdin reductase B (flavin CAAGGTGCCCCCACGACTGCAGGCTGTGACT reductase(NADPH)) (BLVRB), mRNA GATGACCACATCCGGATGCACAAGGTGCT (SEQ ID NO: 539) 147 RRC A_23_P207842 NM_000964 RARA Homo sapiens retinoic acid receptor,alpha AGTTCTCCTCCTCAGCCTTTTCCTCCTCAGTTT (RARA), transcript variant 1,mRNA TCTCTTTAAAACTGTGAAGTACTAACT (SEQ ID NO: 540) 14 3 RBC A_23_P210465NM_002638 PI3 Homo sapiens peptidase inhibitor 3, skin-derivedTCCTGCCCCATTATCTTGATCCGGTGCGCCAT (SKALP) (PI3), mRNAGTTGAATCCCCCTAACCGGTGCTTGAAA (SEQ ID NO: 541) 14 2 RBC A_23_P23850NM_021080 DAB1 Homo sapiens disabled homolog 1 (Drosophila)CTCCCTCACCTGTACCTCAGAGGCCTTCTCCA (DAB1), mRNAGTTACTTCAACAAAGTCGGGGTGGCACA (SEQ ID NO: 542) 14 A_23_P251898 NM_152743C7orf27 Homo sapiens chromosome 7 open reading frameGGCGCAGAAGTCTTGTGACCTCCTTCTCTTCC 27 (C7orf27), mRNATGAGGGACAAGATTGCTTCCTACAGCAG (SEQ ID NO: 543) 14 6 RBC A_23_P332392NM_152479 TTC9B Homo sapiens tetratricopeptide repeat domain 9BACCTCCCCTGCAGACACCAATGTGCTCCGCTA (TTC9B), mRNACATCCAGCTGACTCAGCTGAAGATGAAT (SEQ ID NO: 544) 14 2 RBC A_23_P338168NM_019085 FBXL19 Homo sapiens F-box and leucine-rich repeatTCCTTCCCCCTGACCCTGACTCCTTGAACGTC protein 19 (FBXL19), mRNAACTGAAAACGGCAGCTATTGCAAGGAGT (SEQ ID NO: 545) 14 A_23_P362893 NM_021961TEAD1 Homo sapiens TEA domain family member 1TTTTTTCTCCTTCCCCTTTCTTTAAGAGAGGCT (SV40 transcriptional enhancer factor)(TEAD1), GACAGATCTAGGTGTCAATCAATTGGA (SEQ mRNA ID NO: 546) 14 5 RBCA_23_P377717 NM_0112516 NOVA2 Homo sapiens neuro-oncological ventralantigen 2 CCTCCCCTTCTGGTAGTCATAGGCAGGATTGA (NOVA2), mRNAGTGACGGTTGGGAAGGGGGCTCAGAAGC (SEQ ID NO: 547) 14 A_23_P39265 NM_014400LYPD3 Homo sapiens LY6/PLAUR domain containing 3TCCCCTACTCCCCGCATCTTTGGGGAATCGGT (LYPD3), mRNATCCCCATATGTCTTCCTTACTAGACTGT (SEQ ID NO: 548) 14 5 RBC A_23_P62361NM_014235 UBL4A Homo sapiens ubiquitin-like 4A (UBL4A), mRNAGCTTCCTGCACCCTGAAGTGACTGAGACAATG GAGAAGGGGTTCTCCAAATAGAATTCTC (SEQ IDNO: 549) 14 3 RBC A_23_P67332 NM_007121 NR1H2 Homo sapiens nuclearreceptor subfamily 1, group ACCACCCTCCAGCAGATAGACGCCGGCACCC H, member 2(NR1H2), mRNA CTTCCTCTTCCTAGGGTGGAAGGGGCCCT (SEQ ID NO: 550) 14 4 RBCA_23_P79323 NM_003936 CDK5R2 Homo sapiens cyclin-dependent kinase 5,TCCCTTCAGCCCATTCCCCCTCGGTTTTATCC regulatory subunit 2 (p39) (CDK5R2),mRNA ATTTCCTTGCCTCCTTTTTGTGTCTTCA (SEQ ID NO: 551) 14 A_23_P81717NM_024919 FRMD1 Homo sapiens FERM domain containing 1AGGTTCCTCCCAGACCTGAATCCCTCTCTGCA (FRMD1), mRNAACTCCTGTTTGCAAGCGCTGGGCCTGCC (SEQ ID NO: 552) 14 2 RBC A_24_P102343NM_017957 EPN3 Homo sapiens epsin 3 (EPN3), mRNATCCCTCAGCTTCCTCCTTGGTCAACCTTGACT CGTTGGTCAAGGCACCCCAGGTTGCAAA (SEQ IDNO: 553) 14 A_24_P233078 NM_021093 PYY2 Homo sapiens peptide YY, 2(seminalplasmin) GCCCACCTCATTTACATGTTCACTCCCGACCC (PYY2), mRNATGGAAACCCGGATTTCGCCTCCGGACAG (SEQ ID NO: 554) 14 4 RBC A_24_P256083HS526I14 Human DNA sequence from clone RP3-526I14 onATTTTCACCTCCCCTGGTCCATGCTCAGGAAG chromosome 22, complete sequence.TCTGGTCACCCTGGCAAACTGCACCTGA (SEQ ID NO: 555) 14 3 RBC A_24_P318990HSZ85332 H. sapiens Ig lambda light chain variable regionTCTGACACCTCAGCCTCCCTGGCCATCACTGG gene (22-21SWIA31) rearranged;Ig-Light- ACTCCAGGCTGAAGATGAGGCTGATTAT (SEQ Lambda; VLambda. ID NO: 556)14 4 RBC A_24_P365523 NM_021784 FOXA2 Homo sapiens forkhead box A2(FOXA2), CCTCCTACTACCAGGGGGTGTACTCCCGGCC transcript variant 1, mRNACATTATGAACTCCTCTTAAGAAGACGACG (SEQ ID NO: 557) 14 A_24_P493646 AP002776Homo sapiens genomic DNA, chromosome 11 TCGCCACGCCAGCCCCTTTCCTCAGAACGCCclone: RP11-126P21, complete sequence. GAGGCCTCAGGAGCGTGTGCGCGCCGGGA(SEQ ID NO: 558) 14 2 RBC A_24_P911718 AF240580 Homo sapiens clone17ptel_2111ctg_drft CTTCCTTCCCTAGGATCTCAGCACCCTTTTAGA sequence.TCCCGTGCAGATTGTCTTTCTGTTAAA (SEQ ID NO: 559) 14 A_24_P920188 AY236488Homo sapiens unidentified genomic region, partialCTCCTTCCCCATCTTCTGGTAACACAACCTTTA sequence. TTTATTTGTGGGGAACCTATTCCCTGT(SEQ ID NO: 560) 14 6 RBC A_32_P48536 2772567 7n93b04.x1 NCI_CGAP_Ov18Homo sapiens AATTGCCATGCTGCCCACCTCCCGAAGTGTTA cDNA clone IMAGE: 35719273′, mRNA sequence GGAGGTAACATCTCATCGTCTCATCGCA (SEQ ID NO: 561) 15 allcell types 15 A_23_P101121 NM_031303 KATNAL2 Homo sapiens katanin p60subunit A-like 2 TCAGAAGATCTCGTATTTGTCTTAGCAGCTTCT (KATNAL2), mRNAAACCTGCCGTGGTAAGAGACCAAGAGA (SEQ ID NO: 562) 15 A_23_P120243 NM_024501HOXD1 Homo sapiens homeobox D1 (HOXD1), mRNATTTTTTCTTTAAAAAAGCGGTTTCTACCTCTCTA TGTGCCTGAGTGATGATACAATCGCT (SEQ IDNO: 563) 15 A_23_P132845 NM_004366 CLCN2 Homo sapiens chloride channel 2(CLCN2), mRNA TGGGAGTGGACCATGCTTATGTCACCAGTATTGGCAGACTCATTGGAATCGTTACTCTAA (SEQ ID NO: 564) 15 A_23_P15765 NM_018996TNRC6C Homo sapiens trinucleotide repeat containing 6CGACATTGTGTTTGCAACATGGGCCTCTTATCA (TNRC6C), mRNACATTCCACCTGAATCTGACTCAAGGCAA (SEQ ID NO: 565) 15 A_23_P313623 NM_015198COBL Homo sapiens cordon-bleu homolog (mouse)GTCTACAGGCCAAAATGCGCACAGTTGATTT (COBL), mRNACGGTGTGTTCCTGTATAACGGCTTGAAA (SEQ ID NO: 566) 15 A_23_P319466 NM_020377CYSLTR2 Homo sapiens cysteinyl leukotriene receptor 2GGCAAATAGCAAAAGTTGTTGCACTCCTGAAA (CYSLTR2), mRNATTCTATTAACATTTCCGCAGAAGATGAG (SEQ ID NO: 567) 15 A_23_P369994 NM_004734DCAMKL1 Homo sapiens doublecortin and CaM kinase-like 1AAATGTTTTTACCGTAGCCCTCATCTAACTTAC (DCAMKL1), mRNAACGTGGTGCATATTAAAATAAGCAGAG (SEQ ID NO: 568) 15 A_23_P39294 AC011533Homo sapiens chromosome 19 clone LLNLR- CTCCCAGCAGAGTCATCACTACCTTTGGGGCC240E6, complete sequence. GCAGGATCACCCAGCTTGGAACTAGATA (SEQ ID NO: 569)15 A_23_P399797 AC009014 Homo sapiens chromosome 5 clone P1_748D6,ACAACTGCCCAGAGTGTAATTCCCACCGATAA complete sequence.GCGCGGATCCTTATCTTTGAAACACAAA (SEQ ID NO: 570) 15 A_23_P413923 NM_022160DMRTA1 Homo sapiens DMRT-like family A1 (DMRTA1),CTGTACTTCAGACCAAATCAGGACAATCCGTA mRNA ATGTATATGCCCATTCTCTCTTTCTGGA (SEQID NO: 571) 15 A_23_P45560 NM_000273 GPR143 Homo sapiens Gprotein-coupled receptor 143 ATATTCCTCAGACTCAACAATTCTTGTTCTTTA (GPR143),mRNA GAACTGTGTTCTCACCTTCCCAACACT (SEQ ID NO: 572) 15 A_23_P502413NM_002974 SERPINB4 Homo sapiens serpin peptidase inhibitor, clade BTCCTCTTCTATGGCAGATTCTCATCCCCATAGA (ovalbumin), member 4 (SERPINB4), mRNATGCAATTAGTCTGTCACTCCATTTAGA (SEQ ID NO: 573) 15 A_23_P81103 NM_003013SFRP2 Homo sapiens secreted frizzled-related protein 2ATAACCTACATCAACCGAGATACCAAAATCATC (SFRP2), mRNACTGGAGACCAAGAGCAAGACCATTTAC (SEQ ID NO: 574) 15 A_24_P20091 NM_153041FLJ32955 Homo sapiens hypothetical protein FLJ32955CACAAATTCCTCACTCATCTTGCAGAAGCTCC (FLJ32955), mRNACAGTTTTCAATATTCTCCTAAATGCTGT (SEQ ID NO: 575) 15 A_24_P252780 NM_198514NHLRC2 Homo sapiens NHL repeat containing 2GTTCCTAGTAGAAAAACAGAAGACATTACCCA (NHLRC2), mRNAAACTACCTAAATCTGCTCCAAGCATTAG (SEQ ID NO: 576) 15 A_24_P382187 NM_001552IGFBP4 Homo sapiens insulin-like growth factor bindingGAAAAATCTCATTCCCAGAGTCAGAGGAGAAG protein 4 (IGFBP4), mRNAAGACATGTACCTTGACCATCGTCCTTCC (SEQ ID NO: 577) 15 A_24_P410605 BC080541Homo sapiens receptor tyrosine kinase-like orphanGACATCCCAGCTTGCGGTAAATAGAAGTCATT receptor 1, mRNA (cDNA clone IMAGE:5477978), GCCCCTAATGTATTCAATCATCTTTAAA (SEQ complete cds. ID NO: 578) 15A_24_P499215 NM_001005751 LOC387680 Homo sapiens similar to KIAA0592protein TCAAAGACAAGAGAAAGCAAAAGCCTCCAAGC (LOC387680), mRNATCTCCAAAAAGAAAGCATCTGCCCTGTT (SEQ ID NO: 579) 15 A_24_P744957 AL353653Human DNA sequence from clone RP11-244L4 onAGACACAGGATGTTCCTGTTGGTCCAGATACT chromosome 20 Contains ESTs, STSs andGSSs, TGAGCTAAAAGGTGATGGATACCTGGAT (SEQ complete sequence. ID NO: 580)15 A_24_P82155 NM_182703 ANKDD1A Homo sapiens ankyrin repeat and deathdomain CTACTTCCCAAAATAGTATTTCTCTCAGCAGAT containing 1A (ANKDD1A), mRNAATTTCTTTGGTACTACCATGTATTGTG (SEQ ID NO: 581) 15 A_24_P91165 NM_000723CACNB1 Homo sapiens calcium channel, voltage-TACTTCAAAGGCTCATCAAGTCCCGAGGAAAG dependent, beta 1 subunit (CACNB1),transcript TCTCAGTCCAAACACCTCAATGTCCAAA (SEQ variant 1, mRNA ID NO: 582)15 A_24_P933902 AY358788 Homo sapiens clone DNA129793 AVLL5809TCGCGGTGAGACTGAACATTTCATGAGCTCAT (UNQ5809) mRNA, complete cds.GTTGCCTTTGACCACCATTTCTTAAGGA (SEQ ID NO: 583) 15 A_24_P934063 NM_004978KCNC4 Homo sapiens potassium voltage-gated channel,ATGGGAGATTTTCCACCAGTCCTGTGCAAACA Shaw-related subfamily, member 4(KCNC4), AGGATATCTGAGTCTTTCCCAGCGAAAA (SEQ transcript variant 1, mRNA IDNO: 584) 15 A_32_P102383 HS243L18 Human DNA sequence from cloneRP1-243L18 on TTCTCTTGAGGGTTGAGAGAGTCTGTTTTCCT chromosome 1p36.11-36.23Contains the 5′ end of AAGAATCTGGTTCTCTCCATCAGTCTCT (SEQ a novel gene(KIAA1026) and a CpG island, ID NO: 585) complete sequence. 15A_32_P146764 AC002076 Homo sapiens BAC clone GS1-345D13 from 7,ATGTCTCTTTCAACCATATGATCAATCAGTTGG complete sequence.ACGACTTCTGGTTTTTCCTGAATAAAT (SEQ ID NO: 586) 15 A_32_P181131NM_001005353 AK3L1 Homo sapiens adenylate kinase 3-like 1 (AK3L1),CTCTTCATAGCTCAGTTCTCAGTGCATACAGA nuclear gene encoding mitochondrialprotein, GATTCAATATAGCCCCATCGCTCTCAGT (SEQ transcript variant 1, mRNA IDNO: 587) 15 A_32_P221507 BC066346 Homo sapiens cDNA clone IMAGE:4824446, CATAGAGCAGTTGCTCCCCATTGACACCAAGT partial cds.AATTCCAGTCCACATTTGCCTTTAAGCA (SEQ ID NO: 588)

TABLE 2 Corre- lation- Feature Agilent Probe Gene Description IFI27Sequence 2703 A_23_P48513 IFI27 interferon, alpha- 1ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGG inducible proteinGTGAAATATACCAAATTCTGCAT (SEQ ID NO: 589) 27 variant a 40154 A_23_P48513IFI27 interferon, alpha- 0.999 ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGGinducible protein GTGAAATATACCAAATTCTGCAT (SEQ ID NO: 590) 27 variant a32566 A_23_P48513 IFI27 interferon, alpha- 0.999ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGG inducible proteinGTGAAATATACCAAATTCTGCAT (SEQ ID NO: 591) 27 variant a 7079 A_23_P48513IFI27 interferon, alpha- 0.999 ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGGinducible protein GTGAAATATACCAAATTCTGCAT (SEQ ID NO: 592) 27 variant a508 A_23_P48513 IFI27 interferon, alpha- 0.999ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGG inducible proteinGTGAAATATACCAAATTCTGCAT (SEQ ID NO: 593) 27 variant a 18306 A_23_P48513IFI27 interferon, alpha- 0.999 ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGGinducible protein GTGAAATATACCAAATTCTGCAT (SEQ ID NO: 594) 27 variant a5149 A_23_P48513 IFI27 interferon, alpha- 0.999ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGG inducible proteinGTGAAATATACCAAATTCTGCAT (SEQ ID NO: 595) 27 variant a 13333 A_23_P48513IFI27 interferon, alpha- 0.998 ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGGinducible protein GTGAAATATACCAAATTCTGCAT (SEQ ID NO: 596) 27 variant a6656 A_24_P270460 IFI27 interferon, alpha- 0.997TGAAATATACCAAATTCTGCATCTCCAGAGGAAAATAA inducible proteinGAAATAAAGATGAATTGTTGCA (SEQ ID NO: 597) variant a 16373 A_23_P48513IFI27 interferon, alpha- 0.996 ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGGinducible protein GTGAAATATACCAAATTCTGCAT (SEQ ID NO: 598) 27 variant a5290 A_23_P48513 IFI27 interferon, alpha- 0.996ACCCAGCGAGGAGCCAACTATCCCAAATATACCTGGG inducible proteinGTGAAATATACCAAATTCTGCAT (SEQ ID NO: 599) 27 variant a 27987 A_23_P819G1P2 interferon, alpha- 0.911 CACGGTCCTGCTGGTGGTGGACAAATGCGACGAACCTinducible protein CTGAGCATCCTGGTGAGGAATAA (SEQ ID NO: 600) 27626A_23_P45871 IFI44L chromosome 1 ORF 29 0.893TTGTTCGTTTTGCCTTCTGTCCTTGGAACAGTCATATCT (C1orf29) CAAGTTCAAAGGCCAAAACCT(SEQ ID NO: 601) 11715 A_32_P132206 USP18 ubiquitin specific 0.887AGACTTGTATACTGGCTGAATATCAGTGCTGTTTGTAA protease 18TTTTTCACTTTGAGAACCAACA (SEQ ID NO: 602) 21005 A_24_P28722 RSAD2 viperin(cig5) 0.877 ACTCTGAGTCAGTTGAAATAGGGTACCATCTAGGTCAGTTTAAGAAGAGTCAGCTCAGAG (SEQ ID NO: 603) 30386 A_24_P261929 FAM14B familywith sequence 0.868 TGCAGTCAGTGGGGGCAGCTGGACTCTCTGTGACATC similarity 14,TAAAGTTATCGGGGGCTTTGCTG (SEQ ID NO: 604) member B 36995 A_32_P99533 G1P2interferon, alpha- 0.864 ACCAGGATGTTCAGAGGTTCGTCGCATTTGTCCACCA inducibleprotein CCAGCAGGACCGTGCTGCCGGGG (SEQ ID NO: 605) 36654 A_24_P361896 MT2Ametallothionein 2A 0.863 CGCTCCCAGATGTAAAGAACGCGACTTCCACAAACCTGGATTTTTTATGTACAACCCTGA (SEQ ID NO: 606) 21017 A_24_P316965 RSAD2viperin (cig5) 0.861 ATTCTGGATGAATATATGCGCTTTCTGAACTGTAGAAAGGGACGGAAGGACCCTTCCAAG (SEQ ID NO: 607) 12478 A_23_P64828 QAS12′,5′-oligoadenylate 0.855 CTCTGCATCTACTGGACAAAGTATTATGACTTTAAAAACsynthetase 1 variant CCCATTATTGAAAAGTACCTG (SEQ ID NO: 608) E18 36260A_23_P106844 MT2A metallothionein 2A 0.854CAACCCTGACCGTGACCGTTTGCTATATTCCTTTTTCT ATGAAATAATGTGAATGATAAT (SEQ IDNO: 609) 16580 A_23_P23074 IFI44 interferon-induced 0.852AAGGATGTTCTAATTCTTTCTGCTCTGAGACGAATGCT protein 44 ATGGGCTGCAGATGACTTCTTA(SEQ ID NO: 610) 22208 A_23_P252413 MT2A metallothionein 2A 0.850CTGACCGTGACCGTTTGCTATATTCCTTTTTCTATGAAA TAATGTGAATAATAATTAAAC (SEQ IDNO: 611) 20525 A_23_P201459 G1P3 interferon, alpha- 0.846AGTAGCCAGCAGCTCCCAGAACCTCTTCTTCCTTCTTG inducible proteinGCCTAACTCTTCCAGTTAGGAT (SEQ ID NO: 612) variant 43723 A_23_P105794EPSTI1 epithelial stromal 0.846 AGAAGAGAAGCATTTAGAGAGCATCAGCAATACAAAACinteraction 1 CGCTGAGTTCTTGAGCAAACTG (SEQ ID NO: 613) 16830 A_24_P316257FLJ36208 hypothetical protein 0.839TGGGGGAGCTTCCTACAAGGAGAGACTCCTGCTGCTT FLJ36208 TGGAAAACTGAGAAAAAATAGGG(SEQ ID NO: 614) 25919 A_23_P131255 DNAPTP6 DNA polymerase-trans- 0.836CTGAAGATCAGAGGCTCAGTTAGCAACCTGTGTTGTA activated protein 6GCAGTGATGTCAGTCCATTGATT (SEQ ID NO: 615) 41211 A_32_P227059 RSAD2upsteam 5′ end of Gene 0.835 CAAAATAATCTGAAACTTTACTGGCCAAAGTGGGACTCCTTTAAAATTCCAAAACTTGCC (SEQ ID NO: 616) 41347 A_23_P384355 LOC129607thymidylate kinase 0.834 ACAGTGGATCTTGGAGTGGGATTTCTTGGGTAAATTAT familyLPS-inducible CTTTGCCCTTTGAAATGTCTCC (SEQ ID NO: 617) member 36358A_23_P47955 QAS3 2′-5′ oligoadenylate 0.834AGAAGGCAGAGAAAGTGAAGACCAAGTCCAGAACTGA synthetase 3ATCCTAAGAAATGCAGGACTGCA (SEQ ID NO: 618) 14388 A_24_P335305 OAS32′-5′ oligoadenylate 0.833 TCTTTGGCAATGGCCACCCTGGTGTTGGCATATTGGCsynthetase 3 CCCACTGTAACTTTTGGGGGCTT (SEQ ID NO: 619) 19864 A_24_P943205EPSTI1 downstream from gene 0.824 AACCAAATATCTATGTAGGCAGAGGTAACCAGGAGAGAAGCAAGACTTGCTGCCTAAAGG (SEQ ID NO: 620) 3173 A_23_P132159 USP18ubiquitin specific 0.822 CTGTCATTTTCCATTTCCGTTCCTGGATCTACGGGAGTCprotease 18 TTCTAAGAGATTTTGCAATGAG (SEQ ID NO: 621) 23814 A_23_P139786OASL 2′-5′-oligoadenylate 0.821 GTTTCCAGCCAGTTAGTTTTCTCTGGGAGACTTCTCTGsynthetase-like TACATTTCTGCCATGTACTCCA (SEQ ID NO: 622) variant 28716A_24_P557479 HSXIAPAF1 XIAP associated fac- 0.816CAAATAAACCAACGGGAAAAAAGAAAGGTTCCAGTTTT tor-1 variant 2GTCTGAAAATTCTGATTAAGCC (SEQ ID NO: 623) 39451 A_23 P206724 MT1Emetallothionein 1E 0.816 GGCATGGGAGAAGTGCAGCTGCTGTGCCtGATGTGGGAAGAGCTCTTCTCCCAGATGTAA (SEQ ID NO: 624) 632 A_23_P52266 IFIT1interferon-induced 0.815 ACTTTGAGAACTCTGTGAGACAAGGTCCTTAGGCACC proteinvariant 2 GAGATATCAGCCACTTTCACATT (SEQ ID NO: 625) 7680 A_23 P427703MT1E 602705675F1 NIH_MGC_43 0.813 CTGCTGTGCCTGATGTGGGGACAGACCTGCTCCCAGGclone IMAGE: 4842259 TGTAAACAGAGCAACCTGCACAA (SEQ ID NO: 626) 5′ 18216A_23_P17663 MX1 myxovirus (influenza 0.808CAGCTTATTTGCTCATTTTTATAATGTCCCTTCACAAAC virus) resistance 1,CCAGTGTTTTAGGAGCATGAG (SEQ ID NO: 627) IFI protein p78 1309 A_23_P303242MT1X metallothionein 1x 0.805 TGCCAAGTGTGCCCAGGGCTGCATCTGCAAAGGGACGTCAGACAAGIGCAGCTGCTGTGC (SEQ ID NO: 628) 13366 A_23_P414343 MT1Jmetallothionein 1J 0.804 TGTGCCAAGTGTGCCCACGGCTGCATCTGCAAAGGGACGTCGGAGAAGTGCAGCTGCTGT (SEQ ID NO: 629) 21994 A_23_P60933 MT1Gmetallothionein 1G 0.804 AGCTGCTGTGCCTGATGTCGGGACAGCGCTGCTCCCAAGTACAAATAGAGTGACCCGTAA (SEQ ID NO: 630) 22827 A_23_P166797 IFRG28 28kDinterferon re- 0.798 CAAGCAGGATCAAGTTTGTAGAATAAACACTGGTTTCC sponsiveprotein TAGCCATCCTCTGAAAACAGTA (SEQ ID NO: 631) 34047 A_24_P317762 LY6Elymphocyte antigen 6 0.798 CTACTGCGTGACTGTGTCTGCTAGTGCCGGCATTGGGcomplex, locus E AATCTCGTGACATTTGGCCACAG (SEQ ID NO: 632) 27981A_23_P4286 HSXIAPAF1 XIAP associated fac- 0.796TTTAACAGTGGCATTCCTGCCTACTTGCTGTGGTGGTC tor-1 variant 2TTGTGAAAGGTGATGGGTTTTA (SEQ ID NO: 633) 41919 A_24_P917810 BRCA2 BRCA2intron 0.795 TTTGCACTATGGTAGATTTCAGGAATTTCAAAAGAAATC intronTGATGTCAGTGCAATTATCCG (SEQ ID NO: 634) 42276 A_23_P4283 BIRC4BP X-linkedinhibitor 0.791 TCAACTTGACTTCATGTTAAAAACCCTCAACAAACCAG of apoptosisGCGTCGAAGGAACATACCTCAA (SEQ ID NO: 635) 7108 A_23_P204087 OAS22′-5′-oligoadenylate 0.789 TCTTCAAAGCAAAGCTCTTTACTTTCCCCTTGGTTCTCAsynthetase 2 variant 1 TAACTCTGTGATCTTGCTCTC (SEQ ID NO: 636) 8777A_23_P110196 HERC5 hect domain and RLD 5 0.787TGTCCTGAAAGTTGGAATGAAAGAGACCCTATAAGAG CACTGACATGTTTCAGTGTCCTC (SEQ IDNO: 637) 1565 A_24_P343929 OAS2 2′-5′-oligoadenylate 0.784GGAAGGTCAATTACAACTTTGAAGATGAGACCGTGAG synthetase 2 variant 1GAAGTTTCTACTGAGCCAGTTGC (SEQ ID NO: 638) 18175 A_23_P35412 IFIT4 IFIprotein with 0.779 ATTCGAATAAAGCTCTTGAGAAGGGACTGAATCCTCTGtetratricopeptide re- AATGCATACTCCGATCTCGCTG (SEQ ID NO: 639) peats 418624 A_23_P38346 LGP2 likely ortholog of 0.775CATACTGTACTCAGAATCACGACATTCCTTCCCTACCA mouse D11Igp2AGGCCACTTGTATTTTTTGAGG (SEQ ID NO 640) 28011 A_23_P250353 HERC6 hectdomain and RLD 6 0.764 TTTCACCTCAGTCTGTAATTGGCTGTGAGTCAGTCTTTCATTTACATAGGGTGTAACCATC (SEQ ID NO: 641) 24371 A_23_P37983 MT1Bmetallothionein 1B 0.761 TCATCAGAGAAGTGCCGCTGCTGTGCCTGATGTTGGGAGAGCCCTGCTCCCAGACATAAA (SEQ ID NO: 642) 18869 A_24_P378019 IRF7interferon regulatory 0.760 CAACAGCCTCTATGACGACATCGAGTGCTTCCTTATGGfactor variant a AGCTGGAGCAGCCCGCCTAGAA (SEQ ID NO: 643) 11320A_24_P125096 MT1X metallothionein 1X 0.759CCAGGGCTGCATGTGCAAAGGGACGTCAGACAAGTGC AGCTGCTGTGCCTGATGCCAGGA (SEQ IDNO: 644) 20855 A_23_P152782 IFI35 interferon-induced 0.758CGGAAGTGCCTAAGTCTTTAGTTTCCAATTTGCGGATC protein 35 CACTGCCCTCTGCTTGCGGGCT(SEQ ID NO: 645) 33108 A_32_P15128 OAS2 2′-5′-oligoadenylate 0.755TAAAGAGCTTTGCITIGAAGACACAGAGGATTCCTTTT synthetase 2 variant 1TTAGACTGGAAGGAAAAAGGAG (SEQ ID NO: 646) 40042 A_24_P30194 IFIT5 IFIprotein with 0.741 AATGTGGCTTCTCTAATGTAGTTTCTTTGATTACCGACTtetratricopeptide re- ACACAATTATGTACCATCACA (SEQ ID NO: 647) peats 57065 A_23_P132388 SCO2 SCO cytochrome oxidase 0.738AGTCACAGTTACCGCGTGTACTACAATGCCGGCCCCA deficient homolog 2AGGATGAGGACCAGGACTACATC (SEQ ID NO: 648) 4620 A_23_P63668 IFIT5 IFIprotein with 0.731 AAGATAGATCCAGAAAATGCAGAATTCCTGACTGCTCTtetratricopeptide re- CTGTGAGCTCCGACTTTCCATT (SEQ ID NO: 649) peats 532013 A_23_P38894 FLJ11286 hypothetical protein 0.727ATCCCCCCACCAGGATAAAAGTCCTGACCTTTGTTCTC FLJ11286 TTGACGGAATAAAAGCTTGCTT(SEQ ID NO: 650) 41755 A_23 P29773 LAMP3 lysosomal-associated 0.726ACCATGTTGACTTTCCTCATGTGTTTCCTTATGACTCAG membrane protein 3TAAGTTGGCAAGGTCCTGACT (SEQ ID NO: 651) 3171 A_23_P64343 TIMM10translocase of inner 0.725 ATGAGCGGATGGGCAAAAAGTTGACAGAGTTGTCTATmitochondrial membrane GCAGGATGAAGAGCTGATGAAGA (SEQ ID NO: 652) 10homolog 35302 A_23_P39465 BST2 bone marrow stromal 0.722TGCTCGGCTTTTCGCTTGAACATTCCCTTGATCTCATC cell antigen 2AGTTCTGAGCGGGTCATGGGGC (SEQ ID NO 653) 28820 A_23P_370682 MGC20410hypothetical protein 0.722 TGGAAGTTCAGTTTTGGTGTCTGCTTCAAGAGGGGGTBC012330 TTTACACTCTGATTCCAGGACAA (SEQ ID NO: 654) 16269 A_23_P358944 PMLpromyelocytic leukemia 0.718 GGACTGGCTATCCCAAGACCTGGCAGATGTGGCTGCTvariant 8 CAATAAACACTTGTTGAACCATC (SEQ ID NO: 655) 13700 A_23_P142750PRKR protein kinase, IFI 0.717 AGAACAGATTTCTTCGCAAGACTATGGAAAGGAAGTGdouble-stranded RNA GACCTCTACGCTTTGGGGCTAAT (SEQ ID NO: 656) dependent26554 A_23_P259141 DLM-1 FLJ46548 fis, 0.716ATGTTTGAGTCCCAACAAAATTCATATCAAAACATAATC THYMU3038347, highlyCCAACTGGGTGCAGTGGCTCA (SEQ ID NO: 657) similar to DLM-1 7372 A_32_P54553USP41 ubiquitin specific 0.714 ATATGATCCGGATGAAGGACTCCTTGATTTGCCTTGACprotease 41 TGTGCCATGGAGAGTAGCAGAA (SEQ ID NO: 658) 22061 A_24_P334361FLJ20035 hypothetical protein 0.712GTGAAAATGAAGACGACAACGTTGTCTTAGCCTTTGAA FLJ20035 CAACTGAGTACAACTTTTTGGG(SEQ ID NO: 659) 23517 A_23_P139123 SERPING1 serine proteinase in- 0.710GACAACATTTGATCCCAAGAAAACCAGAATGGAACCCT hibitor, clade GTTCACTTCAAAAACTCAGTTAT (SEQ ID NO: 660) member 1 19683 A_32_P452655LGALS9 lectin, galactoside- 0.708 TGACCAGAGTGTTCTCTTCAGGGGACTGGCTCCTTTCbinding, soluble, 9 CCAGTGTCCTTAAAATAAAGAAA (SEQ ID NO: 661) variant28706 A_23_P218879 TREX1 three prime repair 0.707CAGCCTTGGAGAGAGCAGGGGTACCAAGGATCTTCCT exonuclease 1 variantCCAGTGAAGGACCCTGGAGCCCT (SEQ ID NO: 662) 4 41524 A_24_P332926 SFRS14splicing factor, argi- 0.701 GTGTGTCTCATCCAGGAGCCAAAAGTCCATGAACCAGnine/serine-rich 14 TTCGAATTGCCTATGACAGGCCT (SEQ ID NO: 663) 3797A_23_P20814 DDX58 DEAD (Asp-Glu-Ala-Asp) 0.697TGAGTGGAGAAGAAACAAACATAGTGGGTATAATCAT box polypeptide 58GATCGCTTGTACCCCTGTGAAA (SEQ ID NO: 664) 40576 A_32_P134290 ZCCHC2 zincfinger, CCHC 0.697 AATTAATTGTTAAGCTGCAGTTGAGTTGTTCAAGTGAG domaincontaining 2 AGTTTTGATAAGCCACTTATGG (SEQ ID NO: 665) 8270 A_23P_145874C7orf6 chromosome 7 ORf 6 0.695 CATTGATATCCACTGGTCACATCATAACTGTCTATAGGGCAATAAAATCTGTGTTAAACT (SEQ ID NO: 666) 10995 A_23_P304054 LOC400653hypothetical LOC400653 0.694 AGTTCTTTACGCTTTCTGATTGAACTGATTTGAAGTTCTTATTTCGTGTGTTGGGGAACA (SEQ ID NO: 667) 23236 A_23_P68155 MDA5 melanomadifferentia- 0.693 CTACGTCCTGGTTGCTCACAGTGGTTCAGGAGTTATC tion associatedpro- GAACGTGAGACAGTTAATGATTT (SEQ ID NO: 668) tein-5 40635 A_23_P206441FANCA Fanconi anemia, com- 0.685 ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTATplementation group A ACACTGTCACGTGGCTTCATC (SEQ ID NO: 669) 43149A_23_P17481 SIGLEC1 lectin-like adhesion 0.681GGAAGAGGTGATCACTCTCACACTAAGACTGAGGAAA molecule TAAAAAAGGTTTGGTGTTTTCCT(SEQ ID NO: 670) 1523 A_24_P561165 SERPING1 serine proteinase in- 0.678CGATTTTTCTTCATGACCTTAACCTGTGTGGGCTAACA hibitor, clade G member 1GAGGACCCAGATCTTACAGGTT (SEQ ID NO: 671) 34907 A_23_P111804 ZC3HDC1 zincfinger CCCH type 0.677 TGATTCGGTTTCTCAGAGTCTCATGGCATCATAGTTTTT domaincontaining 1 CCAGAATGACACAGTAGCCAC (SEQ ID NO: 672) 37561 A_24_P304071IFIT2 IFI protein with 0.673 TCTAAGAGAGAATGGAATGTATGGGAAAAGAAAGTTATtetratricopeptide TGGAACTAATAGGACACGCTGT (SEQ ID NO. 673) repeats 237323 A_24_P118892 IRF7 interferon regulatory 0.669TCAGCCGGGAGCTGTGCTGGCGAGAAGGCCCAGGCA factor 7 variant aCGGACCAGACTGAGGCAGAGGCCC (SEQ ID NO: 674) 1157 A_23_P163782 MT1Hmetallothionein 1H 0.668 AAGTGCAAATGCACCTCCTGCAAGAAGAGCTGCTGCTCCTGTTGCCCCCTGGGCTGTGCC (SEQ ID NO: 675) 21378 A_23_P97064 FBXO6 F-boxprotein 6 0.665 CAACAGTGGAACAATGCCACATGGACAGAGGTCTCCTACACCTTCTCAGACTACCCCCGG (SEQ ID NO: 676) 37891 A_23_P18604 LAP3 leucineaminopeptidase 0.660 TTCGTTTCAGTCAAGACAATGCTTAGTTCAGATACTCA 3AAAATGTCTTCACTCTGTCTTA (SEQ ID NO: 677) 1986 A_23_P69109 PLSCR1phospholipid scram- 0.660 GTTTAGCTCTTACACTCTATCCTTCCTAGAAAATGGTAA blase1 TTGAGATTACTCAGATATTAA (SEQ ID NO: 678) 6936 A_23_P203498 TRIM22tripartite motif-con- 0.652 GTACATAAGAATCTATCACTAAGTAATGTATCCTTCAGAtaining 22 ATGTGTTGGTTTACCAGTGAC (SEQ ID NO: 679) 17172 A_23_P120435WFDC3 WAP four-disulfide 0.652 ACCAGTCCTGCCCCCAAAACTGACCATGAACCCCAACcore domain 3 variant TGGACTGTGAGGTCTGATTCCGA (SEQ ID NO: 680) 4 7518A_23_P21838 CNP 2′,3′-cyclic nucleo- 0.651TAACAGGGCCTTGCTAATCGGGTTGTCACTCAAC tide 3′ phosphodi-GTGCTTTGGATTTAAGTTACTA (SEQ ID NO: 681) esterase 36793 A_32_P156746STAT2 signal transducer and 0.651 GAGATTGTCCAGAGTCCTATGACAGACCTTCAAGGTTTactivator of tran- TAAGTTCCACAGACTTGGACTT (SEQ ID NO: 682) scription 222443 A_23_P209995 IL1RN interleukin 1 receptor 0.646TATTCCTGCATTTGTGAAATGATGGTGAAAGTAAGTGG antagonist variant 4TAGCTTTTCCCTTCTTTTTCTT (SEQ ID NO: 683) 23150 A_23_P161125 MOV10 Moloneyleukemia virus 0.642 TCCCCGTACCGGAAACAGGTGGAGAAAATCCGTTACT 10, homologGCATCACCAAACTTGACAGGGAG (SEQ ID NO: 684) 17566 A_24_P395966 ZBP1 Z-DNAbinding protein 0.641 GTCGTCGTCCCGCAGACACACAATCCAGAAGTCACTT 1TCCTCGAGACATTGGTCAGCCCA (SEQ ID NO: 685) 8222 A_23_P250358 HERC6 hectdomain and RLD 6 0.639 CCTTACACCTAAATAATACAAGAGATTAATGAATAGTGGTTAGAAGTAGTTGAGGGAGAG (SEQ ID NO: 686) 41451 A_24_P172481 TRIM22tripartite motif-con- 0.639 TGCCCCTTAAAAGATTGAAGAAAGAGAAACTTGTCAACtaining 22 TCATATCCACGTTATCTAGCAA (SEQ ID NO: 687) 18011 A_24_P7040IFITM3 interferon induced 0.636 CGCCAAGCATGTGAACATCTGGGCCCTGACTGTGGGCtransmembrane protein ATCCTCATGACCATTCTGCTCAT (SEQ ID NO: 688) 15599A_24_P117410 LOC113730 hypothetical protein 0.635GCTCAGGGAAGGGGCTGGGATCGGAACTTCCTGCTCT BC009980 TGTTTCTGGACAACTTTCCCCTT(SEQ ID NO: 689) 2072 A_23_P75741 UBE2L6 ubiquitin-conjugating 0.628AATAGACCGAATATCAGGGAGCCCCTGCGGATGGACC enzyme E2L 6 variant 2TCGCTGACCTGCTGACACAGAAT (SEQ ID NO: 690) 37424 A_23_P71148 BLVRAbiliverdin reductase A 0.627 AGGTGATGTAGCACTTCCAAGATGGCACCAGCATTTGGTTCTTCTCAAGAGTTGACCATT (SEQ ID NO: 691) 28056 A_24_P45446 GBP4guanylate binding pro- 0.627 AGGGGACACAGGCTTCTTAAAACAACCCGGCTTCCTC tein4 ACCCTATGTCCTTTATTTACAAA (SEQ ID NO: 692) 44249 A_23_P101025 LGALS9lectin, galactoside- 0.622 CCCAGCCTTTCCAACCGTGCCTGGGATCTGGGCTTTAbinding, soluble, 9 ATGCAGAGGCCATGTCCTTATCT (SEQ ID NO: 693) variant24243 A_23_P91802 ECGF1 endothelial cell 0.619CCGCCTGGGGGTGGGCGGAGAGCTGCTGGTCGACGT growth factor 1GGGTCAGAGGCTGCGCCGTGGGAC (SEQ ID NO: 694) 3378 A_24_P394246 SCOTINscotin 0.618 TTCTCTTCCTCACCTGAAATTATGCTTCCTAAAATCTCAAGCCAAACTCAAAGAATGGGG (SEQ ID NO: 695) 17300 A_23_P428248 STI2 TPRdomain containing 0.617 GCCATCAACCTACTGAAGTTGTGTGGAGGGATGGAAA STI2GTGGGTCAGTGGAGAAGGGATTC (SEQ ID NO: 696) 9338 A_23_P24004 IFIT2 IFIprotein with 0.615 AGCTGACCCAGCATCAGCCACACTCTGGGTTGGAAAAtetratricopeptide re- TGTTTGCCTGTTGGAATTAATTT (SEQ ID NO: 697) peats 228969 A_23_P42353 ETV7 ets variant gene 7 0.611TGAGCCCTACATCAAGTGGGAAGACAAGGACGCCAAG ATCTTCCGAGTTGTGGATCCAAA (SEQ IDNO: 698) 18692 A_23_P70660 C6orf37 chromosome 6 ORF 37 0.610GCTATCCGGGTGTTAGCTGACCAAAATGTCATTCCTAA TGTGGCTAATGTCACTTGCTAT (SEQ IDNO: 699) 13508 A_23_P212475 SCOTIN scotin 0.610ATCTGTTGTGTTTCTGAGTCTAGGGTCTGTACATTGT TTATAATAAATGCAATCGTTTG (SEQ ID NO:700) 43198 A_23_P216655 TRIM14 tripartite motif-con- 0.609ATAGCCAGAAAGCGGCAGTTTCAGTCCATATCAATTGT taining 14 variant 1GTGACCAGGGCTAGTCACTTTT (SEQ ID NO: 701) 8567 A_23_P72737 IFITM1interferon induced 0.594 ATACAGCAGTTTATACCCACACACCTGTCTACAGTGTCtransmembrane ATTCAATAAAGTGCACGTGCTT (SEQ ID NO: 702) protein 1 24307A_24_P161018 PARP14 poly (ADP-ribose) 0.593AAATATTPAGATTTCCCTGGACCATAAGAGACCTTTGAT polymerase family,TAAGGTTTTGGGAATTAGGAG (SEQ ID NO: 703) member 14 15588 A_23_P140207 PCK2phosphoenolpyruvate 0.589 AGGACATAGCACCCTCATCTGGGAATAGGGAAGGCACcarboxykinase 2 CTTGCAGAAAATATGAGCAATTT (SEQ ID NO: 704) 31781A_32_P38003 EIF2AK2 downstream from gene 0.589AAACTGTGAGGCAAATAAAATGCTTCTCAAATCTGTGT GGCTCTTATGGGGTTAATTTGA (SEQ IDNO: 705) 27401 A_23_P206441 FANCA Fanconi anemia, com- 0.587ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTAT plementation groupACACTGTCACGTGGCTTCATC (SEQ ID NO: 706) A (FANCA) 5503 39922 A_23_P400378GPBAR1 G protein-coupled bile 0.556TGTCGACCTGGACTTGAACTAAAGGAAGGGCCTCTGC acid receptor 1TGACTCCTACCAGAGCATCCGTC (SEQ ID NO: 707) 4393 A_32_P107372 LOC400760similar to Interferon- 0.585 GGTACTGAGCAGAGTCTTAGGTAAAAGTCTTGGGAAAinduced guanylate- TATTTGGGCATTGGTCTGGCCAA (SEQ ID NO: 708) bindingprotein 1 41600 A_23_P206441 FANCA Fanconi anemia, com- 0.580ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTAT plementation group AACACTGTCACGTGGCTTCATC (SEQ ID NO: 709) 24950 A_23_P121011 AXUD1 AXIN1up-regulated 1 0.580 GCGTGATGTTCCTTAGCCCAAAGACGGTGAGACAGGGCTGAAATCAGGTGGCTTCTGCCA (SEQ ID NO: 710) 37768 A_23_P206441 FANCAFanconi anemia, com- 0.577 ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTATplementation group A ACACTGTCACGTGGCTTCATC (SEQ ID NO: 711) 26191A_24_P419286 DNAH3 dynein, axonemal, 0.576CCCAGAAGATCGTTGCGACCTACCGCCTGTGCTCGGA heavy polypeptide 3ACAACTGTCCTCTCAGCATCATT (SEQ ID NO: 712) 10783 A_23_P206441 FANCAFanconi anemia, com- 0.576 ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTATplementation group A ACACTGTCACGTGGCTTCATC (SEQ ID NO: 713) 24951A_23_P15174 MT1F metallothionein 1F 0.573TGCCAGGACAACCTTTCTCCCAGATGTAAACAGAGAG ACATGTACAAACCTGGATTTTTT (SEQ IDNO: 714) 30864 A_24_P148717 CCR1 chemokine (C-C motif) 0.569CTTTTCAAGTTGGGTGATATGTTGGTAGATTCTAATGG receptor 1 CTTTATIGCAGCGATTAATAAC(SEQ ID NO: 715) 38267 A_23_P106226 C14orf123 chromosome 14 ORF 1230.567 CTGAGTGGGTATCCTGATAAATCTGGGCTTGTCTTCCT AATGCTACCTTTGTTGGTCCTT (SEQID NO: 716) 40688 A_24_P274270 STAT1 signal transducer and 0.567TTGAACCCTACACGAAGAAAGAACTTTCTGCTGTTACT activator of tran-TTCCCTGACATCATTCGCAATT (SEQ ID NO: 717) scription 1 variant beta 13093A_23_P206441 FANCA Fanconi anemia, com- 0.565ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTAT plementation group AACACTGTCACGTGGCTTCATC (SEQ ID NO: 718) 30444 A_24_P344711 AGPAT31-acylglycerol-3-phos- 0.565 TCCCATAGAAGTTCCCTCCCTTTGAAATTAATATATAATphate O-acyltrans- GTATAAATTCTGCACTGAGCC (SEQ ID NO: 719) ferase 3 42135A_23_P125624 ACATE2 ortholog of acyl-Co- 0.565TGAAGACCTGATCGAGTGTATTGATTTTAGTATTGCTT enzyme A thioesteraseCGTGTCCTGCACACAGGAGGAG (SEQ ID NO: 720) 2, mitochondrial 32604A_24_P941912 BBAP rhysin 2 0.564 TTTATAATAACGGTAGCCCACATTGTAGTAGTTTTTCAGCTCTTTACTAAGTCCCACCAA (SEQ ID NO: 721) 31047 A_24_P207139 PMLpromyelocytic leukemia 0.564 ACAGTGAATTTTGATGCATTTAAAATAAGATTCTGATGCvariant 1 CAGACTGTTAAAACAGGCGCT (SEQ ID NO: 722) 30304 A_23_P65174 PHF11PHD finger protein 11 0.564 TATGAAGAAATCGGGAGTGCACTTTTTGACTGTAGATTGTTCGAAGACACATTTGTAAAT (SEQ ID NO: 723) 9201 A_23_P355244 FLJ20073FLJ20073 protein 0.564 TCACTGGAGGAAGATTTTCCCTTGCTTCTGCATAAAAT(FLJ20073)6853 TTTAACTCCATAACTTATAAGC (SEQ ID NO: 724) 41835 A_23_P69383BAL B aggressive lymphoma 0.561 TTTTTAGTGGCATGCAGGCTATACCTCAGTATTTGTGGgene ACATGCACCCAGGAATATGTAC (SEQ ID NO: 725) 13417 A_23_P306148 PMLpromyelocytic leukemia 0.560 AGGCAGAGGAACGCGTTGTGGTGATCAGCAGCTCGGvariant 11 AAGACTCAGATGCCGAAAACTCGT (SEQ ID NO: 726) 37690 A_23_P123672TDRD7 tudor domain contain- 0.560 AAATCTTAACTCTGCTACATGGCTCTGACTGCTGTGGGing 7 GGATTGAAAAGAATATGCTTAT (SEQ ID NO: 727) 22106 A_23_P6263 LOC442209FLJ16669 fis, clone 0.555 TCTGGGTCAAATTCTTCTTTTGTATGTCCAGTCTCCTGTHYMU30003O6 CACAGCACCTGCAGCATTGTAA (SEQ ID NO: 728) 33663 A_23_P12044FLJ10199 hypothetical protein 0.554GCCTGATGAACGTAGGCACGTGATGCGTAATAGTCTT FLJ10199 CAATGGTACACTTAACTAGTCTC(SEQ ID NO: 729) 18942 A_23_P206441 FANCA Fanconi anemia, com- 0.549ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTAT plementation group AACACTGTCACGTGGCTTCATC (SEQ ID NO: 730) 22341 A_23_P423331 NTNG2 netrinG2 0.549 AACTATTTTTGTTTGTATTCACTGTCCCCTGCAAGGGG GACGGGGCGGGAGCACTGGTCA(SEQ ID NO: 731) 39663 A_24_P868905 LOC391020 similar to IFI trans-0.544 ATCCTCATGAGCATTCTGCTCATCTTCATCCCAGTGTT membrane protein 3GATCTTTCAAGTCTATCAATAG (SEQ ID NO: 732) 22603 A_32_P92415 PARP14 poly(ADP-ribose) 0.543 GAAGGGTTTCACAATGAAGATGTGTAGCAGGCGTTAT polymerasefamily, CCCATTGTTATCACTGGGCAGAA (SEQ ID NO: 733) member 14 12663A_23_P154488 PNPT1 polyribonucleotide 0.543AAATTCAGGTGAAATACTTTGGACGTGACCCAGCCGAT nucleotidyltransferaseGGAAGAATGAGGCTTTCTCGAA (SEQ ID NO: 734) 1 38515 A_24_P15702 EST highlyconserved re- 0.542 CCAATGCAGACAAACCACCCCTTTTTGTTGGGAAAGG gionAATTACCTTTGACAGTGGTGGTA (SEQ ID NO: 735) 37436 A_32_P53603 EST spacedust 0.542 CTTTTATGTGGTTCCTGCCCCTGAGAATAAAGAAGCCC CAGCGTGGCTGCGAGGCACCAT(SEQ ID NO: 736) 19668 A_23_P116557 LGALS9 lectin, galactoside- 0.542AGTGTGGATCTTGTGTGAAGCTCACTGCCTCAAGGTG binding, soluble, 9GCCGTGGATGGTCAGCACCTGTT (SEQ ID NO: 737) variant 31202 A_23_P87545IFITM3 interferon induced 0.541 GGGCCCTGATTCTGGGCATCCTCATGACCATTCTGCTtransmembrane protein CATCGTCATCCCAGTGCTGATCT (SEQ ID NO: 738) 3 39745A_23_P55564 ZCCHC2 zinc finger, CCHC 0.540GACATCTGACGTAGAGACCTGCGAATGGATCTGAGAT domain containing 2GAGTAGTAACGCAGGTTGTCCGG (SEQ ID NO: 739) 31706 A_24_P350124 KIAA1618KIAA1618 0.540 GCAGATTCTGAGAACAATAACTCCACAATGGCGTCGGCCTCGGAGGGTGAAATGGAGTGT (SEQ ID NO: 740) 31855 A_24_P344087 REC8L1REC8-like 1 0.539 TCCTGGTGCTCTCAGCGCAACAGATTCTTCACGTGAAACAAGAAAAGCCATATGGTCGCC (SEQ ID NO: 741) 27231 A_23_P75811 SLC3A2 solutecarrier family 0.538 ATCCTGAGCCTACTCGAATCCAACAAAGACTTGCTGTT 3 member 2GACTAGCTCATACCTGTCTGAT (SEQ ID NO: 742) 35807 A_23_P138856 DRAP1DR1-associated pro- 0.537 CTTCTGCCCCCCAGACCATAGCCCCTTTTAGTTGGTTT tein 1(negative TAGTTGCTCTGGGGGGAGGAGA (SEQ ID NO: 743) cofactor 2 alpha)14385 A_24_P16124 IFITM4P IFI transmembrane pro- 0.536GGGATTCATAGCATTCACCTACTCCCTGAAGTCTAGG tein 4 pseudogene,GACAGGAAGATGGTTGGAGACCT (SEQ ID NO: 744) chromosome 6 14104 A_23_P62890GBP1 guanylate binding pro- 0.536 CAAAGATGCATTTACCTCTGTATCAACTCAGGAAATCTtein 1, interferon- CATAAGCTGGTACCACTCAGGA (SEQ ID NO: 745) inducible21955 A_24_P197964 TRIM14 tripartite motif-con- 0.536AAATTGCTTGCAGATATTTTTAAATGACAGCAATTTTCT taining 14 variant 4AATATTTGGTTTAATAAAATG (SEQ ID NO: 746) 23148 A_23_P153372 HSH2Dhematopoietic SH2 do- 0.536 GAATCCGAGCCCTTTTCCCATATCATCTGTTTGTTCTG maincontaining TTGTCTAAAAGCACACTGCAAG SEQ ID NO: 747) 11424 A_23_P206441FANCA Fanconi anemia, com- 0.532 ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTATplementation group A ACACTGTCACGTGGCTTCATC (SEQ ID NO: 748) 8658A_23_P202964 PORIMIN pro-oncosis receptor 0.531TCTGAAGCAAAGAAAGGATCAAAATTTGATACTGGGAG inducing membraneCTTTGTTGGTGGTATTGTATTA (SEQ ID NO: 749) injury gene 34298 A_24_P259276LOC254359 hypothetical protein 0.531ACTCAGTAAGGAAGTCGGGTTGGACCTTAACATCTGC LOC254359 ATTGGACAACTCCACCCCTTCCT(SEQ ID NO: 750) 26056 A_23_P98167 UNC93B1 unc-93 homolog B1 0.531TCGCCGGCCTCAGTTTACCACGTCTGAGGTCGGGGG GACCCCCTCCGAGTCCGCGCTGT (SEQ ID NO:751) 43514 A_32_P157846 FLJ31401 FLJ34941 fis, clone 0.529ACAGTTGTTTTGTCTTCAAGCCACTGACTTCTGGAATTT NT2RP7007480GCAGATTTTGCAATCCATGCA (SEQ ID NO 752) 23132 A_24_P50543 LOC400368hypothetical gene 0.527 AAATCAGCCTCCATCAGTATCACTGCAGTTATATATGA supportedby BC031266 TGTATGCCTTATTGCTCAAGAC (SEQ ID NO: 753) 22246 A_23_P214080EGR1 early growth response 1 0.526AAACAAAGTGACTGTTTGGCTTATAAACACATTGAATG CGCTTTATTGCCCATGGGATAT (SEQ IDNO: 754) 3490 A_23_P206441 FANCA Fanconi anemia, com- 0.523ATGAGGGCCTCGTTTATTAAGATCTTTAAACTGCTTTA plementation group AACACTGTCACGTGGCTTCATC (SEQ ID NO: 755) 2659 A_23_P50108 KNTC2kinetochore associ- 0.520 AAAGTGGGAAATAACTTGCAACGTCTGTTAGAGATGGT ated 2TGCTACACATGTTGGGTCTGTA (SEQ ID NO: 756) 21328 A_24_P382319 CEACAM1carcinoembryonic anti- 0.519 CCATGCTGTGCTGTGTTATTTAATTTTTCCTGGCTAAGAgen-related cell TCATGTCTGAATTATGTATGA (SEQ ID NO: 757) adhesionmolecule 1 33919 A_23_P255104 LHFPL2 lipoma HMGIC fusion 0.518CCAAAAGAGTTAAAGGCACGACTGGGATTTCTTCTGA partner-like 2GACTGTGGTGAAACTCCTTCCAA (SEQ ID NO: 758) 27245 A_24_P43588 MAD2L1BPMAD2L1 binding protein 0.518 CCATAAACTGACTGTGACCCTGTCATGTGGCAGACCTTvariant 1 CCATCCGAACCACGGCTTGGGA (SEQ ID NO: 759) 33581 A_23_P502520IL4I1 interleukin 4 induced 0.517 CCAGTTATCTCTCCAAAACACGACCCACACGAGGACC1 variant 2 TCGCATTAAAGTATTTTCGGAAA (SEQ ID NO: 760) 8566 A_24_P54879SCARB2 scavenger receptor 0.516 AGTGATGTACCTCAATGAGAGTGTTCACATTGATAAAGclass B, member 2 AGACGGCGAGTCGACTGAAGTC (SEQ ID NO: 761) 16203A_24_P175188 FLJ20073 FLJ20073 protein 0.515TGCCAATGTACTGGCAGATTAACATACAACCTATGTTT TGAACAAAAACAACCAGCGATA (SEQ IDNO: 762) 11310 A_23_P34915 ATF3 activating transcrip- 0.513GATGTCAATAGCATTGTTTTTGTCATGTAGCTGTTTTAA tion factor 3GAAATCTGGCCCAGGGTGTTT (SEQ ID NO: 763) 26089 A_23_P75769 MS4A4Amembrane-spanning 4- 0.511 CACCAAAAGATCAACAGACAAATGCTCCAGAAATCTATdomains, subfamily A, GCTGACTGTGACACAAGAGCCT (SEQ ID NO: 764) member 4variant 2 7745 A_23_P166459 LGALS1 lectin, galactoside- 0.511CCAGATGGATACGAATTCAAGTTCCCCAACCGCCTCA binding, soluble, 1ACCTGGAGGCCATCAACTACATG SEQ ID NO: 765) 12417 A_32_P71710 IL1RNinterleukin 1 receptor 0.510 AAGATTTTATTGTAAAACAGAGCTGAAGTCACAGGAAGantagonist variant 4 TAGGGAACTTTGCACCCAACAT (SEQ ID NO: 766) 35164A_23_P376488 TNF tumor necrosis factor, 0.509GGGGTATCCTGGGGGACGCAATGTAGGAGCTGCCTT superfamily member 2GGCTCAGACATGTTTTCCGTGAAA (SEQ ID NO: 767) 37407 A_23_P135123 FRMD3 FERMdomain contain- 0.509 CTGGTCTGAAGGGTCACGGGGCTGTCAACAGGTGTTC ing 3CTTACTCATAATTGATTATTCAA (SEQ ID NO: 768) 32481 A_23_P59005 TAP1transporter 1, ATP- 0.507 TCCAGGATGAGTTACTTGAAATTTGCCTTGAGTGTGTT bindingcassette, sub- ACCTCCTTTCCAAGCTCCTCGT (SEQ ID NO: 769) family B 27197A_24_P254933 ATXN2 ataxin 2 0.506 CCGACCATGTCCTGGTCCCTGTTCAACACCCACTTCATGAATGCTGCCTGGGCTTCATAG (SEQ ID NO: 770) 29912 A_24_P326957 WDR23 WDrepeat domain 23 0.506 TGGGTCTTTAGGGTAGGACAGGCTGTGGTATGAGAGG variant 1CAGGAGTCTCCACAAGGCTTCAT (SEQ ID NO: 771) 26767 A_23_P356526 TRIM5tripartite motif-con- 0.506 GAAGCCAGAAACTTTTCCAAAAAATCAAAGGAGAGTGTtaining 5 variant TTCGAGCTCCTGATCTGAAAGG (SEQ ID NO: 772) delta 41790A_23_P165636 CAPG capping protein (actin 0.506CTGCTTGCTTGTCTGGCTGCCTGGTCAGTGCAGAGGT filament), gelsolin-GCCCGCTGCAGATGTTCAATAAA (SEQ ID NO: 773) like 38573 A_24_P127641LOC441109 hypothetical gene sup- 0.503TATATCGTAGGTGGCTTTAATACGTGTTATTTGCTCATC ported by AL713721TGTATTTCTTACTCTTTGCAC (SEQ ID NO: 774) 40160 A_23_P88234 C14orf122chromosome 14 ORF 122 0.503 GATAAGAACTTAGTGATGTGGAGGGACTGGGAAGAGTCACGGCAGATGGTGGGAGCTCTA (SEQ ID NO: 775) 9098 A_24_P383523 SAMD4 sterilealpha motif 0.501 CCATCTTCAGGGTTGCACAGAATCCTCCAAGATACTTT domaincontaining 4 GCAGCCTTTTTTCCCCCTGGTC (SEQ ID NO: 776) 16598 A_24_P242391MPZL1 myelin protein zero- −0.501 GTGTATGCGGATATCCGAAAGAATTAAGAGAATACGTAlike 1 variant 2 GAACATATCCTCAGCAAGAAAC (SEQ ID NO: 777) 39617A_32_P109516 LOC389089 LOC389089 −0.507TCCGTTTTTACAGCATTCTCGACCTGTGATTCTTGGTG GGGGAAACTAGTTATGTGGATA (SEQ IDNO: 778) 36575 A_23_P417282 MGC18216 hypothetical protein −0.507AAATCAAACCAGAAGGCGGGATGGAATGGATGCACCG MGC 18216, cloneCAAATAATGCATTTTCTGAGTTT (SEQ ID NO: 779) IMAGE: 4156235 34695A_23_P403284 OTX1 orthodenticle homolog −0.517TTAGTTGCTGTTGGTTGGTTGAACTGAACATATCTTGT 1 CTTAGCACCCAGGAAACAGAAC (SEQ IDNO: 780) 33205 A_24_P467358 EEF1G eukaryotic translation −0.526CTGGATGCTTACTTGAAGACGAGGACTTTTCTGGTGG elongation factor 1GCGAACGAGTGACATTGGCTGAC (SEQ ID NO: 781) gamma 25932 A_24_P87763 EEF2eukaryotic translation −0.527 CATGTTTGTGGTCAAGGCCTATCTGCCCGTCAACGAGelongation factor 2 TCCTTTGGCTTCACCGCTGACCT (SEQ ID NO: 782) 14152A_23_P124252 CAMK1D calcium/calmodulin- −0.528TCCTGTTTGCCAGGCGCTTTCTATACTTAATCCCATGT dependent proteinCATGCGACCCTAGGAC1TTTTT (SEQ ID NO: 783) kinase ID 35180 A_24_P177653LOC340947 similar to bA508N22.1 −0.528CATGAGTATTGATGAGAGCATTCACCTCCAGCGGTGG (HSPC025) GATAAATACAGCAACAAGATGCT(SEQ ID NO: 784) 38227 A_23_P104318 DDIT4 DNA-damage-inducible −0.529TCGTGGAGGTGGTTTGTGTATCTTACTGGTCTGAAGG transcript 4GACCAAGTGTGTTTGTTGTTTGT (SEQ ID NO: 785) 3684 A_23_P57521 EIF3S6IPeukaryotic TIF 3, −0.529 GAATTTCAGTCAGCCTCAGAGGTTGACTTCTACATTGA subunit6 interacting TAAGGACATGATCCACATCGCG (SEQ ID NO: 786) protein 7635A_32_P172917 LOC389832 similar to chromosome −0.530AACTCAGCAGCAGCACTGCAGAATCTCCATGCCTGCA 2 ORF 27 CCTGCCCAAGGATTTATTCATAG(SEQ ID NO: 787) 39387 A_32_P76399 EIF3S6IP eukaryotic TIF 3, sub-−0.531 AGGTTGACTTCTACATTGATAAGGACATGATCCACATC unit 6 interactingGCGGACACCAAGGTCTCCAGGC (SEQ ID NO: 788) protein 24015 A_23_P105138 CATcatalase −0.532 CTCATCACTGGATGAAGATTCTCCTGTGCTAGATGTGCAAATGCAAGCTAGTGGCTTCAA (SEQ ID NO: 789) 15339 A_24_P8371 MYBBP1A MYBbinding protein −0.536 GCTGCTGATTGTGAATCTCAGAGTCTTAAGAGAGAAG (P160)1aCCAAATATATTCCTCTTGTAAAT (SEQ ID NO: 790) 23589 A_24_P757154 ANP32Aacidic (leucine-rich) −0.536 ACACTTTGCATGCTGGGTCAGGGAAGATTGTGGAGAGnuclear phosphoprotein AGGACAGTGCACCTGGTTTCCCC (SEQ ID NO: 791) 32family, member A 19944 A_24_P32151 MGC45871 hypothetical protein −0.537AAGGAAGTAAGGTACACCTCCTTGGTCAAGTACGACT MGC45871 CCGAGAGGCACTTCATCGACGAC(SEQ ID NO: 792) 11244 A_24_P154037 IRS2 insulin receptor sub- −0.540GATGGTTCGTGTTCATACTGCAGCTTAAAACAAGCAAA strate 2 ATACACAGATGATAATATGCTA(SEQ 10 NO:793) 2728 A_32_P128258 SIGLECP3 sialic acid binding −0.543ACTATGTGCCAGCATTTCCGTATGTGCAGAAGTTCATC Ig-like lectin,AATAGATATAGACTCAAAGAGC (SEQ ID NO: 794) pseudogene 3 43581 A_24_P717462LOC651628 similar to Elongation −0.552TGGATGAATGTGAGCAGAGTACCTTTGTGTTGGATAAA factor 1-gammaTTTCAGTGCAGGTACTCTAAGG (SEQ ID NO: 795) 24821 A_24_P136641 NDUFB6 NADHdehydrogenase −0.552 GCTAAGGAGGAAATACCCAGACAAAATCTTTGGGACG (ubiquinone)1 beta AATGAAAATTTGTAACTCTTCTG (SEQ ID NO: 796) subcomplex, 6 26400A_24_P588235 EIF3S6IP eukaryotic TIF 3, sub- −0.561TGTGGATCATGTCCTTATCAATGTAGAAGTCAACCTCT unit 6 interactingGAGGCTGACTGAAATTCACCAT (SEQ ID NO: 797) protein 40567 A_23_P50081 IMPA2inositol(myo)-1 (or −0.583 TAGCTGTTTCTCTCTTTAATCTCACGTAGCCTTTTTCAG4)-monophosphatase 2 GTTAGTACGTGTTCTTCTGTC (SEQ ID NO: 798) 10228A_24_P299318 FAM101B family with sequence −0.598ACTTAATTTGAGCGAGTACCTTTTCATTTGACACTTTTC similarity 101, memberCTGTTTCTAACCTTAGGAAAC (SEQ ID NO: 799) B 6063 A_24_P856176 EST highlyconserved ge- −0.603 CCAGGCTGTGCAGTGGGTGAACTTTGCTGATGATAGC nomic regionCAGTACCAGGGTGTTCCCACCTT (SEQ ID NO: 800) 14283 A_32_P159289 EST ESTdefined by −0.630 ACTGGCTTTTCTTTCATCTCTGGAGAGAGCTTGATTCG BE677474TCATCTTATTGCTTTGTCTGAA (SEQ ID NO: 801) 19711 A_24_P554408 EFF1Geukaryotic translation −0.636 GGCAATGGCGTTGCTCTCAAACACACAGAATCCATCATelongation factor 1 CACCCTCAAATGCTGGGACCTT (SEQ ID NO: 802) gamma

TABLE 3 Patient ABCoN ID Sample Date SLEDAI INFr Days from 1st SampleINFr Score 1 JHP004-01 QF1 Jul. 26, 2006 2 LOW 0 −2.813 JHP004-02 F Oct.15, 2006 6 LOW 81 −1.864 2 JHP012-02 QF1 Sep. 10, 2006 0 LOW 0 −2.21JHP012-04 F Nov. 5, 2006 8 LOW 56 −2.202 3 JHP017-02 QF1 Nov. 12, 2006 0LOW 0 −2.44 JHP017-03 F Feb. 4, 2007 4 LOW 84 −2.07 4 JHP019-05 QF5 Mar.8, 2007 0 LOW 0 0.255 JHP019-06 QF1 May 16, 2007 2 LOW 69 −0.219JHP019-07 F Aug. 26, 2007 8 LOW 171 −0.124 5 JHP021-02 F Oct. 18, 2006 4HIGH 0 2.882 JHP021-04 QF1 Dec. 19, 2006 0 HIGH 62 1.878 6 JHP023-01 QF4Aug. 30, 2006 0 LOW 0 −1.684 JHP023-02 F Nov. 15, 2006 4 LOW 77 −1.404JHP023-03 QF1 Feb. 14, 2007 0 LOW 168 −1.959 JHP023-04 F May. 9, 2007 8LOW 252 −1.293 7 JHP028-01 QF5 Sep. 13, 2006 4 HIGH 0 2.883 JHP028-03QF1 Mar. 18, 2007 4 HIGH 186 3.57 JHP028-04 F Jun. 17, 2007 16 HIGH 2773.784 JHP028-05 QF4 Jul. 8, 2007 4 HIGH 298 4.696 JHP028-06 F Sep. 30,2007 16 HIGH 382 4.325 8 JHP029-01 QF1 Sep. 13, 2006 4 HIGH 0 3.463JHP029-03 F Mar. 7, 2007 9 HIGH 175 3.867 9 JHP030-03 F Feb. 4, 2007 12LOW 0 1.392 JHP030-09 F Jun. 10, 2007 6 LOW 126 0.815 10 JHP033-02 QF1Dec. 17, 2006 2 LOW 0 1.277 JHP033-03 F Mar. 4, 2007 12 HIGH 77 2.276 11JHP039-02 QF1 Jan. 24, 2007 4 HIGH 0 4.707 JHP039-03 F Mar. 28, 2007 12HIGH 63 4.281 12 JHP068-02 QF5 Apr. 8, 2007 0 HIGH 0 3.389 JHP068-03 QF1Jul. 1, 2007 0 HIGH 84 3.773 JHP068-04 F Sep. 30, 2007 7 HIGH 175 3.99213 JHP072-01 F Jan. 14, 2007 10 HIGH 0 3.178 JHP072-02 QF5 Apr. 15, 20070 LOW 91 0.155 JHP072-03 QF1 Jul. 15, 2007 0 HIGH 182 1.794 JHP072-04 FOct. 7, 2007 8 HIGH 266 2.377 14 JHP074-01 QF1 Jan. 14, 2007 3 HIGH 03.087 JHP074-05 F Jan. 13, 2008 9 HIGH 364 4.226 15 JHP075-02 QF1 Oct.7, 2007 1 LOW 0 −1.516 JHP075-03 F Jan. 13, 2008 11 LOW 98 −0.26 16JHP078-01 QF5 Jan. 14, 2007 4 HIGH 0 3.381 JHP078-02 QF1 Jul. 22, 2007 4HIGH 189 4.042 JHP078-03 F Dec. 12, 2007 10 HIGH 332 4.03 17 JHP079-02 FFeb. 28, 2007 4 LOW 0 −2.02 JHP079-03 QF4 Apr. 15, 2007 0 LOW 46 −2.095JHP079-04 F Jul. 15, 2007 4 LOW 137 −1.931 18 JHP080-03 QF1 Jul. 18,2007 4 HIGH 0 4.606 JHP080-04 F Sep. 12, 2007 8 HIGH 56 4.35 19JHP081-01 QF5 Jan. 17, 2007 0 LOW 0 −2.31 JHP081-02 QF1 May 16, 2007 0LOW 119 0.595 JHP081-03 F Jul. 18, 2007 4 LOW 182 −1.632 JHP081-04 QQOct. 17, 2007 0 LOW 273 −1.729 20 JHP100-01 QF1 May 16, 2007 4 HIGH 03.896 JHP100-03 F Mar. 26, 2008 12 HIGH 315 3.88 21 JHP102-01 QF5 May20, 2007 4 HIGH 0 3.993 JHP102-02 QF1 Jun. 17, 2007 4 HIGH 28 4.048JHP102-03 F Sep. 23, 2007 8 HIGH 126 3.19 JHP102-04 QF4 Dec. 23, 2007 0HIGH 217 3.704 JHP102-05 F Feb. 20, 2008 4 HIGH 276 3.054 22 JHP104-01QF5 Jun. 6, 2007 4 HIGH 0 4.508 JHP104-02 QF1 Sep. 5, 2007 4 HIGH 913.259 JHP104-04 F Feb. 27, 2008 12 HIGH 266 3.59 23 JHP111-02 QQ Sep.12, 2007 0 HIGH 0 3.585 JHP111-04 QF1 Mar. 30, 2008 2 HIGH 200 3.503JHP111-05 F Jun. 25, 2008 6 HIGH 287 2.196 24 JHP117-02 QF1 Sep. 30,2007 0 LOW 0 −0.932 JHP117-03 F Dec. 19, 2007 4 LOW 80 0.251 25JHP120-04 QQ Nov. 11, 2007 0 HIGH 0 3.736 JHP120-06 QF1 Apr. 27, 2008 0HIGH 168 2.258

1. A method of diagnosing or monitoring the status of systemic lupuserythematosus (SLE) in a subject or patient comprising: detecting theexpression of all genes of a diagnostic set in the subject or patientwherein the diagnostic set comprises two or more genes having expressioncorrelated with the classification or status of SLE; and diagnosing ormonitoring the status of SLE in the subject or patient by applying atleast one statistical method to the expression of the genes of thediagnostic set.
 2. The method of claim 1 wherein the statistical methodis a prediction algorithm.
 3. The method of claim 2 wherein theprediction algorithm produces a number or single value indicative of thestatus of SLE in the subject or patient.
 4. The method of claim 1wherein the statistical method further comprises classification of thesubject or patient into one of at least two classes of SLE.
 5. Themethod of claim 4 wherein the statistical method is optimized tomaximize the separation among longitudinally stable classes of SLE. 6.The method of claim 1 wherein the diagnostic set further comprises atleast one gene selected from each of at least two gene clusters selectedfrom cluster 1, cluster 2, cluster 3, cluster 4, cluster 5, cluster 6,cluster 7, cluster 8, cluster 9, cluster 10, cluster 11; cluster 12,cluster 13, cluster 14, and cluster 15 of Table
 1. 7. The method ofclaim 4 wherein classification of the subject or patient into one of atleast two classes of SLE further comprises: detecting the expression oftwo or more gene whose expression correlates with the expression of theIFI27 from about 0.5 to about 1.0 and from about −0.5 to about −1.0calculated using a Pearson correlation; and classifying a subject orpatient as having type 1 or type 2 SLE based on the expression of thetwo or more genes.
 8. The method of claim 7 wherein one of the two ormore genes is selected from Table
 2. 9. The method of claim 7 whereinthe classifying step uses a linear algorithm to produce an interferonresponse (INFr) score.
 10. The method of claim 9 wherein a high INFrscore is correlated with type I SLE and a low INFr score is correlatedwith type II SLE.
 11. The method of claim 9 wherein at least one of thelinear algorithm that produces an INFr score comprisesIFI27+IFI144*(1.1296)+OAS3*(1.8136).
 12. The method of claim 7 whereinthe Pearson correlation is selected from a range of 0.5, 0.4, 0.3, and0.2 of these genes.
 13. A method of diagnosing or monitoring the statusof systemic lupus erythematosus (SLE) in a subject or patientcomprising: detecting the expression of all genes of a diagnostic set ina subject or patient wherein the diagnostic set comprises at least onegene from each of at least two gene clusters selected from cluster 1,cluster 2, cluster 3, cluster 4, cluster 5, cluster 6, cluster 7,cluster 8, cluster 9, cluster 10, cluster 11; cluster 12, cluster 13,cluster 14, and cluster 15 of Table 1; and diagnosing or monitoring thestatus of SLE in the subject or patient based on expression of the genesin the diagnostic set.
 14. The method of claim 1 wherein the expressionof all genes in the diagnostic set is detected using a nucleic acidtechnology.
 15. The method of claim 14 wherein the nucleic acidtechnology further comprises hybridization or amplification in aquantitative real-time polymerase chain reaction.
 16. The method ofclaim 15 wherein hybridization occurs in solution or on a substrateselected from magnetic or nonmagnetic beads, chips, fibers, filters,gels, membranes, microparticles, plates, polymers, slides, capillarytubing, and wafers with surface features selected from channels,columns, pins, pores, trenches, and wells.
 17. The method of claim 1wherein detecting expression of all genes further comprises isolatingRNA from a subject or patient sample.
 18. The method of claim 19 whereinexpression is proportional to the amount of RNA isolated from thesample.
 19. The method of claim 17 wherein the sample further comprisesa body fluid or tissue obtained by any sampling means.
 20. The method ofclaim 19 wherein the body fluid is selected from ascites, bile, wholeblood or a blood fraction, cerebrospinal fluid, lymph, sputum, andurine.
 21. The method of claim 19 wherein the tissue sample is selectedfrom central nervous system, joints, kidneys, liver, lungs, oral cavity,sinuses, skin, and vasculature.
 22. The method of claim 19 wherein thesampling means is selected from aspiration of a body fluid, a biopsy ofa tissue or an organ, drawing of peripheral blood, endoscopy, and lavagefollowed by aspiration.
 23. The method of claim 1 wherein detectingexpression comprises using at least one primer or probe set to detectthe expression of each of the genes in the diagnostic set.
 24. Themethod of claim 23 wherein the primers or probe sets areoligonucleotides selected from natural or synthetic cDNA, genomic DNA,locked nucleic acids, peptide nucleic acids, and RNA.
 25. The method ofclaim 23, wherein the primers or probe sets comprise a diagnostic kit.26. The method of claim 7 wherein classifying a subject or patient astype 1 SLE or type 2 SLE comprises assigning a subject or patient to aclinical trial.
 27. A method of diagnosing a patient as having alongitudinally stable classification of SLE comprising: detecting theexpression of two or more genes whose expression correlates with theexpression of the IFI27 from about 0.5 to about 1.0 and from about −0.5to about −1.0 calculated using Pearson correlation; and diagnosing thepatient as having type I or type II SLE based analyzing the expressionof the two or more genes using a statistical method.
 28. The method ofclaim 1 wherein the statistical method is selected from analysis ofvariance, classification algorithms, classification and regressiontrees, Fisher's Exact Test, linear algorithm, linear discriminatoryanalysis, linear regression, logistic algorithm, multiple regression,nearest shrunken centroids classifier, Pearson correlation, predictionalgorithm, significance analysis of microarrays, one-tailed T-tests,two-tailed T-tests, voting algorithm, and Wilcoxon's signed ranks test.29. The method of claim 1 wherein status of SLE in a subject or patientis incipient flare or disease activity.
 30. The method of claim 1wherein status of SLE in a subject or patient comprises a response to atherapeutic agent administered to the patient.
 31. The method of claim30 wherein the therapeutic agent is selected from ACE inhibitors,aspirin, azathioprine, B7RP-1-fc, β-blockers, brequinar sodium,campath-1H, celecoxib, chloroquine, corticosteroids, coumadin,cyclophosphamide, cyclosporin A, dehydroepiandrosterone,deoxyspergualin, dexamethasone, diclofenac, dolobid, etodolac,everolimus, FK778, feldene, fenoprofen, flurbiprofen, heparin,hydralazine, hydroxychloroquine, CTLA-4 or LFA3 immunoglobulin,ibuprofen, indomethacin, ISAtx-247, ketoprofen, ketorolac, leflunomide,meclophenamate, mefenamic acid, mepacrine, 6-mercaptopurine, meloxicam,methotrexate, mizoribine, mycophenolate mofetil, naproxen, oxaprozin,Plaquenil, NOX-100, prednisone, methyprenisone, rapamycin (sirolimus),sulindac, tacrolimus (FK506), thymoglobulin, tolmetin, tresperimus,U0126, and antibodies including but not limited to alpha lymphocyteantibodies, adalimumab, anti-CD3, anti-CD25, anti-CD52 anti-IL2R, andanti-TAC antibodies, basiliximab, daclizumab, etanercept, hu5C8,infliximab, OKT4, and natalizumab.
 32. The method of claim 1 whereinstatus of SLE in a subject or patient comprises response to animmunosuppressant administered to a patient.
 33. The method of claim 32wherein the immunosuppressant is selected from aspirin, azathioprine,chloroquine, corticosteroids, cyclophosphamide, cyclosporin A,dehydroepiandrosterone, deoxyspergualin, dexamethasone, everolimus,fenoprofen, hydralazine, hydroxychloroquine, immunoglobulin, ibuprofen,indomethacin, leflunomide, ketoprofen, meclophenamate, mepacrine,6-mercaptopurine, methotrexate, mizoribine, mycophenolate mofetil,naproxen, prednisone, methyprenisone, rapamycin (sirolimus), solumedrol,tacrolimus (FK506), thymoglobulin, tolmetin, tresperimus, andtriamcinoline.
 34. The method of claim 1 wherein diagnosing andmonitoring the status of SLE further comprises screening a subjectexhibiting symptoms of a rheumatic disease for SLE.
 35. The method ofclaim 34 wherein the rheumatic disease is selected from ankylosingspondylitis, dermatomyositis, autoimmune hepatitis, hepatitis-C (hep-C),polymyalgia rheumatica, polymyositis, rheumatoid arthritis (RA),scleroderma, systemic sclerosis, Sjogren's disease, systemic vasculitis,and Whipple's disease.
 36. A method of producing a probe set fordiagnosing or monitoring SLE in a subject or patient comprising:selecting at least one gene from each of at least two of the geneclusters of Table 1 and at least two genes from Table 2; and producing aprobe set consisting of at least one oligonucleotide that detects theexpression of each of the selected genes.
 37. The method of claim 36wherein the probe set is used in a diagnostic kit.
 38. A method forpredicting flare in a patient diagnosed with SLE comprising: analyzingexpression in a sample from the patient to produce a gene expressionprofile wherein a first portion of the analysis comprises using theexpression of at least one gene selected from each of at least two ofthe clusters 1 through 15 of Table 1 and at least one statistical methodto produce a patient gene expression profile, and a second portion ofthe analysis comprises using expression of at least two genes selectedfrom Table 2 and a linear algorithm to classify the patient as havingtype 1 SLE or type 2 SLE; and predicting flare by comparing the patientgene expression profile at least one reference profile.
 39. The methodof claim 38 wherein reference profile is selected from at least onenormal subject, at least one patient classified as having type 1 SLEwith quiescent status, at least one patient classified as having type 1SLE in flare, at least one patient classified as having type 2 SLE withquiescent status, at least one patient classified as having type 2 SLEin flare.